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ABSTRACT 
 Methods for the preparation of novel antifungal saponins have been investigated in 
order to further explore their medicinal utility and provide the opportunity to synthesize 
their derivatives. 
Through this work, several partially protected stereoisomers of Cholestane, 
Androstane and Spirostane have been prepared which could be used for the synthesis of 
various saponin derivatives in order to discover novel saponin based antifungal agent. 
Various mono and disaccharide derivatives of these steroids have been synthesized and 
evaluated for their antifungal activity against four pathogenic fungal strains. Among the 
various derivatives maltose derivatives were found to have the best antifungal activity. 
However there is a need for more extensive SAR studies to discover compounds with 
better potency.  
Additionally, the branched oligosaccharide synthesis was explored in two parts. 
First, these results demonstrated that the central 2,3-branched portion can be synthesized 
efficiently from a partially protected glucopyranosyl acceptor since the C-2 and C-3 
alcohols differ in their reactivity in glycosylation reactions. Second, a tagged sugar based 
strategy for synthesis of branched oliogosaccharides was developed, and found to be 
effective for general synthesis of branched oligosaccharides.  
Microwave assisted synthesis of cyclic imides have been explored this was a key 
precursor for the synthesis of our tag molecules which were required for synthesis of 
branched oligosachharides. A comparison of microwave versus conventional methods for 
synthesis of cyclic imides has been studied. The synthesis of tagged sugars and their 
selective deprotection to remove tag molecules were successfully explored in order to 
have proof of concept for its applicability towards synthesis of branched 
	   xiv	  
oligosaccharides. 
Benzylic mono and dibromination was achieved in very high yields using 
microwave conditions using environmentally friendly solvent in order to avoid use of 
carcinogenic carbon tetrachloride as solvent for this type of reactions. In addition reaction 
time was reduced to 30 minutes to 3 hours compared to convention methods, which 
needed more than 15 hours for the benzylic bromination reaction.  
 
Keywords: Saponins, Oligosaccharide, Stereoisomer, Aglycone, Cholestane, Androstane, 
Spirostane, Triterpenes, Alkaloids, Cyclic-imides, Glycosylation, Benzylic-Bromination, 
Pathogenic, Antifungal agents, Steroids, Fatty-acids, Azols, Polyenes, Echinocandins, 
Sordarines, Tag-Molecules, Tagging, Detagging, Glycolipids, Glycosides, Enolization, 
Epoxidation, Regioselective, Anomerization, Trichloroacetimidates, Anomeric Effect, 
Catalytic, Medications, Phthalimides, Naphthalimides, Succinimides, Maleimides, 
Tagged sugar, Partial protection, Deprotection, Hydrolysis, Hydrogenation, 
Isomerization. 
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CHAPTER-1: INTRODUCTION 
 
The clinical needs for novel antifungal agents have increased steadily with the rise and 
fall of AIDS-related mycoses, and the increased spectrum of fatal fungal infections that has 
accompanied changes in immunosuppressive therapies. The search for new molecular targets for 
antifungals has generated considerable research using modern genomic approaches, so far 
without generating new agents for clinical use. Invasive fungal infections have transitioned from 
a rare curiosity to an everyday problem for the practicing physician. Invasive candidiasis is the 
third to fourth most common bloodstream infection in surveys in the United States. Similar 
trends have been reported in several regions throughout the world1-3. Rates of invasive 
aspergillosis and mucormycosis are increasing parallel to the growth of immunocompromised 
patient populations4-8. Invasive fungal infections are associated with substantial morbidity and 
mortality, despite optimal antifungal therapy, and carry a high financial burden. Improved 
diagnostics, recent epidemiological studies and the availability of variety of new antifungals 
have advanced the field of medical mycology in the past few decades. 
Although systemic antifungals have been available since the 1950s, compounds 
characterized the early antifungal pipeline had limited efficacy and high toxicity, such as the 
polyenes nystatin and amphotericin B9. Triazoles were developed in the 1980s, which 
revolutionized medical mycology due to their availability in both intravenous and oral 
formulations. They were effective against fungal pathogens that were refractory to the polyenes. 
Triazoles were further developed and amphotericin B reformulations with lipid compounds were 
reported in 1990s (Fig.1.1). Lipid-based formulations were much less toxic and allowed the true 
efficacy of polyenes to be explored, expanding the pharmacokinetic and pharmacodynamic limits 
of these agents9. The twenty first century brought the echinocandins, a new class of antifungals 
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to the market. They inhibit the synthesis of (1,3)-β-glucan (a key component of fungal cell walls) 
and represent the first class of antifungal agents that act against a specific component of the 
fungal cells and not mammalian cells10-12.   
 
 
Figure 1.1 Timeline of systemic antifungals.13 
 
Antifungal research and development is challenging because apart from the fungal cell 
wall, fungal cells are metabolically similar to mammalian cells and offer few pathogen-specific 
targets. Clinical development is further hampered by challenges of timely and definitive 
diagnoses of the more resistant fungi.  
Over the past two decades, fungi have emerged as important causes of infectious 
morbidity and mortality in immunocompromised patients. The most significant risk factors 
include profound and prolonged granulocytopenia, immunosuppression with corticosteroids, 
acquired deficiencies in the number and/or function of T-helper cells, and severe illness requiring 
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multiple invasive medical procedures, such as the use of intravascular devices and extensive 
abdominal surgery14. While the species Aspergillus fumigatus and Candida albicans traditionally 
account for the majority of invasive opportunistic infections, more recent epidemiological trends 
indicate a shift toward infections by non-fumigatus Aspergillus spp., non-albicans Candida spp., 
and previously uncommon fungi that often display resistance to current antifungal agents in vitro 
and in vivo14. Human immunodeficiency virus (HIV)-infected patients with advanced immune 
dysfunction are particularly susceptible to cryptococcal meningitis, disseminated histoplasmosis, 
coccidioidomycosis, and penicillosis, and recent outbreaks highlight that endemic fungi can 
become a significant public health concern beyond their baseline prevalence15. 
Improved blood culture, antigen, and nucleic acid detection techniques, the advent of 
high-resolution two-dimensional imaging, and an increased awareness among physicians of the 
fungal pandemic have all had considerable impact on improving the early clinical diagnosis of 
invasive fungal infections, and major advances have been achieved in disease definitions, in 
defining paradigm for antifungal interventions, and in designing and implementing clinical 
trials16-17. Finally, standardized methods for testing the in vitro susceptibility of fungi have 
become available and are continuously refined, and concentration-effect relationships in vitro 
and in vivo are increasingly explored. Nevertheless, despite these advances, invasive fungal 
infections remain difficult to diagnose and to manage, and there is a continuing need for 
improved antifungal therapy. 
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1.1 Pharmacological Need for Novel Antifungal Compounds 
Members of the genera Candida and Aspergillus most commonly cause invasive fungal 
infections. For example, the incidences of invasive Candida and Aspergillus infections in bone 
marrow transplant recipients are 10-15% and 3-7% respectively, and the mortality rate is 60-
95%18a. Overall, Candida infections are the fourth most common type of nosocomial 
bloodstream infection in the United States and have a higher mortality rate (33-47%) than any 
other bloodstream infection18b. Furthermore, there has been a 14-fold increase in the frequency 
of opportunistic invasive fungal infections from 1980-1992 in the United States and Europe19. 
This increase in incidence of invasive fungal infections in immunocompromised 
individuals is largely attributed to medical advancements in the treatment of these patients, 
especially in the management of bacterial infections. It has been estimated that the development 
of antibiotics has increased the life expectancy of humans by ten years20. Although physicians 
have had success in increasing the life expectancy of immunocompromised patients by treating 
bacterial infections, they are now struggling to treat the resulting opportunistic invasive fungal 
infections. Just as antibiotic resistant bacteria appeared soon after the introduction of the first 
antibiotics, the problem of antifungal resistance has been emerging as the use of existing 
antifungal agents has increased in response to increasing incidences of life-threatening fungal 
infections. 
In order to avert the problem of antimicrobial resistance, the successful management of 
fungal infections requires a large number of antifungal agents belonging to a wide variety of 
classes with different mechanisms of action. Additionally, the patients most at risk for invasive 
fungal infections are typically taking several medications to treat the underlying diseases causing 
their neutropenia (a hematological disorder characterized by abnormally low number of 
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neutrophils, the most important type of white blood cell). Therefore, it is also important that 
physicians have access to a large number of antifungal medications to improve their chances of 
finding one that is both effective for treating the infection and will not interact with other 
medications the patient may be taking. Unfortunately, due to increased resistance and the 
emergence of new opportunistic infections, there is still a dire need for the development of new 
antifungal compounds. As of 2000, there were only ten medications approved by the U.S. Food 
and Drug Administration (FDA) for use in the treatment of invasive fungal infections and these 
drugs belong to only three classes: polyenes, pyrimidines, and azoles. 
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1.2 Classes of antifungal compounds: 
1.2.1 Polyenes: The broad-spectrum polyene antifungal amphotericin B (Fig.2) was an early 
mainstay for the treatment of various types of invasive antifungal infections. Amphotericin B 
binds strongly to ergosterol, the principal sterol in fungal cell membranes. The preferential 
binding of Amphotericin B to ergosterol results in the formation of a membrane pore, which 
leads to leakage of ions from the internal of the cell. This ultimately results in the disruption of 
the osmotic integrity of the fungal cell and leads to cell death21. The polyene, nystatin (fig.1.2) 
was originally isolated from Streptomyces noursei in 1951 is a conjugated tetraene, it was first 
clinically useful polyene antifungal 22. Natamycin, another polyene, was isolated from cultures of 
Streptomyces natalensis intended for the treatment of fungal conjunctivitis, blepharitis and 
keratitis.  
 
Figure 1.2 Antifungal Polyenes. 
1.2.2 Azoles: The azoles are the largest class of synthetic antimycotics and account for 
approximately 20 antifungal agents on the market today. The class itself can be broken down into 
two subdivisions, the imidazoles and the triazoles.  The first members of the class were highly 
substituted imidazoles (clotrimazole, miconazole). Imidazole antifungals were not absorbed 
orally and were primarily formulated for topical use, usually because of toxicity or 
bioavailability problems that limited their potential as systemic agents. However the imidazole 
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Ketoconazole was introduced in 1984 and was the first effective oral therapy in the class of 
imidazoles for treatment of Candida spp. Subsequently, the triazoles Itraconazole and 
Fluconazole (Fig.3) were developed as more potent azoles that are more potent azoles that are 
less toxic and provide effective oral therapy for many systemic fungal infections23. Since then, 
triazoles remain the mainstay of treatment for antifungal infections and their development is 
currently ongoing. Posaconazole and Voriconazole (Fig. 1.3) represent specific advances in the 
understanding of the SAR for the antifungal azole class, as evident by their progression over past 
30 years. Albaconazole (UR-9825) is currently under development by Stiefel under licence from 
its dicoverer, Uriach 24. Isavuconazole (BAL-4815) is undergoing development in the form of 
orally active, Isavuconazole is currently in phase-III clinical trials 25.  
 
Figure 1.3 Antifungal Azoles. 
1.2.3 Sordarins: Sordarins are semi-synthetic natural products shown to have antifungal activity 
in early 1970s 26. Sordarin R-135853 (Fig.4) has shown in vivo efficacy in various experimental 
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models of candidiasis27. FR290581 is a sordarin derivative that in under development has shown 
excellent antifungal activity against Candida albicans28. (Fig. 1.4) To date, neither compounds 
has made it through FDA, and are currently not available as a drug. 
 
Figure 1.4 Antifungal Sordarines. 
1.2.4 Echinocandins: The echinocandins are fungal secondary metabolites comprising a cyclic 
hexapeptide core with a lipid side-chain responsible for antifungal activity. Random screening in 
the 1970s discovered antifungal activity in the prototypes, echinocandin B and aculeacin A. A 
modified form of echinocandin B, cilofungin, was developed to the point of phase 2 trials, but 
was abandoned when its formulation showed toxicity to patients 29. In the late 1990s, three 
echinocandin-class compounds, anidulafungin, caspofungin and micafungin, all entered clinical 
development. The three-dimensional configuration of all three molecules is similar. A central, 
common core bears a long, ‘gun-barrel’-like side chain known to be a determinant of the 
spectrum of susceptible species (Fig.1.5), and a hydroxylated side chain that appears opposite the 
‘gun barrel’ in flat structural representations but is adjacent in energy-minimized 3-D structures.  
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Figure 1.5 Antifungal Echinocandins. 
The FDA approved caspofungin in 2001 for therapy of aspergillosis. The echinocandin 
spetrum excludes some pathogenens such as Cryptococcus neoformans, Fusarium spp. and 
Scedosporium spp. However, they are active against the opportunistic pathogen Pneumocystis 
jiroveci. All of the three new echinocandins can only be administered by intravenous injection, 
which also restricts their use 30. 
1.2.5 Saponins: The saponin is a family of natural product compounds that shows promise in the 
identification of novel antifungal compounds. They are divided based on the structure of their 
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combination of glucose, arabinose, glucuronic acid, rhamnose, or xylose 31. 
 
 
Figure 1.6 Classes of saponin. 
 
Saponins are named after one of their most notable characteristics, their amphiphilicity 
due to the lipophilic steroidal moiety and the hydrophilic oligosaccharide moiety32. Many plants 
produce saponins as secondary metabolites that primarily serve as antimicrobial agents and 
traditionally it was believed that plants were the only natural source of saponins. More recently, 
however, biologists have discovered that saponins are also abundant in many marine animals, 
most notably in echinoderms, but they also appear occasionally in higher animals such as fish.33 
Saponins have a wide range of biological activity that goes beyond their antimicrobial 
roles to include hypocholesterolemic, anti-inflammatory, anti-diabetic, anti-allergenic, 
immunomodulatory, anti-hepatotoxic, and anti-cancer capabilities34. It has been shown that both 
the aglycone and oligosaccharide moieties of saponins are important for their biological 
activity.35-39 While the effectiveness of saponins has been recognized for centuries in herbal 
medicine, they were not typically viewed as potential drug targets in the past due to their 
structural complexity. One exception is digoxin (Fig.1.7), a cardiac glycoside that has been 
isolated from the leaves of the foxglove plant Digitalis lanata and marketed for over 200 years to 
treat congestive heart failure. Digoxin binds to Na+/K+ ATPase pumps in cardiac cell 
membranes. This alters the membrane potential by changing the concentrations of ions and 
ultimately leads to an increase in the strength of the contraction of the cardiac muscles.34 
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Unfortunately, digoxin is an unusual saponin. Its availability is only by isolation from natural 
sources in sufficient quantities for distribution. Even so, recent advances in the synthesis of 
glycoconjugates allowed further exploration of additional medicinal uses for saponins.  
 
 
Figure 1.7 Antifungal saponins. 
 
In fact, saponins have drawn much attention in recent years owing in large part to OSW-1 
(Fig.7); a steroidal saponin isolated from bulbs of the lily plant Ornithogalum saudersiae. OSW-
1 shows in vitro anti-tumor activity levels that are 10-100 times more effective than many well-
known anticancer compounds including taxol and cisplatin40. Furthermore, this saponin has the 
potential to be effective against cancers that are resistant to currently available chemotherapy 
because it has an unusual mechanism of action. Upon entering a cancer cell, OSW-1 causes 
damage to the mitochondrial membranes, which in turn disrupts the calcium levels in the 
cytoplasm of the cell and ultimately causes cell death by apoptosis. Like OSW-1 many other 
saponins have also been well documented to possess potent in vitro antifungal properties. For 
example, a derivative of the triterpene medicagenic acid (Fig.1.7), which was isolated from 
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guinea pigs and did not show dermal toxicity in rhesus monkeys. It also showed promise toward 
the treatment of invasive fungal infections by successfully treating Cryptococcus neoformans 
infections in mice with a minimal inhibitory concentration of 4 µg/mL. This saponin was also 
effective against amphotericin B-resistant strains of Candida tropicalis41. It was synthesized in 
three steps from medicagenic acid and acetobromomaltose in 49% overall yield.41  
With respect to the scope of this work, CAY-1 is an important newly identified saponin 
that has the potential to be effective in the treatment of invasive fungal infections (Fig.1.8). 
CAY-1 was isolated in 0.1 % yield from the fruit of the cayenne pepper plant, Capsicum 
frutescens. Sufficient quantities of CAY-1 were available by this isolation from cayenne pepper 
plant in order to perform preliminary testing for antifungal activity and cytotoxicity toward 
mammalian cells42. Following these preliminary studies- CAY-1 was shown to be an effective 
antifungal agent against sixteen fungal strains of Candida species, Aspergillus fumigatus, 
Cryptococcus neoformans, and Neurospora crassa. Further, each of these strains are human 
pathogens known to cause invasive fungal infections in immunocompromised patients. The most 
promising result was the activity of CAY-1 against C. neoformans (IC90 < 1µg/mL), a fungal 
species responsible for cryptococcal meningitis in HIV/AIDS patients, a fatal disease if left 
untreated.43 
 
 
Figure 1.8 Structure of antifungal saponin CAY-1. 
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CAY-1 was tested in vitro for cytotoxicity against 55 mammalian cell lines. Nevertheless 
given these preliminary results, we opted to use CAY-1 as a model saponin for the development 
of the project. 
1.3 Antifungal Agents: Mode of Action: 
Of the given antifungals on the market today, there are a number of mechanism of action, 
all of which have selective toxicity for the fungal cell over the mammalian cell. In terms of 
number of classes of antifungal agents that can be used to treat life-threatening mycoses, the 
targets are highly focused, directly or indirectly, on the cell envelope (wall and plasma 
membrane), and particularly on the fungal membrane sterol, ergosterol, and its biosynthesis.   
1.3.1 Polyene antifungal agents 
Amphotericin B has for many years been the only antifungal polyene that can be 
administered systemically to treat a visceral infection. Its mode of action is atypical for an 
antimicrobial molecule: instead of inhibiting an enzyme, it binds to ergosterol, the principal 
sterol in fungal membranes (Fig.1.9), thereby perturbing membrane function to the point of 
causing leakage of cellular contents. The precise way in which this fungicidal effect occurs still 
remains unclear. The ergosterol molecule of fungi has a cylindrical three-dimensional structure, 
unlike cholesterol, the major sterol in mammalian membranes, which has a sigmoid shape11. This 
conformational difference is probably sufficient to explain the greater binding affinity of 
amphotericin B for ergosterol over cholesterol. 
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Figure 1.9 Schematic representation of the interaction between amphotericin B and ergoesterol in fungal 
cell membrane.53 
 
 
Figure 1.10 Mode of action of  antifungals. a)Echinocandins and nikkomycin Z inhibit the formation of the fungal 
cell wall. b) Sordarins interfere with protein assembly. c) Azoles, polyenes and terbinafine disrupt the fungal cell 
membrane. d) Flucytosine interferes with DNA synthesis. Antibodies and vaccines prevent fungal infection or block 
and/or destroy the fungal cells.13 
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low and suggests that amphotericin B can be toxic to mammalian cells. Binding to a sterol leaves 
the amphoteric amphotericin B molecule with its hydrophilic edge unbalanced relative to the 
larger hydrophobic portion of the complex. Almost certainly, such a complex when formed in a 
membrane will migrate to align the hydrophilic faces within aggregations of complexes, thus 
creating areas of local tension within the membrane. The mechanism of action correctly predicts 
that amphotericin B will act on a broad spectrum of fungal species. As predicted on the basis of 
its mechanism of action, amphotericin B is toxic to mammalian cells, particularly causing 
nephrotoxicity46. This was observed from the earliest days of clinical use of the drug. To 
overcome amphotericin B toxicity, a variety of reformulated versions of the agent have been 
introduced. These reformulations reduce nephrotoxicity by slowing the rate at which 
amphotericin B is delivered to the kidneys.  
The most successful, clinically proven versions of novel formulations are based on lipid 
combinations with amphotericin B, encapsulated in liposomes or in ribbon-like and disc-like 
lipid complexes. Other formulations are under investigation, including an amphotericin B – 
cochleate preparation and an arabinogalactan complex. The antifungal polyene nystatin  is also 
being developed in a liposomal formulation for systemic use. 
1.3.2 Antifungal azoles 
Imidazoles and triazoles (‘azoles’) are the largest class of antifungal agents in clinical 
use. Their main effect is to inhibit 14α-demethylation of lanosterol in the ergosterol biosynthetic 
pathway47, but in some fungal species, they can also inhibit the subsequent Δ22-desaturase step 
(Fig.1.11) 48. With ergosterol depleted and replaced with unusual sterols, the normal permeability 
and fluidity of the fungal membrane is altered, with secondary consequences for membrane-
bound enzymes, such as those involved in cell wall synthesis49. Antifungal azoles bind to the 
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iron atom via a nitrogen atom in the imidazole or triazole ring. The remainder of the azole 
molecule binds to the apoprotein in a manner dependent on the individual azole’s structure. The 
exact conformation of the active site differs between fungal species and amongst the many 
mammalian P450 mono-oxygenases (P450 mono-oxygenases are heme protein-dependent mixed 
function oxidase systems that utilize NADPH and/or NADH to reductively cleave atmospheric 
dioxygen to produce a functionalized organic substrate and a molecule of water). The precise 
nature of the interaction between each azole molecule and each kind of P450 therefore 
determines the extent of the azole’s inhibitory effect in different fungal species. A triazole 
nucleus has replaced imidazole in the active pharmacophore, to enhance the specificity of 
binding to fungal P450. For molecules derived from the fluconazole prototype, the inclusion of 
an α-O-methyl group confers activity against Aspergillus species and many other filamentous 
fungi. For molecules derived from the ketoconazole prototype, extension of the side chain 
enhances binding of the azole to the P450 apoprotein. The principal molecular target of azole 
antifungals is a cytochrome P450 – Erg11p or Cyp51p, according to different gene-based 
nomenclatures, which catalyzes the oxidative removal of the 14α-methyl group of lanosterol 
and/or eburicol in fungi by a typical P450 mono-oxygenase activity53. This protein contains an 
iron protoporphyrin moiety located at the active site, and the structural differences might seem 
small, but they dictate antifungal potency and spectrum, bioavailability and drug interaction and 
toxic potential – very important considerations for compounds that bind to heme groups in 
P450s. Voriconazole, which is the first approved and so far the most fully characterised of the 
three new triazoles, enjoys a very broad spectrum of target fungal species and, like itraconazole, 
is even fungicidal against some isolates of filamentous species. Furthermore, it shows activity 
against the hard-to-treat Fusarium and Scedosporium infections.  
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However, there is a long list of other drugs with which voriconazole interacts (similar to 
the list for itraconazole), including some immunosuppressants, benzodiazepines, prednisolone, 
digoxin and other drugs in common use, which can cause problems for physicians treating 
seriously ill patients who receive multiple medications. Posaconazole also acts against a broad 
spectrum of susceptible fungi, and shows interestingly promising efficacy against 
coccidioidomycosis in preclinical studies. Ravuconazole, with an identical pharmacophore but a 
longer side-chain than voriconazole, stands out for its unusually long plasma half-life in humans.  
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Figure 1.11 Ergosterol bio-synthetic pathway. Steps at which various antifungal agents exert their inhibitory 
activities are shown. FLU, fluconazole; ITRA, itraconazole; VOR, voriconazole.53 
 
1.3.3 Echinocandins 
The target for the echinocandins is the complex of proteins responsible for synthesis of 
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complex is involved. There is no doubt that the component to which echinocandins bind is 
Fks1p, but their non-competitive inhibitory effects on glucan synthesis do not necessarily imply 
that Fks1p itself is the catalytic subunit, nor is it clear whether the echinocandin-binding site on 
Fks1p is external or internal to the cell membrane. 
 
 
                               Figure 1.12 The transmembrane complex of two proteins, Fks1p and Fks2p,  
involved in synthesis of β-1:3 glucan in the cell walls of Saccharomyces cerevisiae.11 
 
The rationale is similar to that used to treat tuberculosis and HIV infection, in which effects on 
two or more disparate targets are a better guarantee of clinical efficacy than effects on a single 
target. So far, resistance to caspofungin has only appeared by mutation of the FKS1 gene in C. 
albicans29. The known fungal efflux pumps do not export the drug. 
1.3.4 Sordarins 
Sordarins inhibit protein synthesis by blocking the function of fungal translation 
Elongation Factor 2. Interest in sordarins was increased as a result of a prospective screen for 
inhibitors of C. albicans protein synthesis in vitro, which pinpointed the nature of the sordarin 
antifungal effect. When refined research work revealed EF2 as the specific target of the 
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sordarins, the result engendered surprise because C. albicans EF2 displays more than 85% amino 
acid sequence identity to the human equivalent, and EF2 would never have emerged as a 
potential target from genomics-based screening50. Different sordarin derivatives have different 
spectra of susceptible species, for reasons that are not yet clear. This might reflect problems of 
penetration of these agents into target fungi. Nevertheless, their high specificity for the fungal 
target and the relative ease with which new sordarin variants can be synthesized holds promise 
for positive future developments with this series. 
1.3.5 Saponins 
Saponins are known to alter the permeability of fungal cell membranes, which allows 
intracellular components to leak out of the cell and ultimately causes cell death31a. This was 
demonstrated with CAY-1 by treating N. crassa spores with [14C]-alpha-amino- isobutyric acid. 
The radioactivity remaining in the cells after treatment with 25 μg/mL of CAY-1 was measured 
using a liquid scintillation counter and compared to controls that were dosed with 
dimethylsulfoxide (DMSO) (Fig.1.13). The results show that the radioactivity in the treated cells 
decreased significantly after five minutes, suggesting that the integrity of the cellular membranes 
had been compromised.31a 
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Figure 1.13 The effect of CAY-1 (20 µM) compared to DMSO controls on fungal cell permeability.31a 
 
 However the exact mechanism by which saponins alter the permeability of fungal cell 
membranes is not clear. The tendency of saponins to bind to steroids suggests that antifungal 
saponins, which are not toxic toward mammalian cells may bind preferentially to ergosterol, the 
major sterol component in fungal cell membranes, rather than cholesterol, the major sterol 
component in mammalian cell membranes (Fig. 1.14)31b. Once bound, the sterol-saponin 
complexes may aggregate to create pores in the membrane or to extract the sterol components 
from the membrane. Evidence to support the formation of pores in fungal membranes upon 
exposure to saponins has been provided by electron microscopic analysis. 
The mechanism of saponin resistance may vary. Whereas saponin resistance can be 
conferred by non-degradative mechanism, a number of pathogenic fungi degrade the saponins of 
their respective host plants, usually by hydrolysis of sugar molecule from the sugar chain 
attached at C-3 of the saponin backbone. 
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Figure 1.14 Proposed mechanism for membrane disruption by saponins. 31b 
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1.4 Mechanisms of resistance to azoles 
 
As noted above, there are as yet no reports of modification of azole antimicrobials as a 
mechanism of resistance. Resistant strains therefore either exhibit a modification in the quality or 
quantity of target enzyme, reduced access to the target, or some combination of these 
mechanisms. These mechanisms are discussed in detail below and are summarized in Fig.15.53 
Several lines of evidence implicate a modification in the quantity or quality of 14α-demethylase 
in the expression of resistance to azole antifungal agents. A recent study examined the 
biochemical mechanisms for resistance to fluconazole by comparing sterol composition, 
fluconazole accumulation, and inhibition of 14α-demethylase by fluconazole in two clinical C. 
krusei strains (expressing intrinsic resistance to fluconazole) and a susceptible C. albicans 
isolate51. No significant differences in the sterol content of C. krusei and C. albicans were 
detected (ergosterol was the major sterol in both species). Studies performed on cell extracts in- 
dicated that the concentration of fluconazole required to inhibit the synthesis of ergosterol by 
50% was approximately 24 to 46-fold higher in C. krusei than in C. albicans, suggesting that 
affinity of the target enzyme is different in the two species51. A comparison of fluconazole 
accumulation by C. albicans and C. krusei indicated that fluconazole accumulation in the first 60 
min was similar in all study strains. However, analysis after 90 min of incubation revealed that 
C. krusei accumulated 60% less fluconazole than did C. albicans, implicating active efflux in the 
fluconazole resistance expressed by these C. krusei strains. The potential coexistence of two 
resistance mechanisms precludes a precise calculation of the level of resistance contributed by 
the low-affinity 14α-demethylase. Over expression of 14α-demethylase has also been implicated 
as a mechanism of resistance to azole antifungals. Vanden Bosse et al. characterized as azole-
resistant C. glabrata strain and showed that its ergosterol content was increased compared with 
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that of the permanent isolate. This increase was accompanied by a decrease in susceptibility to 
both azoles and amphotericin B52.  
 
 
Figure 1.15 Mechanisms by which microbial cell might develop resistance. 1, The target enzyme is overproduced, 
so that the drug does not inhibit the biochemical reaction completely. 2, The drug target is altered so that the drug 
cannot bind to the target. 3, The drug is pumped out by an efflux pump. 4, The entry of the drug is prevented at the 
cell membrane/cell wall level. 5, The cell has a bypass pathway that compensates for the loss-of-function inhibition 
due to the drug activity. 6, Some fungal “enzymes” that convert an inactive drug to its active form are inhibited. 7, 
The cell secretes some enzymes to the extracellular medium, which degrade the drug.53 
 
Prevention And Control of Antifungal Resistance 
Strategies to avoid and suppress the emergence of antifungal resistance have not been 
defined. However, approaches analogous to those recommended for antibacterials could be 
suggested54-55. These measures include  
(i) Prudent use of antifungals. 
(ii) Appropriate dosing with emphasis on avoiding treatment with low antifungal dosage.  
(iii) Therapy with combinations of existing agents.  
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(iv) Treatment with the appropriate antifungal.  
(v) Use of surveillance studies to determine the true frequency of antifungal resistance.  
It should be emphasized that data supporting the use of the suggested measures is largely 
lacking, and ongoing studies may provide some specific guidelines in the near future. 
Additionally, advances in rapid diagnosis of fungi may be helpful in reducing the use of inap- 
propriate antifungals to treat organisms that are resistant to a particular agent 56. 
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1.5 Fungal Strains for antifungal assay 
The kingdom fungi include yeasts, molds, rusts and mushrooms. Fungi, like animals, are 
hetrotrophic, that is, they obtain nutrients from environment, not from endogenous sources (like 
plants with photosynthesis). Most fungi are beneficial and are involved in bio-degradation; 
however, a few can cause cutaneous infections if they are introduced into the skin through 
wounds, or into the lings and nasal passages if inhaled. To enter the alveolar spaces of the lungs 
and establish pulmonary infection, an organism must produce viable forms smaller than 4µm in 
diameter. Organisms that cause opportunistic infections will not gain a foothold in healthy 
individuals, but in immunocompromised they can cause serious, sometimes life-threatening 
infections.  
Table-1.1: Fungal diseases, symptoms and causing agents.  
Opportunistic Infections Causative agent Target Organs 
Candiaisis, Thrush, 
Vulvovaginitis 
Candida albicans GI tract and vagina 
Cryptococcal meningitis Cryptococcus neoformans Lung infection, Mainly affects 
CNS 
Aspergillosis Aspergillus sp. Lung, brain, sinuses and other 
organs 
Mucormycosis Murcor sp. Sinuses, eyes, blood and brain 
Penumocystis carinii pneumonia Penumocystis carinii Lungs (especially in HIV 
patients) 
Candiaisis, Thrush, 
Vulvovaginitis 
Candida glabrata GI tract and vagina 
 
Patients susceptible to these infections include individuals with leukemia and other blood 
diseases, cancer, HIV and other immunodeficeincies, and diabetes. These organisms can be 
found throughout U.S.  
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Taking these facts into consideration we decided to do antifungal assay on four different fungal 
strains that are central cause for most of the immunocompromised fungal infection. Fungal 
species for our study are following: 
1.5.1 Candida albicans: Candida albicans is a diploid fungus (a form of yeast) and a causal 
agent of opportunistic oral and genital infections in humans (Fig.1.16). Systemic fungal 
infections (fungemias) have emerged as important causes of morbidity and mortality in 
immunocompromised patients (e.g., AIDS, cancer chemotherapy, organ or bone marrow 
transplantation). C. albicans biofilms readily form on the surface of implantable medical devices. 
In addition, hospital-acquired infections in patients not previously considered at risk (e.g., 
patients in an intensive care unit) have become a cause of major health concern. C. albicans is 
commensal and is found among the gut flora, the many organisms that live in the human mouth 
and gastrointestinal tract. Under normal circumstances, C. albicans lives in 80% of the human 
population with no harmful effects, although overgrowth results in candidiasis57. Candidiasis is 
often observed in immunocompromised individuals such as HIV-positive patients. Candidiasis 
also may occur in the blood and in the genital tract. Candidiasis, also known as "thrush", is a 
common condition, usually easily cured in people who are not immunocompromised. To infect 
host tissue, the usual unicellular yeast-like form of C. albicans reacts to environmental cues and 
switches into an invasive, multicellular filamentous form57. 
 
Figure 1.16 Candida albicans.57 
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1.5.2 Cryptococcus neoformans: Cryptococcus neoformans usually grows as yeast (unicellular) 
and replicates by	   budding. Under certain conditions, both in nature and in the laboratory, C. 
neoformans can grow as a filamentous fungus. When grown as yeast, C. neoformans has a 
prominent capsule composed mostly of polysaccharides. Microscopically, the India ink stain is 
used for easy visualization of the capsule. The particles of ink pigment do not enter the capsule 
that surrounds the spherical yeast cell, resulting in a zone of clearance or "halo" around the cells. 
This allows for quick and easy identification of C. neoformans. They are encapsulated fungal 
organism that can cause disease in apparently immunocompetent, as well as 
immunocompromised, hosts58. Most susceptible to infection are patients with T-cell deficiencies. 
Organism enters the host by the respiratory route in the form of dehydrated haploid yeast or as 
basidospores. After sometime in lungs, the organism hematogenously spreads to extrapulmonary 
tissues; since it has a predilection for the brain. Infected persons usually contract 
meningoencephalitis. If untreated, cryptococcal meningoencephalitis is 100% fatal, and even if 
treated with most effective antifungal drugs, cryptococcal infections can be fatal if the host doest 
not have adequate T-cell-dependent immune function.58 
 
 
Figure 1.17 Proposed means of infection by Candida neoformans.58 
In high glucose and salt conditions that may be found in the nature Cryptococcus 
neoformans becomes un-capsulated. The small size is necessary for the organism to get into the 
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Synopses
To be classified as a pathogen, an organism
must be able to cause infection under certain
conditions. By this definition, C. neoformans can
certainly be classified as a pathogen. Because the
immunodeficient are more susceptible than the
immunocompetent to infection with this yeast-
like organism, C. neoformans is frequently
referred to as an opportunistic pathogen. The
factors that make C. neoformans a pathogen can
be divided into two major groups. The first
comprises the basic characteristics needed to
establish an infection and survive in the human
host; the second comprises the virulence factors
that affect the degree of pathogenicity.
Basic Characteristics for Pathogenicity
The Infectious Particle
To enter the alveolar spaces of the lungs and
establish pulmonary infection, an organism must
produce viable forms smaller than 4 µm in
diameter. The typical vegetative form of C.
neoformans is the yeast form with a cell diameter
of 2.5 µm to 10 µm. The organism can also
undergo sexual reproduction, and since it is a
basidiomycete (Filobasidiella neoformans), it
forms basidiospores. Sexual reproduction ap-
pears to occur much less frequently in nature
than asexual or vegetative reproduction. The
sexual spores (basidiospores) are approximately
1.8 µm to 3 µm in diameter and result from crosses
of the !- and a-mating types on an appropriate
medium (1). Although the exact nature of the
infectious particles of C. neoformans is not
known, they are presumed to be the dehydrated
yeast cells or basidiospores of the appropriate
size range to get into the lungs. Once inside the
lungs, the yeast cells become rehydrated and
acquire the characteristic polysaccharide capsule
(Figure 2). In the case of basidiospores, they
would convert to encapsulated blastoconidia.
Recently, Wickes et al. (5) reported that the
!-mating type of C. neoformans can produce
monokaryotic hyphae on a solid medium without
a nitrogen source or water. The monokaryotic
hyphae contain clamp connections and basidia
with short chains of basidiospores and are similar
in all respects except in nuclei number to the
dikaryotic hyphae of the sexual forms (5). The
haploid fruiting bodies formed by nitrogen-starved
!-mating type isolates also produce abundant
amounts of blastoconidia, which on the appropri-
ate medium can produce haploid hyphae (5).
None of the a-mating type strains tested
produced the haploid fruiting bodies. Backcross
studies indicated that the ability to undergo
haploid fruiting lies within (or is tightly linked to)
the MAT! locus, which is responsible for the !-
mating type phenotype (5). These results suggest
basidiospores from the monokaryotic hyphae
may be another source of the infectious particle in
nature. Regardless of the nature of the infectious
particle (yeast cell or basidiospore), if a cryptococcal
isolate is not able to produce small infectious
particles, it cannot be pathogenic under the usual
conditions for establishing the disease.
Mating Types
Kwon-Chung and Bennett (6) surveyed the
mating types of C. neoformans isolates from
environmental and clinical sources and found a
30- to 40-fold higher frequency of !-mating type
than a-mating type. The skewed ratio of !-mating
type to a-mating type was not thought to be due to
a genetic preponderance towards !-mating type
progeny because crosses between two test strains
resulted in a 1:1 ratio of !-mating and a-mating
type progeny (7). To examine the reason for the
disparate ratio, Kwon-Chung and colleagues (8)
constructed a pair of congenic strains of C.
neoformans that differed only in their mating
type. Survival studies with these congenic strains
demonstrated that the !-mating type (B-4500)
was significantly more virulent than the a-
mating strain (B-4476) when injected intrave-
nously into mice (8). Eighty percent of mice
infected with 106 B-4500 (!-mating type) were
Figure 2. Proposed means of infection by C.
neoformans.
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may be another source of the infectious particle in
nature. Regardless of the nature of the infectious
particle (yeast cell or basidiospore), if a cryptococcal
isolate is not able to produce small infectious
particles, it cannot be pathogenic under the usual
conditions for establishing the disease.
Mating Types
Kwon-Chung and Bennett (6) surveyed the
mating types of C. neoformans isolates from
environmental and clinical sources and found a
30- to 40-fold higher frequency of !-mating type
than a-mating type. The skewed ratio of !-mating
type to a-mating type was not thought to be due to
a genetic preponderance towards !-mating type
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alveolar spaces in the lungs. Once in the lungs the organism can become rehydrated and acquire 
the thick polysaccharide capsule (fig.1.17) 58. 
1.5.3 Candida glabrata: 
Candida glabrata is haploid yeast of the genus Candida previously known as Torulopsis 
glabrata. This species of yeast is non-dimorphic and no mating activity has been observed. Until 
recently, C. glabrata was thought to be a primarily non-pathogenic organism59. However, with 
the ever-increasing population of immunocompromised individuals, trends have shown C. 
glabrata to be a highly opportunistic pathogen of the urogenital tract, and of the bloodstream 
(Candidemia). Historically, Candida glabrata has been considered a relatively nonpathogenic 
saprophyte of the normal flora of healthy individuals, rarely causing serious infection in humans. 
However, following the widespread and increased use of immunosuppressive therapy together 
with broad-spectrum antimycotic therapy, the frequency of mucosal and systemic infections 
caused by C. glabrata has increased significantly. In fact, depending on the site of infection, C. 
glabrata is often the second or third most common cause of candidiasis after C. albicans. C. 
glabrata infections can be mucosal or systemic and are common in abnormal hosts (e.g., 
immunocompromised persons or those with diabetes mellitus). In contrast to other Candida 
species, C. glabrata is not dimorphic; consequently, it is found as blastoconidia both as a 
commensal and as a pathogen (Fig.1.18). C. glabrata infections are difficult to treat and are often 
resistant to many azole antifungal agents, especially fluconazole. Consequently, C. glabrata 
infections have a high mortality rate in compromised, at-risk hospitalized patients. 
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Figure 1.18 59Endoscopic appearance of Candida glabrata esophagitis grade II of Wilcox (A) demonstrating white 
plaques and exudate characteristic of Canadida esophagitis and direct examination of the lesion clarified with 20% 
potassium hydroxide solution showing numerous blastoconidia (B). 
 
 
C. glabrata, together with other Candida species, belongs to the class Fungi Imperfecti, the order 
Moniliales, and the family Cryptococcaceae. C. glabrata is a nondimorphic yeast that exists as 
small blastoconidia under all environmental conditions as a pathogen.  
 
1.5.4 Aspergillus fumigatus: Aspergillus fumigatus is a fungus of the genus Aspergillus, and is 
one of the most common Aspergillus species to cause disease in individuals with an 
immunodeficiency disease60. A. fumigatus, a saprotroph widespread in nature, is typically found 
in soil and decaying organic matter, such as compost heaps, where it plays an essential role in 
carbon and nitrogen recycling. Colonies of the fungus produce from conidiophores thousands of 
minute grey-green conidia (2–3 µm) that readily become airborne (Fig.1.19). For many years, A. 
fumigatus was thought to only reproduce asexually, as neither mating nor meiosis had ever been 
observed. In 2008, however, A. fumigatus was shown to possess a fully functional sexual 
reproductive cycle, 145 years after its original description by Fresenius.60 
The fungus is capable of growth at 37°C/99 °F (normal human body temperature), and can grow 
at temperatures up to 50°C/122 °F, with conidia surviving at 70°C/158°F—conditions it 
regularly encounters in self-heating compost heaps61. Its spores are ubiquitous in the atmosphere, 
and it is estimated that everybody inhales several hundred spores each day; typically these are 
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quickly eliminated by the immune system in healthy individuals. In immunocompromised 
individuals, such as organ transplant recipients and people with AIDS or leukemia, the fungus is 
more likely to become pathogenic, over-running the host's weakened defenses and causing a 
range of diseases generally termed aspergillosis. 
 
Figure 1.19 Aspergillus fumigates.61 
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1.6 Specific Aims for the synthesis and biological assay of steroidal antifungals: 
The rationale for the research towards the synthesis of novel steroidal antifungal 
compounds is threefold. First, due to the difficulty in characterizing the structure of saponins 
isolated from nature, the synthesis of these compounds will provide verification for the precise 
structure and stereochemistry of the complex glycoconjugates.  
Second, the development of a practical synthesis of steroidal saponins will potentially 
provide a sample in sufficient quantity and purity to further explore its biological activity and 
medicinal utility as well as its mechanism of action. While the isolated yield of most of the 
naturally occurring saponins from the plant is exceptionally low, the laborious isolation process 
has limited their availability in sufficient quantity and purity for additional biological testing. 
Finally, a practical synthetic strategy would also allow for the opportunity to synthesize 
various derivatives of saponins, which could be investigated in the future in structure- activity 
relationship studies. Since CAY-1 is only one of many biologically active saponins contained in 
the epithelial cells of the Capsicum frutescens plant, it is likely that the synthesis of structurally 
similar saponins will yield other biologically active compounds. Simple oligosaccharide 
derivatives of aglycone moiety of CAY-1 will also be explored for antifungal activity in search 
of possibly more active compounds, which might have a much simpler structure.  
Perform antifungal assay for various steroidal derivatives synthesized against four 
pathogenic fungal strains Candida albicans, Aspergillus fumigates, Candida glabrata and 
Cryptococcus neoformans. Structure activity relationship studies will be done in order to get 
novel and highly active antifungal steroid based compounds. Cell line assay for active 
compounds will also be done for their toxicity in vitro. Preliminary effect of most active 
compounds on animal models like mice will be done depending on their toxicity results in vitro. 
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CHAPTER-2: SYNTHESIS OF CHOLESTANE AND ANDROSTANE DERIVATIVES 
 
As opportunistic fungal infections continue to represent continuous obstacles to individuals 
with compromised immune systems, the development of novel and efficient antifungal therapeutic 
agents that have the capability of broad-spectrum activity becomes inevitable1-3. Synthetic 
derivatives of natural steroids have become a promising approach for discovery of new antifungal 
agents. According to J. M. Brunel et al. the best antifungal in vitro activity for oxygenated 
cholesterol was observed for hydroxy ketones 1, 3 and 4 and diketone 6 exhibiting activity against 
S. cerevisiae and Candida albicans (Fig.2.1).4  
 
Figure 2.1 Oxygenated cholesterol derivatives reported for antimicrobial activity by J. M. Brunel et al.4 
 
Shamsuzzaman et al. have synthesized 6,5-fused steroidal oxazoles in cholestane series and 
tested for their inhibitory action against five different fungal strains and minimum inhibitory 
concentration (MIC) of all compounds were determined. (Scheme-2.1) All compounds 13, 14 and 
15 synthesized were active against all the five strains of fungi (Candida albicans, Candida 
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glabrata, Penicillium spp.,Fusarium oxyporium and Aspergillus niger) and both types of bacteria 
(Gram-positive and Gram-negative).5 
 
Scheme 2.1 6,5-fused steroidal oxazoles in cholestane series by Shamusuzzaman et al.5 
 
C. Loncle et al. have also explored a series of cholesterol-hydrazone derivatives for 
antifungal activity against human pathogens. The best results were reported for tosylhydrazone 
cholesterol derivatives 16 and 17 exhibiting activities against Candida albicans at a concentration 
of 1.5µg/ml (Scheme 2.2). 6  
 
Scheme 2.2 Synthesis of hydrazone derivatives of cholesterol by C. Loncle et al.6 
In addition, a number of fatty-acid derivatives have been characterized as antimicrobials and 
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antifungals yet fatty acid esters of cholesterol have not been explored exhaustively as potent 
therapeutic antifungal agents7-8. M. R. Banday et al. have reported synthesis and antifungal activity 
of eight different fatty acid derivatives of cholesterol and found that two of these compounds 18 and 
19 were having excellent antifungal activity. (Fig. 2.2) 8 
 
Figure 2.2 Active fatty acid analoges of cholesterol reported by M. R. Banday et al. 8 
 Finally, 2,3-functionalized steroids are well known compounds with potentially interesting 
biological properties9-12. Furthermore, proper functionalization of 2,3-steroids can be an important 
step in the development of building blocks for novel fatty-acid esters of cholesterol and other 
oxygenated and hydrazone-cholesterol derivatives. A novel approach to the synthesis of 2,3-
functionalized cholesterol and androstane derivatives needs to be developed which will be further 
explored and optimized for synthesis of tigogenin derivatives. As we had previously tried syntheses 
of tigogenin derivatives, after several attempts we were able to synthesize desired product in eight 
steps and the final step leads to two isomers, which was then purified. We figured out that there was 
an intensive need for development of simple and efficient synthetic procedure to prepare the desired 
derivatives in a stereo selective way.  
Since the starting material for this synthesis was hecogenin acetate which is a very expensive 
starting material we decided to develop synthetic methodology with a fairly inexpensive model 
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steroid molecule and then apply the optimized synthesis for tigogenin. We selected for cholesterol 
as our as our model compound to establish synthetic scheme, as it have the similar skeleton as our 
target saponin except the aliphatic chain in place of furan ring system in tigogenin. We also 
hypothesized that the spiral structure of the spirostandiol is not a pharmacophore and therefore can 
be totally removed, as in the case of androstane derivatives, or replaced by a hydrocarbon chain, as 
in the case of cholestane derivatives, to yield novel 2,3-functionalized targets that maintain the 
potential to elicit antifungal activity (Fig. 2.3) 
 
Figure 2.3 2α, 3β- Cholestane and Spirostane derivatives 
 
  Over the last few decades, many naturally occurring products have been deemed effective 
antimicrobial agents, including saponins, typically isolated from plant and marine species13-15. 
Synthetic modifications of cholesterol and other traditional steroid molecules have become a 
promising area for the exploration and development of novel antifungal agents, especially with 
respect to the development of fatty-acid esters of steroids. In addition, 2,3-functionalized steroids 
have potentially interesting biological properties and proper functionalization of 2,3-steroids can 
lead to the development of efficient syntheses of building blocks for novel fatty-acid esters of 
steroids. An efficient approach for the synthesis of 2,3-functionalized cholestane and androstane 
derivatives would be developed and further optimized for the synthesis of similar tigogenin 
derivatives. 
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G. A. G. Santos et al. have reported on synthesis of cholestane derivatives starting from 
commercially available 3β-hydroxy-5α-cholestane in four steps to get compound 24.16 (Scheme-
2.3) Although it gives us an idea about synthesis of cholestane derivative but we are not looking for 
the same isomer (2β, 3α) they synthesized instead our goal was to develop synthesis of 2α, 3β- 
isomer, more over we would like our end product to be selectively protected 2α, 3β-isomer in order 
to attach oligosaccharide moiety at C-3 position for the purpose of exploration of SAR in search of 
lead candidate for antifungal activity.  
 
Scheme 2.3 i) p-TsCl, pyridine; ii) LiCO3, LiBr, DMF; iii) m-CPBA, H2O-CH2Cl2; iv) H2SO4, THF.16 
 
2.1 Retro-analysis for 2α , 3β- Cholestane derivative: 
The retro-analysis of 2α, 3β- Cholestane derivative indicates that we could get it by 
reduction of carbonyl group of compound 37, which can be obtained in two different ways, Firstly 
by enolization and protecting enol group with TMS or acetyl group followed by epoxidation to form 
epoxide ring which can be opened in presence of acetic anhydride/acetic acid to get compound 
37(Scheme 2.4). Secondly leadtetraacetate in presence of acetic acid and acetic anhydride reflux 
HO
H
H
i
TsO
H
ii
H
iii
H
O
iv
H
HO
HO
20 21 22
2324
	   45	  
will stereoselectively form 37 from compound 26. Cholestane 26 can be obtained from cholesterol 
in two steps by reduction of double bond followed by oxidation of alcohol group at 2-position. 
 
Scheme 2.4 Retro-analysis of 2α, 3β-Cholestane derivatives 
 
2.2 Synthesis of Cholestane derivatives: 
Min Serk Kwon at el. have reported oxidation of alcohol to keto group by air oxidation in 
presence of a new aluminum hydroxide-supported palladium catalyst made by one-pot synthesis 
through nanoparticle generation and gelation shows dual activity for olefinic hydrogenation and 
aerobic alcohol oxidation. They were able to get cholestan-3-one from cholesterol very effectively 
(Scheme-2.5).17 It gave us an idea that we should be able to reduce the not easily accessible double 
bond in cholesterol, but conditions have to be found and optimized. However, we were not 
interested in using nanoparticle generation and gelation techniques in our synthesis for the shake of 
simplicity and expertise required to handle and characterize those materials. 
 
HO
H
Cholesterol
HO
O
RO
RO
O
O
AcO
H
HO
AcO
R= TMS  34 
      OAc  35
25
26
20
36
3738
	   46	  
 
Scheme 2.5 Synthesis of Chlestan-3-one by Min Serk et al.17a 
Our synthesis of the cholestane derivatives began with cholesterol  (25, Scheme-2.11), 
which is very inexpensive and commercially available in bulk quantities. The double bond of 25 
was then reduced by platinum dioxide catalyzed hydrogenation, which led to the formation of 
intermediate alcohol 20.17b The intermediate alcohol 20 was later oxidized by chromic acid (Jone’s 
oxidation) by following standard procedures.23 From this point, we then branched the synthetic 
scheme into two different paths; the first involved the direct introduction of an acetyl group into the 
2α-position with lead tetraacetate to generate 2α-acetoxycholestan-3-one (37, Scheme-2.11). This 
approach was inspired by a literature report for synthesis of 2α-acetoxy-3-ketone starting from 
lupan-3-one by A. D. Boul et al., they further explored the rearrangement of 2α-acetoxy-3-ketone 
into 3β-acetoxy-2-ketone under various conditions including treatment with alkaline alumina. 
(Scheme-2.6) The position of the acetoxy groups follows from the NMR results, also the equatorial 
conformations for these groups were suggested by high C=O stretching frequency in IR spectra.24, 25 
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Scheme 2.6 Synthesis of 2α-acetoxy-lupan-3-one and its rearrangement to 3β-acetoxy-lupan-2-one 
The second approach generated the same compound 37 using a three-step procedure 
(Scheme 2.11, steps iv–vi). Initially we tried enolization by lithium bis(trimethylsilyl)amide and 
trimethyl silyl chloride at -78oC in dry tetrahydrofurane to give compound OTMS protected enol in 
an isolated yield of 60% (Note- Purification by column chromatography should be done fast). 
Regioselective enolization 3-keto steroids have been reported by M. Sobukawa et al. and have very 
good selectivity of 9:1 for the desired regio-isomer 27(Scheme 2.7). 19  
  
Scheme 2.7 Regioselctive enolization of ketone 19 
TMS group was found to be cleaving while running column chromatography for 
purification; shortening the time for column purification helped to minimize this problem to certain 
extent. That was one of the reasons for low to moderate yield for this step of the synthesis. Since we 
already had issues with same strategy in case of spirostane derivatives synthesis and were hoping 
for some improvement, which didn’t happen in this case, so we decided to go for acetyl-enol 
protection instead of TMS to simplify and in hope to find a better way to achieving synthesis of 
desired cholestane isomers. 
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The first step of the alternative preparation of 37 is the synthesis of vinyl acetate 35 
(Scheme 2.11, step iv) using montomorillonite KSF clay was inspired by acid catalyzed enolization 
reported by Biswajit kalita et al. for the preparation of enol acetates from ketones using 
montmorillonite KSF clay at room temperature in excellent yields20 (Scheme-2.8). They also tried 
these reactions in microwave irradiation to dramatically reduce the reaction time. Very simple and 
mild conditions attracted our attention towards this method.  
 
Scheme 2.8 Synthesis of enol acetates using montmorillonite KSF clay.20 
  Stereoselective epoxidation of 35 with m-CPBA was done to obtain corresponding 
epoxide product 36 (Scheme 2.12, step v). Epoxidation of enolic double bond happens only from 
behind the plane in cholestane-based molecule as C-19 methyl group sterically hinders the top face 
of the steroid so epoxidation occurs from α-face nearly exclusively. (Scheme-2.9) This result is 
reasonable since epoxidations with m-CPBA generally occur from the least hindered side of the 
alkene.21, 22 
 
Scheme 2.9 Mechanism-stereo selective epoxidation 
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Vinyl acetate 35 have peak for H-2 proton at 5.23 ppm whereas after epoxidation H-2 peak 
moves to 3.38 ppm. Compound 35 have H-2 proton at 5.23 ppm which is up field compares to H-2 
proton in case of TMS-enol at 4.78 ppm as would be expected by having ester protection of enol 
instead of alcoholic TMS protection. (Fig. 2.4) 
 
Figure 2.4 1H-NMR for enolization and epoxidation 
Finally, epoxide ring opening was done by treatment with acetic acid and acetic anhydride 
to yield the desired compound 37. We have proposed Probable mechanism for epoxide ring opening 
by acetic acid and acetic anhydride involving esterification at the last step by acetic anhydride 
seems to be the reason for retained steroselectivity at C-2 position by acetyl group (Scheme-2.10). 
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The carbonyl group of acetyl gets protonated in first step followed by nucleophilic attack by actate 
ion on carbonyl carbon would give the acetal intermediate, which rearrange to give 2α-hydroxy 
cholest-3-one. Acid catalyzed esterification by acetic anhydride would give 2α-acetoxy-cholestan-
3-one (37). Streochemistry of compound 37 was confirmed by 1H-NMR showing a doublet of 
double at 5.25ppm which will be otherwise be a nice triplet for the 2β-acetoxy-cholestan-3-one due 
to coupling with two prochiral protons (Fig. 2.5). 
 
Scheme 2.10 Probable mechanism for epoxide ring opening by acetic acid and acetic anhydride  
 
Although longer, the alternative route through the preparation of vinyl ester 35 and 
epoxide 36 has an added advantage with respect to the purification of the product, and this 
method gave us comparable yields of 37 (Scheme-2.11). Moreover use of lead tetraacetate was 
avoided without much compromise of yield. Finally, to generate the 2,3-functionalized steroids, 
we followed a straightforward Luche’s reduction NaBH4/CeCl3 reduction of the carbonyl group 
at C-3 position gave desired 2α, 3β-Cholestane derivative, 38 in very good yield.26, 27  
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Scheme 2.11 i) PtO2/CH2Cl2-CH3CO2H; ii) CrO3/H2SO4; iii) (CH3CO)2O/ Montmorillonite clay; iv) m-
chloroperbenzoicacid CH2Cl2; v) (CH3CO)2/N(C2H5)3; vi) Pb(O2CCH3)4/(CH3CO)2O-CH3CO2H; vii) 
CeCl3x7H2O/CH3OH/tetrahydrofuran/NaBH4; viii) NaOH/CH2Cl2/CH3OH; ix) succinic anhydride/pyridine. 30 
 
The acetate ester hydrolysis of 38 gave hydrolyzed product 42 which was clearly evident 
from 1H-NMR, multiplet for H-2 proton have shifted from 4.8 to 3.6 ppm and singlet for acetyl 
group at 2.23 ppm have vanished completely in the compound 42 (Fig. 2.5). Succinic acid 
derivatives were prepared from the corresponding alcohols by a well-reported classical alcohol 
esterification by succinic acid anhydride.28, 30  
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                    Figure 2.5 1H-NMR for regioselctive acylation and carbonyl reduction 
 
We were able to develop a very efficient and short synthetic methodology for synthesis of 
various 2α, 3β-cholestane derivatives. Succinic acid mono and di-derivative of 2α, 3β-cholestane  
were also synthesized and were tested for antifungal activity. Streochemistry for various isomers 
were well compared and confirmed by 1H-NMR studies and reported literature evidences for these 
kinds of compounds.  
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2.3 Synthesis of Androstane derivatives: 
Since synthesis was well developed and optimized for cholestane based derivatives, we 
decided to use the same strategy for synthesis of androstane derivatives. The reason we wanted to 
synthesize these derivatives in order to complete the SAR study of antifungal assay and see if our 
hypothesis of not having spirostane ring for antifungal activity is actually true or not. We wanted to 
have comparison among three steroid derivatives bearing siprostane ring system (tigogenin), 
aliphatic chain (in cholestane) and no substitution on the basic four-ring skeleton (Fig. 2.6).  
 
Figure 2.6 2α, 3β- Cholestane, Androstane and Spirostane derivatives 
This will give us a fair idea about if the entire ring system in spirostane is needed for better 
antifungal activity. Adrosterone derivatives have been reported to have antifungal activity by N. R. 
Moamed et al. against Sacharomyces cerevisiae, Candida albicans and Aspergillus flavus.29 Four 
compounds were found to be active antifungal agents with activity close to Nystatin by disc-
diffusion method for the antifungal assay. (Fig. 2.7) 
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Figure 2.7 Androsterone derivatives with antifungal activity reported by N.R. Mohamed et al.29 
 
The synthesis of androstane derivatives began with 5-androsten-17-one-3β-acetate (49, 
Scheme 2.12) (Sigma–Aldrich). A Wolff–Kishner reduction of the carbonyl group of dehydroiso-
androsterone-3β-acetate (49, Scheme 2.12) followed by the hydrolysis of the acetate group was 
performed in one step by applying Reyes and coworkers’ elegant steroid carbonyl reduction 
procedure. This method was used to prepare 5-androsten-3β-ol (50, Scheme 2.12) in large 
quantities with very high yields. The double bond of 50 was then reduced by platinum dioxide 
catalyzed hydrogenation, which led to the formation of intermediate alcohol 51. The intermediate 
alcohol 51 was later oxidized by chromic acid by following standard procedures. From this point, 
we then branched the synthetic scheme into two different paths; the first involved the direct 
introduction of an acetyl group at 2α-position of 52 with lead tetraacetate to generate 55 (Scheme 
2.12, step vii). 
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Scheme 2.12  i) NH2NH2, 2-ethoxyethanol, KOH; ii) PtO2/CH2Cl2-CH3CO2H; iii) CrO3/H2SO4; iv) (CH3CO)2O/ 
Montmorillonite clay; v) m-chloroperbenzoic acid/ CH2Cl2; vi) (CH3CO)2/(C2H5)3N); vii) Pb(O2CCH3)4/(CH3CO)2O-
CH3CO2H; viii) CeCl3x7H2O/CH3OH/tetrahydrofuran/NaBH4; ix) NaOH/CH2Cl2/CH3OH, 98%. 30 
 
The second approach generated compound 55 using a three-step procedure (Scheme 2.12, 
steps iv–vi). The first step of the alternative preparation of compound 55 is the synthesis of vinyl 
acetate (53, Scheme 2.12, step iv), followed by epoxidation of 53 with mCPBA to yield epoxide 54 
(Scheme 2.12, step v). Vinyl acetate, 53 have peak for H-2 proton at 5.23ppm whereas after 
epoxidation H-2 peak moves to 3.38 ppm. Finally, epoxide ring opening occurs following treatment 
with acetic acid to yield the desired compound 55. Although longer, the alternative route through 
the preparation of vinyl ester and epoxide has an added advantage with respect to the purification of 
the product, and this method gave us comparable yields of compound 55 (Scheme-2.12). 
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Figure 2.8 1H-NMR for androstane derivatives. 
 Streochemistry of 2α-acetoxy-androstan-3-one was confirmed by 1H-NMR showing a 
doublet of double at 5.25 ppm which will be otherwise be a nice triplet for the 2β-acetoxy-
androstan-3-one due to coupling with two prochiral protons. 
 Finally, to generate the 2,3-functionalized steroids, we followed a straightforward 
NaBH4/CeCl3 reduction of the carbonyl group of 2α-acetoxy-androstan-3-one, followed by the 
acetate ester hydrolysis to produce desired 2α, 3β-androstane, 56 and 2α, 3β-androstandiol, 57 
derivative respectively. The acetate ester hydrolysis of 2α, 3β-androstane gave corresponding diol 
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57 which was clearly evident from 1H-NMR, multiplet for H-2 proton have shifted from 4.8 to 
3.6ppm and singlet for acetyl group at 2.23 ppm have vanished completely (Fig. 2.8).  
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2.4 Antifungal assay of Cholestane And Androstane derivatives 
The antifungal activity of the synthesized stereoisomers of the 2,3-functionalized steroids 
evaluated in vitro. The susceptibility studies and minimal inhibitory concentrations (MIC) values 
for Candida albicans (ATCC no. 10231), Cryptococcus neoformans (ATCC no 36556),Candida 
glabrata (ATCC no 48435), and the filamentous fungus Aspergillus fumigates (ATCC no. 16424) 
were determined by the broth dilution technique in accordance with NCCLS reference documents 
M27-A.31 Dilution panels ranged from 0.01 to 128 μg/mL. Master stock concentrations of drugs 
(soluble in DMSO) were prepared to ensure that the maximum final concentration of DMSO in 
tested antifungal solutions was 1% or less. Subsequent 2-fold serial dilutions were made using 
RPMI 1640 broth or sterile water to a final concentration of 1280-0.1 ug/ml. A final 10-folddilution 
of each drug was made by aliquotting 0.1 mL of each dilution to 0.9 mL of inoculating media, 
giving final drug concentrations tested in the range of 128-0.01 ug/mL. Antifungal drug controls 
used for these studies were Amphoteracin B and Itraconazole (Sigma-Aldrich). All controls used 
were diluted to 1.0 ug/mL concentrations, according to the manufacturer’s instructions and run in 
parallel to each in vitro screening of the 2,3-functionalized steroid analogs. The results of these 
screenings are summarized in Table 2.1. Several of the derivatives from the andostane and 
cholestane groups showed reasonable antifungal activity (as measured spectroscopically by a >25% 
reduction in fungal growth compared to control wells) against at least one species of fungus.30 
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Table 2.1 Antifungal activity of cholestane and androstane derivatives 30 
MIC25 (µg/mL)a,f  
Compound 
 
Structure C. albicans b C. glabrata c C. neoformans d A. fumigates e 
 
51 
 
NC* NC* NC* NC* 
 
54 
 
4.0 NC* NC* NC* 
 
55 
 
0.125 NC* NC* 1.0 
 
56 
 
NC* NC* NC* NC* 
 
57 
 
NC* NC* NC* NC* 
 
20 
 
NC* NC* NC* NC* 
 
37 
 
NC* NC* NC* 128 
 
36 
 
128 NC* NC* 8.0 
 
38 
 
NC* NC* 4.0 NC* 
 
42 
 
NC* NC* 32 NC* 
 
44 
 
NC* NC* 8.0 2.0 
 
43 
 
NC* 32 NC* 8.0 
a MIC values are reported only for compounds displaying (1) a prominent decrease in turbidity by visual comparison to the control wells 
containing no antifungal and (2) a >25% reduction in fungal growth compared to controls containing no antifungal, as measured spectroscopically 
by absorption at 530 nm. 
b ATCC no. 10231.      c ATCC no. 48435.  
d ATCC no. 36556.      e ATCC no. 16424.  
f All values were determined after incubation at 30–35 °C for 48 h.  
g Compounds that had (1) a slight reduction in turbidity to no change and (2) had less than a 10% reduction in growth compared to   
controls, as measured spectroscopically by absorption at 530 nm. 
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2.5 Conclusions 
We have successfully developed and optimized a very efficient and elegant four to six step 
synthesis for 2α, 3β- isomers of cholestane and androstane. Large quantities of these derivatives 
have been synthesized and preliminary antifungal evaluation was done in vitro. Antifungal assay 
protocols were optimized and reproduced several times in order to check reproducibility of 
susceptibility assay experiments. The susceptibility studies and minimal inhibitory concentrations 
(MIC) values for Candida albicans, Cryptococcus neoformans, Candida glabrata, and the 
filamentous fungus Aspergillus fumigates were determined by the broth dilution technique in 
accordance with NCCLS reference documents M27-A.31 Several of the derivatives from the 
androstane and cholestane groups showed reasonable antifungal activity (as measured 
spectroscopically by a >25% reduction in fungal growth compared to control wells) against at least 
one species of fungus. Most of these derivatives were showing good inhibition of fungal growth in 
case of filamentous fungi Aspergillus fumigates. Further, the 2,3-functionalized derivatives can 
further be used as building blocks for the synthesis of novel fatty-acid esters of steroids with 
potential antimicrobial activities. Although we found some good antifungal activity with some 
cholestane and androstane derivatives, they were not potent enough to get a probable lead 
compound, this gave an indication that we need to have spirostane ring system for better activity. 
The next step at this stage of the project was to optimize synthesis of 2α, 3β-spirostane derivatives 
and test them for antifungal activity to complete a SAR study towards finding a good antifungal 
agent in the saponin class. We also decided to synthesize some glycosidic derivatives of active 
compounds from cholestane and androstane series and test them for antifungal assay. The details of 
glycosides derivatives of cholestane and androstane will be discussed in chapter 4 along with their 
antifungal activity and comparison them with similar derivatives from the spirostane class. 
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2.6 Experimental 
2.6.1 General Experimental 
All reagents and solvents were purchased from Sigma-Aldrich and were analytical grade.  Thin-
layer chromatographic analysis (TLC) was performed using silica gel on glass plates and was 
detected under ultraviolet (UV) light and using PMA solution. Column chromatography was 
performed using silica gel porosity 60 Å, partial size 40-75 mm from Sorbent Technologies.  The 
1H and 13C NMR spectra were run on Varian 400 MHz Unity in CDCl3 or DMSO-d6 as solvents 
and internal standards.   
 
Preparation of 5α-cholestan-3β-ol (20):  A suspension of cholesterol (25) (1.0 g; 2.6 mmol) 
and platinum dioxide (100 mg) in dichloromethane (20 ml) and acetic acid (20 ml) was shaken 
under hydrogen pressure (60 psi) for 16 hours.  The catalyst was separated by filtration and the 
filtrate was neutralized with 10% potassium carbonate.  The resulting mixture was extracted with 
dichloromethane (3x50 ml).  The combined organic extracts were dried over anhydrous 
magnesium sulfate and evaporated to give 0.98 g (98%) white solid as pure product. Selected 1H-
NMR (400 MHz, CDCl3): δ 3.61 (1H, m, CH-3), 1.12 (3H, s,CH3-19), 0.85, 0.91 (9H, CH3-21, 
CH3-26 and CH3-27), and 0.67 ppm (3H, s, CH3-18). 13C-NMR δ: 74.4, 56.1, 56.0, 53.7, 47.8, 
44.8, 43.5, 42.5, 39.7, 39.4, 37.1, 36.1, 35.7, 34.6, 31.5, 28.3, 28.2, 27.9, 24.1, 23.7, 22.8, 22.5, 
21.6, 20.7, 18.6, 12.7 and 12.0 ppm. 
 
Preparation of 5α-cholestan-3-one (26):  Into a stirring acetone (200 ml) solution of 5α-
cholestan-3β-ol (20) (0.95 g; 2.45 mmol), chromic acid made from chromium trioxide (1 g) and 
40% sulfuric acid (4 ml) was added drop-wise at 30ºC.  The reaction mixture was stirred at 30ºC 
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for an additional 2 hours then diluted with water (50 ml) and extracted with dichloromethane 
(3x50 ml).  Combined dichloromethane extracts were dried over anhydrous magnesium sulfate 
and evaporated to dryness to give pure product (0.9 g; 95%).  Selected 1H-NMR (400 MHz, 
CDCl3): δ 1.12 (3H, s,CH3-19), 0.85, 0.91 (9H, CH3-21, CH3-26 and CH3-27), and 0.67 ppm 
(3H, s, CH3-18). 13C-NMR δ: 160.2, 74.4, 56.1, 56.0, 53.7, 47.8, 44.8, 43.5, 42.5, 39.7, 39.4, 
37.1, 36.1, 35.7, 34.6, 31.5, 28.3, 28.2, 27.9, 24.1, 23.7, 22.8, 22.5, 21.6, 20.7, 18.6, 12.7 and 
12.0 ppm.   
 
Preparation of 3-acetoxy-5α-cholest-2-ene (35):  Acetic anhydride (10 ml) suspension of 5α-
cholestan-3-one (26) (1 g; 2.6 mmol) and monomorillonite clay (500 mg) was stirred at room 
temperature overnight.  The catalyst was separated by filtration and diluted by diethyl ether (100 
ml).  The ether solution was washed with saturated sodium bicarbonate (3x20 ml), dried on 
anhydrous magnesium sulfate, and evaporated to give pure product (1.0 g; 90%). Selected 1H- 
and 13C-NMR spectra. 1H-NMR (400 MHz, CDCl3): δ 5.20( d,1H), 2.15 (3H, s, CH3CO), 1.12 
(3H, s,CH3-19), 0.85, 0.91 (9H, CH3-21, CH3-26 and CH3-27), and 0.67 ppm (3H, s, CH3-18). 
13C-NMR (CDCl3) δ: 170.1,74.4, 56.1, 56.0, 53.7, 47.8, 44.8, 43.5, 42.5, 39.7, 39.4, 37.1, 36.1, 
35.7, 34.6, 31.5, 28.3, 28.2, 27.9, 24.1, 23.7, 22.8, 22.5, 21.6, 20.7, 18.6, 12.7 and 12.0 ppm. 
  
Preparation of 3β-acetoxy-2α , 3α-epoxy-5α-cholestane (36):  Dichloromethane (15 ml) 
solution of 3-aceto-5α-cholest-2-ene (35) (1g; 2.16 mmol) and m-chloroperbenzoic acid (0.443 
g; 2.56 mmol) was stirred at 10ºC for 1 hour.  The reaction mixture was mixed with 10% sodium 
sulfite (15 ml) stirred at 10ºC for additional 20 minutes.  Into this reaction mixture ethyl ether 
(100 ml) was added.  The organic layer was separated from water, washed with saturated sodium 
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bicarbonate (3x20 ml), brine (3x20 ml), dried over anhydrous magnesium sulfate and evaporated 
to a solid residue. Isolated yield of white powder is 0.380 mg (85%). 1H-NMR (400 MHz, 
CDCl3): δ 3.21( d,1H), 2.15 (3H, s, CH3CO), 1.12 (3H, s,CH3-19), 0.85, 0.91 (9H, CH3-21, CH3-
26 and CH3-27), and 0.67 ppm (3H, s, CH3-18). 13C NMR (CDCl3) δ: 170.1, 74.4, 56.1, 56.0, 
53.7, 47.8, 44.8, 43.5, 42.5, 39.7, 39.4, 37.1, 36.1, 35.7, 34.6, 31.5, 28.3, 28.2, 27.9, 24.1, 23.7, 
22.8, 22.5, 21.6, 20.7, 18.6, 12.7 and 12.0 ppm. 
 
Preparation of 2α-acetoxy-5α-cholestan-3-one (37):  Method I: Acetic anhydride (20 ml) 
solution of 3β-acetoxy-2α,3α-epoxy-5α-cholestane (36) (700 mg; 1,57 mmol) and triethylamine 
(0.25 ml) was refluxed for 2 hours.  Reaction mixture was cooled to room temperature and 
extracted with diethyl ether (3x20 ml).  Combined ether extracts were dried over anhydrous 
magnesium sulfate, and the solvent was evaporated under reduced pressure to give 0.62 mg 
(89%) product as white solid. Method II: A mixture of acetic acid (40 ml) and acetic anhydride 
(5 ml) was refluxed for 10 minutes.  After reaction mixture was cooled to room temperature 5α-
cholestan-3-one (1.0 g; 2.57 mmol) and lead tetraacetate (1.6 g; 4.36 mmol) were added reaction 
mixture was refluxed for 24 hours.  The reaction mixture was diluted with diethyl ether (100 ml) 
and extracted with 5% hydrochloric acid (3x15 ml), saturated sodium bicarbonate (3x15 ml), 
brine (3x15 ml).  Solvent was evaporated and the oily residue was purified by silica gel column 
chromatography (20% ethyl acetate in hexane).  The isolated yield was 80% of pure product.  
1H-NMR (400 MHz, CDCl3): δ 5.29 (1H, dd ), 2.15 (3H, s, CH3CO), 1.12 (3H, s,CH3-19), 0.85 
0.91 (9H, CH3-21, CH3-26 and CH3-27), and 0.67 ppm (3H, s, CH3-18). 13C-NMR (CDCl3) δ: 
204.3, 170.1, 74.4, 56.1, 56.0, 53.7, 47.8, 44.8, 43.5, 42.5, 39.7, 39.4, 37.1, 36.1, 35.7, 34.6, 31.5, 
28.3, 28.2, 27.9, 24.1, 23.7, 22.8, 22.5, 21.6, 20.7, 18.6, 12.7 and 12.0 ppm.  
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Preparation of 2α-acetoxy-5α-cholestan-3β-ol (38):  Tetrahydrofuran (20 ml) solution of 
methanol (10 ml), 2α-acetoxy-5α-cholestan-3-one 37 (0.35 g; 0.8 mmol), and CeCl3x7H2O (373 
mg; 1 mmol) was stirred at room temperature for 10 minutes.  Into this solution sodium 
borohydride was added (60 mg; 1.6 mmol) and continued to stir at room temperature for 
additional 30 minutes.  The excesses of the borohydride were quenched with 5% hydrochloric 
acid.  The resulting reaction mixture was poured into water (100 ml) and the water mixture was 
extracted by ether (3x50 ml).  Combined ether extracts were dried over anhydrous magnesium 
sulfate and evaporated to dryness yielding 0.32 g (90%) of pure . Selected 1H- and 13C-NMR 
spectra. 1H NMR (400 MHz, CDCl3): δ 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, 
JZ5.4, 9.5, 11.1 Hz, H-3a), 2.08 (3H, s, CH3CO), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, 
CH3-27), and 0.64 ppm (3H, s, CH3-18). 13C-NMR (CDCl3) δ:171.5, 76.4, 73.5, 56.2, 56.1, 54.1, 
44.4, 42.5, 42.1, 39.8, 39.4, 37.2, 36.1, 35.8, 35.7, 34.7, 31.7, 28.1, 27.9, 27.7, 24.1, 23.7, 22.8, 
22.5, 21.4, 18.6, 13.1 and 12.0 ppm.  
Preparation of 5α-cholestan-2α ,3β-diol (42):  A methanol (2 ml) and dichloromethane (10 ml) 
solution of 2α-Acetoxy-5α-cholestan-3β-ol (38) (0.5 g; 1.12 mmol) and sodium hydroxide (0.12 
g; 3 mmol) was stirred at room temperature overnight. Into the reaction mixture acidic resin-
dowex (1g) was added and this suspension was stirred at room temperature for 5 minutes.  The 
resin was separated by filtration and solvent was removed on rotavapour to get pure product in 
98% (0.44 g) isolated yield.   1H NMR (400 MHz, CDCl3): δ 3.59 (1H, ddd, JZ4.7, 9.0, 11.5 Hz, 
H-2b), 3.40(1H, ddd, JZ5.1, 8.9, 10.9 Hz, H-3a), 0.84–0.91 (12H, CH3-19, CH3-21, CH3-26, 
CH3-27),  and 0.64 ppm (3H, s, CH3-18). 13C-NMR (CDCl3) δ: 73.1, 72.3, 56.3, 56.2, 54.2, 45.0, 
44.8, 39.9, 39.5, 38.1, 37.5, 36.1, 35.8, 35.6, 34.7, 31.9, 28.2, 28.0, 27.9, 24.1, 23.8, 22.8, 22.5, 
21.3, 18.6, 13.5 and 12.0 ppm.  
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Preparation 4-(2α-acetoxy-5α-cholestan-3β-yloxy)-4-oxobutanoic acid (44):  Pyridine (5 ml) 
solution of 2α−acetoxy-5α-cholestan-3β-ol (38) (150 mg, 0.32mmols) and succinic anhydride 
(96mg, 0.96mmols) was refluxed for 4 hours. The reaction mixture was cooled to room 
temperature and added to crushed ice (~100 g).  Resulted mixture was extracted with ethyl 
acetate (100 ml).  Ethyl acetate extract was washed with water (3x30 ml), dried over anhydrous 
magnesium sulfate and evaporated to dryness. Selected 1H-NMR (400 MHz, CDCl3): δ 4.82 (1H, 
ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, H-3a), 2.60(m, 2H), 2.08 
(3H, s, CH3CO), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm (3H, s, CH3-
18). 13C NMR (CDCl3) δ:180.2, 175.3, 171.5, 76.4, 73.5, 56.3, 56.2, 54.2, 44.4, 42.5,42.1, 41.0, 
40.9, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.3, 
18.6, 13.0 and 12.0 ppm. 
 
Preparation of 4,4'-(5α-cholestan-2α ,3β-diyloxy)bis(4-oxobutanoic acid) (43):  Pyridine 
solution (5 ml) of 5α-cholestan-2α,3β-diol (42) (100 mg, 0.25mmols) and succinic anhydride 
(63.3mg, 0.63mmols) was refluxed for 16 hours.  Room temperature cooled reaction mixture was 
poured over crushed ice (~100 g) and extract with ethyl acetate (3x50 ml).  Combined organic 
layers were washed with water (3x20 ml), dried over anhydrous magnesium sulfate and 
evaporate to dryness to yield pure product. 1H NMR (400 MHz, CDCl3): δ 5.15 (1H, ddd, JZ5.4, 
9.5, 11.1 Hz, H-3a), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 2.60 (m, 2H), 0.84-0.90 (12H, 
CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm (3H, s, CH3-18). 13C NMR (CDCl3) δ:180.2, 
178.2, 175.3,174.6, 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 41.0, 40.9, 39.8, 39.4, 37.2, 
36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.3, 18.6, 13.0 and 12.0 
ppm. 
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Preparation of 5-androsten-3β-ol (50):  A mixture of 5-androsten-17-one-3b-yl acetate (49) 
(1g, 2.12 mmol), hydrazine hydrate (1ml,19.98mmol) and 2-ethoxyethanol (10ml) was stirred at 
room temperature and under nitrogen atmosphere for 20 minutes followed by 1 hour refluxing.  
After cooling to room temperature potassium hydroxide (1g, 17.82 mmol) was added and the 
resulting mixture was heated at 136ºC for an additional three hours.  After cooling to room 
temperature, the reaction mixture was neutralized with concentrated hydrochloric acid and the 
formed white solid was separated by filtration, washed with water (3x20 ml) and dried in the air.  
The isolated yield of the product was 0.863 mg (98%). Selected 1H NMR (400 MHz, CDCl3): δ 
5.41(d, 1H), 3.47(m, 1H), 0.90 (3H, d, JZ6.5 Hz, CH3-21), 0.87 (6H, two d, J = 6.5 Hz, CH3-26 
and CH3-27), and 0.82 ppm (3H, s, CH3-19). 13C NMR δ: 171.5, 73.0, 68.1, 56.3, 56.2, 44.1, 
42.5, 41.7, 39.8, 39.4, 39.3, 36.7, 36.1, 35.8, 34.7, 32.2, 31.7, 28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 
22.5, 21.3, 20.8, 18.6, 12.5, and 12.0 ppm. 
 
Preparation of 3α-androstan-3β-ol (51): A suspension of 5-androstene-3β-ol (50) (1.0 g; 3.64 
mmol) and platinum dioxide (200 mg) in dichloromethane (20 mL) and acetic acid (20 mL) 
under hydrogen pressure (60 psi) was shaken in a Parr hydrogenator for 16 hours.  The solid 
catalyst was separated by filtration. The filtrate was neutralized with aqueous (10%) potassium 
hydroxide and extracted with dichloromethane (3x50 mL).  Dichloromethane extracts were dried 
over anhydrous magnesium sulfate and evaporated to yield a solid residue that corresponded to 
pure product (0.987g; 98%).	  	  Selected 1H NMR (400 MHz, CDCl3): δ 3.47(m, 1H), 0.90 (3H, d, J 
= 6.5 Hz, CH3-21), 0.87 (6H, two d, J = 6.5 Hz, CH3-26 and CH3-27), and 0.82 ppm (3H, s, CH3-
19). 13C NMR δ: 171.5, 73.03, 68.1, 56.3, 56.2, 44.1, 42.5, 41.7, 39.8, 39.4, 39.3, 36.7, 36.1, 
35.7, 34.7, 32.2, 31.7, 28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 21.3, 20.9, 18.6,12.5 and 12.0 ppm. 
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Preparation of 5α-androstan-3-one (52): Cromic acid (4 mL solution made from equal amount 
of CrO3 and 40% sulfuric acid) was slowly added into an acetone (200 ml) solution of 51 (0.95 
g; 3.44 mmol) by keeping the temperature of the reaction mixture below 30°C.  The resulting 
reaction mixture was stirred at 30°C for an additional 2 hours.  The reaction mixture was diluted 
with water (50 mL) and extracted with dichloromethane (3x30 mL).   The combined 
dichloromethane extracts were dried over anhydrous magnesium sulfate and evaporated to a 
solid residue.  Isolated yield of the product is 0.93 g (95%). Selected 1H NMR (400 MHz, 
CDCl3): δ 0.90 (3H, d, J = 6.5 Hz, CH3-21), 0.87 (6H, two d, J = 6.5 Hz, CH3-26 and CH3-27), 
and and 0.82 (3H, s, CH3-19). 13C NMR δ: 171.5, 73.0, 68.1, 56.3, 56.2, 44.1, 42.5, 41.7, 39.8, 
39.4, 39.3, 36.7, 36.1, 35.7, 34.7, 32.2, 31.7, 28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 21.3, 20.9, 
18.6,12.5 and 12.0 ppm. 
 
Preparation of 3-acetoxy-5α-androst-3-ene (53):  Acetic anhydride (10 ml) suspension of 3-
androstanone (52) (1g; 3.64 mmol) and montomorillonite clay (500mg) was stirred at room 
temperature overnight.  The reaction was monitor by TLC (15% ethyl acetate in hexane).  Upon 
reaction completion (~ 12 hours) the clay catalyst was separated by filtration, the filtrate was 
diluted by ether (150 ml) and washed with saturated sodium bicarbonate (5x 20 ml).   the ether 
layer was dried over magnesium sulfate and evaporated to solid residue to give pure product 
(1.04g; 90% yield. Selected 1H NMR (400 MHz, CDCl3): δ 5.20 (d, 1H), 2.12 (3H, s, CH3CO), 
0.90 (3H, d, JZ = 6.5 Hz, CH3-21), 0.87 (6H, two d, J = 6.5 Hz, CH3-26 and CH3-27), and 0.82 
(3H, s, CH3-19). 13C NMR δ: 171.5, 120.2, 73.0, 68.1, 56.3, 56.2, 44.1, 42.5, 41.7, 39.8, 39.4, 
39.2, 36.7, 36.1, 35.7, 34.71, 32.2, 31.7, 28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 21.3, 20.8, 
18.6,12.5 and 12.0 ppm. 
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Preparation of 3β-acetoxy-2α ,3α-epoxy-5α-androstane (54): To a dichloromethane (15 ml) 
solution of 53 (1g, 2.16 mmol) m-chloroperbenzoic acid (0.44g, 2.56 mmol) was added at 10ºC.   
The resulting reaction mixture was stirred at room temperature for1 hour.  Into the reaction 
mixture 10% sodium sulfite (10 ml) was added and resulting mixture was stirred at room 
temperature for additional 20 minutes.  The reaction mixture was diluted with ether (100 ml). 
The aqueous layer was discarded and the organic layer was washed with saturated sodium 
bicarbonate (3x20 ml), dried over anhydrous magnesium sulfate and evaporated to a white 
powdery residue, which was the pure product. The isolated yield 85%. Selected 1H NMR (400 
MHz, CDCl3): δ 3.20 (d, 1H), 2.12 (3H, s,CH3CO), 0.90 (3H, d, J = 6.5 Hz, CH3-21), 0.87 (6H, 
two d, J = 6.5 Hz, CH3-26 and CH3-27), and 0.82 (3H, s, CH3-19) ppm. 13C NMR δ: 171.5, 
73.03, 68.1, 56.3, 56.2, 44.1, 42.5, 41.7, 39.9, 39.4, 39.2, 36.7, 36.1, 35.7, 34.7, 32.2, 31.7, 28.2, 
27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 21.3, 20.8, 18.6, 12.5 and 12.0 ppm. 
 
Preparation of 2α-acetoxy-5α-androstan-3-one (55) from epoxide (54): The acetic anhydride 
(20 ml) solution of epoxide 54 (700 mg; 2.1 mmol) and triethylamine (0.250 ml) was refluxed 
for 2 hours.   The reaction mixture was extracted with diethyl ether (3x15 ml) and the combined 
ether extracts were evaporated and the solid white residue was dried under reduced pressure 
yielding pure product (620 mg, 89%).4 	  1H NMR (400 MHz, CDCl3): δ 5.29 (dd, 1H), 2.12 (3H, 
s,CH3CO), 0.90 (3H, d, J = 6.5 Hz, CH3-21), 0.87 (6H, two d, J = 6.5 Hz, CH3-26 and CH3-27), 
and 0.82 (3H, s, CH3-19) ppm. 13C NMR δ: 171.5, 73.0, 68.1, 56.3, 56.2, 44.1, 42.5, 41.7, 39.8, 
39.4, 39.2, 36.7, 36.1, 35.7, 34.7, 32.2, 31.7, 28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 21.3, 20.8, 
18.6,12.5 and 12.0 ppm. 
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Preparation of 2α-acetoxy-5α-androstan-3-one (55) from ketone (52):  A mixture of acetic 
acid (40 ml) and acetic anhydride (5 ml) was refluxed for 10 minutes.  This mixture was cooled 
to room temperature and the compound 2 (1g; 2.57 mol) was added followed by the addition of 
lead tetraacetate (1,6 g; 4.36 mmol).  The reaction mixture was refluxed with stirring for 24 
hours. After cooling, the reaction mixture was diluted by ether (100 mL) and washed 5% 
hydrochloric acid (3x20 ml), saturated sodium bicarbonate (3x20 ml), and brine (3x20 ml).  The 
solvent was evaporated and the oily residue was purified by column chromatography on silica 
gel (15% ethyl acetate in hexane).  The isolated yield of the product was 0.855 g (80%).  1H 
NMR (400 MHz, CDCl3): δ 5.29 (dd, 1H), 2.12 (3H, s,CH3CO), 0.90 (3H, d, J = 6.5 Hz, CH3-
21), 0.87 (6H, two d, J = 6.5 Hz, CH3-26 and CH3-27), and 0.82 (3H, s, CH3-19) ppm. 13C NMR 
δ: 171.5, 73.0, 68.1, 56.3, 56.2, 44.1, 42.5, 41.7, 39.8, 39.4, 39.2, 36.7, 36.1, 35.7, 34.7, 32.2, 
31.7, 28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 21.3, 20.8, 18.6,12.5 and 12.0 ppm.  
 
Preparation of 3β-hydroxy-5α-androstan-2α-yl acetate (56):  A methanol (10 ml) and 
tetrahydrofuran (20 ml) solution of ketone 55 (270 mg; 0.8 mmol) 2:1 and CeCl3.7H2O 
(373mg,1.0 mmol) was stirred at room temperature for 10 minutes.  The reaction mixture was 
stirred for additional 30 minutes after NaBH4 (60 mg; 1.6 mmol) was added.  After sodium 
borohydride was quenched with 5% hydrochloric acid (~0.5 ml) the reaction mixture was diluted 
with water and extracted with ether (3x20 ml).  Combined ether extracts were dried over 
anhydrous magnesium sulfate and evaporated to dryness yielding to 245 mg (90%) of pure 
product. Selected 1H NMR (400 MHz, CDCl3): δ 4.82 (1H, ddd, J = 4.8, 9.4, 11.6 Hz, H-2b), 
3.59 (1H, ddd, J = 4.7, 9.0, 11.5 Hz, H-2b), 2.12 (3H, s, CH3CO), 0.90 (3H, d, J = 6.5 Hz, CH3-
21), 0.87 (6H, two d, J = 6.5 Hz, CH3-26 and CH3-27), and 0.82 (3H, s, CH3-19) ppm. 13C NMR 
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δ: 171.5, 73.0, 68.1, 56.3, 56.2, 44.1, 42.5, 41.7, 39.9, 39.5, 39.3, 36.7, 36.1, 35.7, 34.7, 32.2, 
31.7, 28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 21.3, 20.9, 18.6,12.5 and 12.0 ppm. 
 
Preparation of 2α ,3β-dihydroxy-5α-androstane (57):  A methanol-dichloromethane (10 ml 
1:1) solution of potassium hydroxide (120 mg; 2 mmol) and ester 56 (170 mg; 0.5 mol) was 
stirred at room temperature for five hours.  The solvent was evaporated, the solid residue was 
partitioned between dichloromethane (20 ml) and water (20 ml).  The organic layer was 
separated, washed with water (3x10 ml) and dried over anhydrous magnesium sulfate.  Solvent 
was evaporated yielding 165 mg (98%) of pure diol 9. Selected 1H NMR (400 MHz, CDCl3): δ 
3.59 (1H, ddd, J = 4.7, 9.0, 11.5 Hz, H-2b), 3.40(1H, ddd, J = 5.1, 8.9, 10.9 Hz, H-3a), 0.90 (3H, 
d, J = 6.5 Hz, CH3-21), 0.87 (6H, two d, J = 6.5 Hz, CH3-26 and CH3-27), and 0.82 ppm (3H, s, 
CH3-19). 13C NMR (CDCl3) δ: 82.2, 73.0, 68.1, 56.3, 56.2, 44.1, 42.5, 41.7, 39.9, 39.4, 39.3, 
36.7, 36.1, 35.7, 34.7, 32.2, 31.7, 28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 21.3, 20.9, 18.6, 12.5, 
and 12.0 ppm. 
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CHAPTER-3. SYNTHESIS ANTIFUNGAL EVALUATION OF FUNCTIONALIZED 2,3-
SPIROSTANES  
Several saponins have been described as having potent antimicrobial properties. 
Furthermore, a number of saponins with either a spirostanol or a 2,3-spirostandiol moiety linked to 
a glycoside exhibit broad-spectrum antifungal activity against multiple fungal species, where the 
mechanism of action is probably through the formation of a complex with sterols in fungal 
membranes causing a loss of membrane integrity or by inhibiting 1,3-β glucan synthase activity. 
Therefore, it is reasonable to investigate the development of novel 2,3-spirostane based glycosides 
as potential antifungal agents. Nonetheless, while there are reports showing successful syntheses of 
spirostanols, a major obstacle remains in the limited synthetic methodology applicable to large-
scale preparations of functionalized 2,3-spirostanes. Developing this synthetic methodology would 
not only allow the preliminary investigation of functionalized 2,3-spirostanes as potential antifungal 
agents but would also provide a library of functionalized 2,3- spirostane derivatives that could be 
used as building blocks for the development of novel synthetic spirostane-linked glycosides with 
potential antimicrobial properties. Functionalized steroids are well known compounds with 
potentially interesting biological properties1-3. Many of these compounds are only available in 
milligram quantities, as they are isolated from natural sources. This limited availability hampers 
both chemical and biological exploration of these compounds and their analogs. Therefore, there is 
an urgency to develop well-defined synthetic procedures for the preparation of these valuable 
compounds in large quantities starting with inexpensive and commercially available steroid 
precursors.  
Our overarching goal was to develop an efficient synthetic procedure for the synthesis and 
isolation of functionalized 2,3-spirostanes that could be further used to develop novel saponin-like 
analogs with potential therapeutic value. We explored a number of different synthetic pathways in 
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the preparation of functionalized 2,3-spirostanes. Our main goal was to develop most efficient 
routes, each of which will be superior to other alternative synthetic routes in simplicity, isolated 
yields, and applicability to the preparation of other substituted steroids in large quantities. In 
designing the synthetic methodology to prepare functionalized 2,3-spirostane stereoisomers, we 
identified two major obstacles that required resolution prior to the development of a practical 
synthetic approach. The first was (a) how to selectively introduce hydroxyl groups into the C-2 
position; and the second was (b) how to differentiate one of the two-hydroxyl groups for hydroxyl 
group protection in order to modify the other synthetically. We have already developed a synthesis 
of similar isomers of cholestane and androstane, which will be explored and optimized for 
spirostane derivatives to achieve the desired goal for the synthesis. 
The non-protected 2α, 3β-aglycone (26, R = H) is a known compound derived from the 
hydrolysis of the saponin gitonin (1). This saponin is one of the minor saponin components 
obtained during the isolation of the saponin digitonin (2) from Digitalis purpurea.4 Digitonin is a 
toxic saponin, which precipitates cholesterol and is therefore useful in the permeabilization of 
cellular and nuclear membranes. While this saponin mixture is commercially available from a 
number of sources, it is impractical as a starting material for the preparation of 2α, 3β-aglycone . 
This is due to the fact that gitonin is only a minor component of the commercially available 
digitonin mixture. Consequently, obtaining 26 from commercial sources would require separation 
of a minor saponin component from a saponin mixture followed by hydrolysis of the saponin to 
obtain non-protected aglycone component 26. Furthermore, selective protection and isolation of one 
of two neighboring equatorial secondary alcohols would need to be accomplished before a 
glycosylation with an oligosaccharide moiety could be performed. 
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A strategy for the synthesis of aglycone 25 from more abundant sterols was investigated. A 
literature search revealed a synthesis by Sondheimer et al. of the 2α, 3β-aglycone in 5 steps from 
diosgenin (Scheme 3.1). 4-6 In this synthesis, diosgenin (3) was oxidized to α,β-unsaturated ketone 4 
by an Oppenauer oxidation which was then subjected to an allylic bromination to give 5. The key 
step in this approach, involving an acetolysis of 5 to form α-acetoxy ketone 6, proceeded in only 
25% yield, severely limiting the usefulness of this strategy in a more complicated synthesis. To 
complete the synthesis, hydrogenation of the alkenyl functionality of 6 was followed by reduction 
of both the C-2 acetate protecting group and the C-3 ketone of 7 by LiAlH4 to give unprotected 
trans-1,2 diol 8 in 5% overall yield from diosgenin. (Scheme-1) There were two concerns about the 
utility of this synthesis for the preparation of 2α, 3β-aglycone . The first concern was the low yield 
since aglycone 26 would be an intermediate in the saponin synthesis. More importantly, the lack of 
a protecting group on either the C-2 or C-3 alcohol in 7 renders it unusable in a glycoconjugate 
preparation. Since both of these secondary alcohols are equatorial, it would not be feasible to 
selectively protect one over the other. The development of a new synthetic strategy was therefore 
considered necessary in the hopes of discovering a practical synthesis of 2α, 3β-aglycone moiety.  
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Scheme 3.1 Literature reported synthesis of 2α, 3β-aglycone moiety by Sondheimer et al.4-6  
Holzapfel et al. reported the synthesis of a glycoconjugate containing the same steroid 
moiety as 2α, 3β-aglycone  (Scheme 3.2). Their synthesis began with diosgenin (3), which 
provided tigogenin (9) by catalytic hydrogenation.7 Tigogenin was oxidized using chromic acid 
to spirostan-3-one (23), which was then converted to trimethylsilyl enol ether 19. Enol ether 19 
was oxidized with dimethyldioxirane (DMDO) and the resulting α-hydroxy ketone was protected 
as allyl carbonate 19a. To this point, each step in this literature report was accomplished in high 
yields of no less than 83%. Unfortunately, the last step, requiring a stereoselective reduction of 
the C-3 ketone of 19a to the β-alcohol using sodium borohydride, provided the desired 
stereoisomer 19b in only 63% yield. 
Successful syntheses of trans-1,2 diols from trimethylsilyl enol ethers using 
hydroboration-oxidation has been reported for substituted cyclohexenol derivatives. Therefore, a 
new retrosynthesis (Scheme 3.2) for the steroid moiety of 2α, 3β-aglycone  was designed using 
the trimethylsilyl enol ether intermediate 19 described in the synthesis by Holzapfel et al. 
Although the reported yields for the hydroboration-oxidation of trimethylsilyl enol ethers are low 
(~60%), this method would still provide the opportunity for a higher yielding synthesis since it 
would require fewer steps. In this proposed synthesis, the aglycone would be prepared by the 
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hydroboration-oxidation of trimethylsilyl enol ether 23 to give selectively protected diol 19b. 
This silyl enol ether 19 would be synthesized from spirostan-3-one 23, which is available from 
the oxidation of tigogenin (9). 
 
Scheme 3.2 i) H2, Catalytic; ii) H2CrO4; iii) HMDS, TMSCl; iv) DMDO, ClCO2Allyl; v) NaBH4. Literature 
reported synthesis of 2α, 3β-aglycone by Holzapfel et al.7 
 
Even so, it is worth highlighting the fact that these authors choose to invert the axial C-3 
alcohol of 17a by oxidizing it to ketone 17b and then reducing it to the corresponding equatorial 
alcohol 17c. Yu et al.8 employed a Luche reduction and made no improvement on the yield of 
this step. 
 
Scheme 3.3 Reagents and conditions: (i) H2, Pd/C, CH2Cl2–MeOH, r.t.; (ii) TsCl, pyridine, 0°C then r.t.; (iii) silica 
gel, EtOAc–PE, r.t.; (iv) OsO4, NMO, t-BuOH–THF–H2O (10:8:1), r.t.; (v) Bu2SnO, toluene, reflux, 6 h; then BnBr, 
Bu4N+Br–, reflux, 2 h; (vi) Dess–Martin periodinane, CH2Cl2, r.t.; (vii) NaBH4, CeCl3·7H2O, MeOH, –40 °C, 55% 
(two steps for 17c), 28% (two steps for 17). Literature reported synthesis of the 2α, 3β-aglycone  by Yu et al.8 
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Synthesis of 2β, 3α-spirostane and 2β, 3β-spirostane isomers have been previously 
developed in our group previously starting from hecogenin acetate. Tigogenin 9 was easily 
obtained in quantitative yield by Wolff-Kishner reduction of hecogenin acetate. It is well 
documented that the α-steroid face is less sterically hindered and therefore is the more reactive 
face of the steroid.  This selective reactivity was used to prepare the axial trans dihydroxy 
derivatives 12 and 13 (Scheme-3.4).  The synthesis started with a modified Chugaiev water 
elimination9 from tigogenin 9.  As in many other cases, epoxidation of 2-spirostene (10, Scheme-
3.4) occurred from the α-face10, 11 and generated epoxide 11. The acetic acid epoxide ring 
opening resulted in the axial hydroxyl acetate 12 and 13.  The structure of 13 was also confirmed 
by X-ray crystallography.  
In addition to produce functionalized isomers 12 and 13, cis-diols from compound 10 
were also generated synthetically. This was accomplished by using an established procedure 
involving OsO4 oxidation8 of unsaturated steroids, such as 10.  Using this method, 5α-spirostan-
2α, 3α-diol (17) was prepared in 83% isolated yield. Of the isomers prepared, the more 
demanding was 5α-spirostan-2β, 3β-diol.  Considering that the preparation of acetyl 13 was a 
straightforward process, it was decided to use this compound as a starting point to explore its C-3 
stereochemical inversion.  Inversion through acetyl group rearrangement is a well-known 
reaction12. This approach was used to explore the effect of acetyl neighboring group participation 
on the hydrolysis of mesylate 14 (Scheme 3.4). Hydrolysis of mesylate in compound 14 gave 
major product 15 and minor product 16 by refluxing with pyridine/water, which were purified 
and characterized by 1H and 13C-NMR (Fig. 3.3). 
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Scheme 3.4  (i) NaH/CS2/propagyl bromide/THF; (ii) collidinium trifluoromethanesulfonate (0.1 
equiv)/toluene/reflux; (iii) m-chloroperbenzoic acid/ CH2Cl2 ; (iv) acetic acid/ reflux; (v) MsCl/Et3N/CH2Cl2; (vi) 
Pyridine/water/reflux; (vii) OsO4/ N-methylmorpholine-N-oxide. 
 
3.1 Retro-analysis for 2α , 3β-spirostane: 
The retro-analysis of 2α, 3β-spirostane derivative indicated that we can get it by reduction 
of 2α-acetoxy-spirostan-3-one (7), which can be obtained in two different ways, Firstly by 
enolization and protecting enol group with TMS or acetyl group followed by epoxidation to form 
epoxide ring which can be opened in presence of acetic anhydride and acetic acid to get. Secondly 
leadtetraacetate in presence of acetic acid and acetic anhydride reflux will stereoselectively form 7. 
Spirostan-3-one (23) could be obtained from Diosgenin in two steps by reduction of double bond 
followed by oxidation of alcohol group at 2-position alternatively from commercially available 
hecogenin acetate in two steps by classical Wolff-Kishner reduction followed by oxidation of 
hydroxyl group to keto. (Scheme 3.5) 
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Scheme 3.5 Retro-synthetic analysis of 2α, 3β-spirostane isomers 
 
3.2 Synthesis of Spirostane derivatives: 
Efficient and simple synthesis of 2α, 3β-spirostane isomers was not successfully explored 
so far as having both group equatorial at C-2 and C-3 is naturally not favoured due to sterically 
hindered attack to form 2α functionality. We have developed a method for synthesis of 2α, 3β-
cholestane and 2α, 3β-androstane derivatives which was discussed in chapter-2 in details, the 
developed synthesis needs to be explored to optimize reaction conditions for the synthesis of 2α, 
3β-spirostane isomer. Our first attempt towards this synthesis started well before we actually have 
developed synthesis of 2α, 3β-cholestane and 2α, 3β-androstane derivatives, there were constant 
problems involved in the synthesis which led us to look for another strategy and to reduce the cost 
of synthesis we decided to develop synthesis with some starting material which is much cheaper 
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compared to hecogenin acetate. Thus we decided to use cholesterol as our model starting material to 
explore the synthesis and apply the developed strategy for the synthesis of 2α, 3β-spirostane 
isomer. 
3.3 First attempt for synthesis of 2α , 3β-spirostane isomer. 
Our first attempt towards synthesis of 2α, 3β-spirostane derivative started with hecogenin 
acetate as starting material, with the one-pot simultaneous ester group hydrolysis and Wolff-
Kishner keto group reduction to get tigogenin13. This procedure was adapted from a well-developed 
method for the preparation of tigogenin from hecogenin acetate14. Using this approach, we 
produced a large quantity of tigogenin in excess of 98% yield, which was then used for further 
chemical modification. Jones oxidation of tigogenin gave keto compound 23 in 93 % of isolated 
yield15. Enolization was done by lithium bis-(trimethylsilyl)amide and trimethylsilyl chloride at -
78oC in dry tetrahydrofurane to give compound 19 in an isolated yield of 60% (Note- Purification 
by column chromatography should be done fast)7. TMS group was found to be cleaving while doing 
column chromatography for purification; shortening the time for column purification did improved 
the yield but not with very high success towards minimizing this problem. That was one of the 
reasons for low to moderate yield for this step of the synthesis. Regioselectivity for this type of 
enolization was not an issue as it was well documented by M. Sobukawa et al. and has very good 
selectivity of 9:1 for the desired regio-isomer in case of cholestan-3-one16. (Scheme-2.5)  
Epoxidation of O-TMS enol 19 was achieve by m-CPBA after several attempts to optimize 
the reaction to get epoxide compound 21 in 70% of isolated yield after purification. Epoxidation 
occurs selectively from α-face of the spirostane molecule due to steric hindrance by methyl groups 
on the β-face. (Scheme 3.7) 
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Scheme 3.6 i) Hydrazine hydrate, 2-ethoxyethanol, KOH, 136oC; ii) CrO3/H2SO4/dry Acetone; iii) 
LiN(Me3Si)2,TMSCl, dry THF; iv) m-chloroperbezoic acid/ CH2Cl2; v) (CH3CO)2O, reflux  vi) CH3OH/THF/NaBH4 
 
Most notably, the chemical shift for the C-19 methyl group for 11a was 0.75 ppm as 
compared to 1.04 ppm for 11b. The downfield shift for this signal in the case of 11b is due to the 
fact that the methyl group is on the same side of the molecule as the epoxide in this isomer. This 
result is supported by the fact that in ring systems, nucleophilic attack on epoxides generally occurs 
from an axial approach.17  
 
Scheme 3.7 Stereoselective mechanism for epoxidation.  
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The epoxide ring opening of 11a and 11b was explored previously in our group. In both 
cases the acetic acid nucleophile approaches each epoxide axially to give the diaxial isomers 12 and 
13 in 84% and 71% yield respectively (Scheme 3.8).   
Additionally, the appearance of H-2 and H-3 as broad singlets in the 1H-NMR of 3α-
hydroxy-spirostan-2β-yl acetate (13) confirms their equatorial orientation (Figure 3.1). Axial 
protons, as in H-3 of tigogenin (9) which is also shown in Figure 1 for comparison, appear as 
multiplets. This is due to the difference in the coupling constants between equatorial and axial 
protons. The stereochemistry of 13 was further confirmed by X-ray crystallography (fig. 3.2) 
Therefore, further attempts to synthesize 11b in good yield were abandoned considering the fact 
that either epoxide leads to a diaxial trans-1,2 diol derivative upon reaction with acetic acid.17 
 
Scheme 3.8 Epoxide ring opening with acetic acid.  
 
 
Figure 3.1 Portion of 1H-NMR of 3α-hydroxyspirostan-2β-yl acetate (13) and tigogenin (9)  
showing C-2 and C-3 stereochemistry. 
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Figure 3.2 ORTEP drawing of 3α-hydroxyspirostan-2β-yl acetate (13). (Courtesy of E. D. Stevens, University of New 
Orleans) 
 
Epoxide ring was successfully opened by acetic acid and acetic anhydride mixture on 
reflux to give compound 7 in 65% of isolated yield after column purification. TMS group present at 
C-3 tends to favor formation of 2α-acetyl groups and the mechanism of reaction is assumed to be 
similar as in case of cholestane and androstane epoxide ring opening step. 
A sodium borohydride reduction of compound 8 gave us a mixture of two isomers 8 and 
24. Although our major product was the desired isomer but were not able to purify more than 90% 
by column chromatography, there was a 10% mixture of two were confirmed by several trials of 
purification. The minor isomer 24 was purified successfully and confirmed by 1H-NMR in 10-25% 
yield. At this point of synthesis we decided to change our strategy as there were four synthetic steps 
involving column purification with moderate yield of 60-70%, more over gives two isomers at the 
last step, which were practically hard to purify by column chromatography. 
3.4 Second attempt for synthesis of 2α , 3β-Spirostane isomer. 
The problem associated with previous approach forced us to look for alternate synthetic 
strategy. Hecogenin acetate being very expensive made the whole process of exploration very 
expensive; we were constantly looking for alternate starting material, which is cheaper. Since we 
always wanted to design a viable and economic synthetic pathway, we decided to use Diosgenin as 
our starting material, which is at least five times cheaper than Hecogenin acetate. Structural features 
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of Diosgenin were attractive for us as it have similar double bond as cholesterol and synthesis for 
which was well developed and reported by us previously. Reduction of double bond was performed 
with platinum dioxide in dichloromethane and acetic acid (1:1) mixture as solvent at high-pressure 
hydrogen parr apparatus for 12 hours (Scheme 3.9)). Initially we thought that the reaction is going 
well and we have very nice product, monitored reaction by 1H-NMR. The doublet proton peak at 
5.2 for double bond proton was completely vanished. We continued next step, which was oxidation 
of the double bond by chromic acid solution (40% sulfuric acid) in dry acetone.  
After completion of oxidation reaction and purification of product analysis was done by 
1H-NMR. It was to our surprise that the nice peaks for proton at C-17 have changed their pattern to 
nice quartet instead of doublet of doublet signature peak at 3.4 ppm. We were surprised but wanted 
to make sure that every thing was done in desired way and various parameters, which could lead to 
opening of the oxygen containing spirostane ring. When we did a series of repeated trials to see 
what is going wrong we realized that the spirostane rings were opening up in presence of acetic acid 
under high pressure of oxygen.  
Very low percentage of acetic acid and lesser amount of platinum oxide catalyst was also 
tried for this reduction reaction, which indeed hampers the reduction reaction.  
 
 
Scheme 3.9 Platinum catalyzed reduction of diosgenin. 
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3.5 Third attempt for synthesis of 2α , 3β-spirostane isomer. 
Since there was not much success with optimization of double bond reduction reaction we 
decided to go with second strategy, which was to use previous starting material hecogenin acetate. 
The preparation of our functionalized 2,3-spirostanes started with the one-pot simultaneous ester 
group hydrolysis and Wolff-Kishner keto group reduction of hecogenin acetate13. This procedure 
was adapted from a well-developed method for the preparation of tigogenin from hecogenin 
acetate14. Using this approach, we produced a large quantity of tigogenin in excess of 98% yield, 
which was then used for further chemical modification to produce alternative stereoisomers. In 
designing the synthetic methodology to prepare functionalized 2,3-spirostane stereoisomers, we 
identified two major obstacles that required resolution prior to the development of a practical 
synthetic approach. The first was (a) how to selectively introduce hydroxyl groups into the C-2 
position; and the second was b) how to differentiate one of the two-hydroxyl groups for hydroxyl 
group protection in order to modify the other synthetically. In the first step, a Jones oxidation15 of 
the OH group in the C-3 position of tigogenin was used to prepare ketone (23, Scheme 3.7). This 
oxidation was necessary because it allows for an acetoxy group to be introduced into the α-position 
to the carbonyl18. Typically, this reaction produces several acetoxy isomers, but in the case of 
steroid substitution, the reaction is both highly site and stereospecific. The acetoxy group is 
introduced in the C-2 position rather than in C-4 position due to steric hindrance of C-4 steroids. 
Further, the reaction occurs from the α-face of steroid, due to β-face steric hindrance, and therefore 
the only isolated product is the keto ester 7 (Scheme 3.10). The preference for α-face substitutions 
in steroid reactions has been well documented. Finally, to generate the 2α, 3β-spirostnae (8) we 
followed a straightforward NaBH4/CeCl3 reduction of the carbonyl group of 7 in 90% isolated 
yield.19 Finally, to complete our synthetic route toward the preparation of 5α-spirotsan-2α, 3β-diol 
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(Scheme 3.7) the ester group of was hydrolyzed in NaOH/methanol + dichloromethane to yield 
compound 25.  
Alternatively, we also developed a highly efficient alternative synthetic approach for the 
preparation of keto acetate 7, avoiding the use of lead tetraacetate, due to pharmacological 
controversy surrounding this reagent20. In our alternative approach, we replaced the lead 
tetraacetate step (Scheme 3.10, step iv) with three very simple and efficient synthetic steps: (a) the 
transfer of ketone 23 into its vinyl acetate 20 (step iii-Scheme 3.10) 21 (b) the mCPBA epoxidation 
of vinyl acetate into epoxide 22 (step v-Scheme 10), and finally; (c) the acetic acid epoxide 22 ring 
opening (step vii-Scheme 3.10). This three step combination that replaced lead tetraacetate with less 
controversial reagents did ultimately give a slightly lower overall yield (75%) for compound 7 than 
what is isolated from a direct reaction with lead tetraacetate (80%), however it can still be used as a 
safe alternative for the preparation of intermediate 5 in our synthesis of functionalized 2,3-
spirostanes.22 
 
 
Scheme 3.10 i) Hydrazine hydrate, 2-ethoxyethanol, KOH, 136oC; ii) CrO3/H2SO4/dry Acetone; iii) (CH3CO)2O/ 
Montmorillonite clay; iv) Pb(O2CCH3)4/(CH3CO)2O-CH3CO2H;  v) m-chloroperbezoic acid/ CH2Cl2; 
vi) CeCl3x7H2O/CH3OH/tetrahydrofuran/NaBH4; vii) (CH3CO)2/N(C2H5)3;   viii) NaOH/CH2Cl2/CH3OH.22 
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Stereoselective 2α- acetylation of ketone 23 was clearly evident from 1H-NMR spectra a 
doublet of doublet at 5.25 ppm indicates that acetyl group is on α-face of the molecule, which 
would have been a nice triplet if the acetyl group has been on β-face. Epoxidation of the vinyl 
acatate occurred from the α-face was indicated by similar peak at 3.68 ppm for H-2 proton as was 
in case of cholestane and androstane derivative. 
 
 
Figure 3.3 Portion of 1H-NMR spectra of 2,3-spirostane isomers showing C-2 and C-3 stereochemistry. 
 
The stereochemistry of 2α, 3β-spirostane derivative was confirmed by 1H-NMR spetra 
comparison with the previously reported isomers as well as literature. There is nice multiplet at 4.80 
ppm for H-2 proton and a multiplet at 3.61 ppm for H-3 proton due to differential coupling with the 
proximal prochiral and chiral protons in case of compound 8. Whereas in case of 2β, 3α -spirostane 
13 peaks for H-2 at 4.81 ppm and for H-3 at 3.80 ppm are broad singlet (figure 3.3). Compound 15 
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shows nice multiplet at 3.65 ppm for H-3 proton, which a 3β-isomer hence have similar splitting as 
compound 8. Similar is the case with compound 16, which is a 3β -isomer, have nice multiplet 
splitting for H-3 proton whereas H-2 proton peak is broad singlet as in case of compound 13. 
Switching of acetyl group from C-2 in compound 15 to C-3 in compound 16 can be easily seen by 
H-3 proton peak going up field from 3.65 ppm to 4.81 ppm. The 1H-NMR spectrum was also found 
to be matching with literature report of reported 1H-NMR of 2α, 3β -spirostane by Sondheimer et 
al. Moreover the spilitting patten for H-2 and H-3 proton for similar isomers from cholestane and 
androstane were well matching. 
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3.6 Antifungal assay of spirostane derivatives 
The antifungal activity of the synthesized functionalized 2,3-spirostanes were evaluated in 
vitro using four species of fungi, including Candida albicans, Cryptococcus neoformans, Candida 
glabrata, and the filamentous fungus Aspergillus fumigatus. The results of these screenings are 
summarized in Table 3.1.  Of the nine analogs tested, 2α-acetoxy-5α-spirostan-3β-ol (65) was the 
only compound that showed significant antifungal activity (>50% inhibition at the minimal 
concentration) against all four species tested, with C. glabrata being the most sensitive at the lowest 
concentration (6.25 µg/mL) and the filamentous fungi A. fumigatus being the least sensitive (where 
50% inhibition was only observed in the highest dose tested- 128µg/mL).  Hydrolysis of the 
acetoxy group of 8 (yielding compound 25) resulted in the total loss of antifungal activity against 
all species tested, as did inversion of the stereocenter on the C-3 (to yield compound 15) as well as 
on the C-2 and C-3 positions (to yield compound 13) of isomer 8 (Table 3.1). The combination of 
the change in stereochemistry of both the chiral C-2 and C-3 centers and the acetyl group migration 
from C-2 to C-3 of 8 resulted in the total loss of antifungal activity (see 12-Table 3.1). Finally, the 
inversion of only one of the chiral centers of 8 (C-2 inversion to yield 16-Table 3.1) resulted in the 
total loss of antifungal activity.   
In addition to analyzing in vitro the antifungal properties of all acetate ester and free 2,3-
spirostane isomers, we also analyzed three intermediate compounds with structural similarities to 
compound 8.  These analogs included compounds 9 (tigogenin), 23 and 7 (Table 3.1).  Interestingly, 
the analog tigogenin (9), which contains a β-face OH group in the C-3 position, similar to 8,  
displayed significantly increased activity against C. glabrata and A. fumigatus (>62 µg/mLand 16 
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µg/mL, respectively) compared to 8 (Table 3.1).  One can speculate this might be due to the 
orientation of the binding sites to which these compounds may be binding.  Further studies with 
analogs that contain various sugar and hydrocarbon substitutions to both the α- and β-faces of the 
spirostane molecule were tested (see chapter-4). Nonetheless, the preliminary antifungal evaluation 
of 2,3-functionalized spirostanes identified several of the derivatives that showed moderate 
antifungal activity (as measured spectroscopically by a >50% reduction in fungal growth compared 
to control wells), against at least one species of fungus.   
These 2,3-functionalized derivatives were be used as building blocks for the synthesis of 
novel spirostane-linked glycosides (chapter-4). At this stage of the project we knew that some of 
these derivatives were very active and have potential to be taken further and SAR of these active 
compound could give us a molecule which might be much more active than the naturally occurring 
saponin CAY-1. There are several reports of glycosides linked spirostane molecules having decent 
antifungal activity23, 24. We decided to synthesize branched and linear oligosaccharide and attach 
them to various spirostane derivatives. Detailed synthetic strategy for oligosaccharide synthesis will 
be discussed in details in chapter-4 various approaches for glycosidation with steroid moiety were 
explored. We have synthesized more than thirty compounds with glycosides attached to various 
steroid derivatives with a variation of mono, di and trisaccharides. Similar compounds originated 
from all the three different steroid derivatives we synthesized so far were synthesized and tested in 
vitro for their antifungal activity details of which will be discussed in chapter-5.  
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 Table 3.1 Antifungal activities of novel spirostane analogs (MIC in µg/mL). 
MIC50 (µg/mL)a,f  
Compound 
 
Structure C. albicans b C. glabrata c C. neoformans d A. fumigatus e 
 
9 
 
 
NC* 
 
>62.5 
 
NC* 
 
16 
 
23 
 
 
NC* 
 
NC* 
 
NC* 
 
NC* 
 
7 
 
 
32 
 
NC* 
 
NC* 
 
>128 
 
8 
 
 
16 
 
6.25 
 
62.5 
 
>128 
 
25 
 
 
NC* 
 
NC* 
 
NC* 
 
NC* 
 
13 
 
 
NC* 
 
NC* 
 
NC* 
 
NC* 
22 
 
 
NC* 
 
NC* 
 
NC* 
 
NC* 
 
15 
 
 
NC* 
 
NC* 
 
NC* 
 
NC* 
 
16 
 
 
NC* 
 
NC* 
 
NC* 
 
NC* 
	  aMIC values are reported only for compounds displaying 1) a prominent decrease in turbidity by visual comparison 
to the control wells containing no antifungal and 2) a >50% reduction in fungal growth compared to controls 
containing no antifungal, as measured spectroscopically by absorption at 530 nm. 
bATCC no. 10231;cATCC no. 48435;dATCC no. 36556;eATCC no. 16424 
fAll values were determined after incubation at 35°C for 48 h. 
*denotes compounds that had 1) a slight reduction in turbidity to no change and 2) had less than a 25% reduction in 
growth compared to controls, as measured spectroscopically by absorption at 530 nm. 
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3.7 Conclusions 
The syntheses discussed above by Sondheimer et al. and by Holzapfel et al., Yu et al. 
published a 7-step synthesis of the 2α, 3β-aglycone from diosgenin in 28% yield. Although their 
report is more recent than that of Holzapfel et al., it is less efficient in that it is both lower yielding 
and requires more steps. Even so, it is worth highlighting the fact that these authors chose to invert 
the axial C-3 alcohol of 17a by oxidizing it to ketone 17b and then reducing it to the corresponding 
equatorial alcohol 17c. Yu et al. employed a Luche reduction and made no improvement on the 
yield of this step. Synthesis for 2α, 3β-spirostane derivatives were successfully achieved and after a 
lot of hurdles we finally have a method to synthesize these derivatives in large quantities in just 
four to six steps with very good yield (60-56% overall yield for synthesis). Comparison of 1H-NMR 
spectrum of synthesized isomer was done with previously synthesized isomers and literature 
reported 1H-NMR of similar isomers has proved to be good evidence for the stereochemistry at C-2 
and C-3 positions. Antifungal susceptibility tests for various derivatives of spirostane against four 
different fungal strains have shown some very promising activity. At this stage of the project we 
knew that some of these derivatives were very active and have potential to be taken further and 
SAR of these active compound could give us a molecule which might be much more active than the 
naturally occurring saponin CAY-1. We decided to take these active compounds further and make 
glycosides linked steroidal saponins in hopes that antifungal activity would improve and we might 
find our lead compound in nanomolar range of activity. 
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3.8 Experimental 
3.8.1 General Remarks– All necessary starting materials for the preparation of targeted 
molecules were purchased from Aldrich and were used without further purification.  Thin-layer 
chromatographic analysis (TLC) was performed using silica gel on glass plates and was detected 
under ultraviolet (UV) light and using PMA solution. Column chromatography was performed 
using silica gel porosity 60 Å, partial size 40-75 mm from Sorbent Technologies.  The final 
products of the steroid derivatives were purified by silica gel chromatography and were more 
than 96% pure, as determined by HPLC chromatography (Agilent Technologies, 1200 series).  
Structures of all intermediates and final products were determined by 1H NMR, 13C NMR 
spectroscopy (Varian Unity 400 MHz).  In one instance, the structure was also determined by X-
ray analysis (Steroid 11) using a Bruker SMART 1KCCD automated diffractometer.  Crystals of 
compound were obtained by slow crystallization from a diluted dichloromethane solution.  
Computing x-ray data collection and the cell refinement was performed by Bruker SMART.  
Computing x-ray data reduction was performed by Bruker Saint.  Computing structure solution 
and structure refinement from x-ray data were performed by SHELXL-97. 
3.8.2 Biological Evaluation: Antifungal susceptibility studies and minimal inhibitory 
concentrations (MIC) values for Candida albicans (ATCC no. 10231), Cryptococcus neoformans 
(ATCC no 36556),Candida glabrata (48435), and the filamentous fungus Aspergillus fumigatus 
(ATCC no. 16424) were determined by the broth microdilution technique in accordance with 
NCCLS reference documents M27-A. Microdilution panels ranged from 0.01 to 128 µg/mL.  All 
organisms were subcultured on Sabouraud or potato dextrose agar and passaged to ensure purity 
and viability.  The initiating inocula were prepared by picking 5 isolated colonies ~1mm in 
diameter from freshly prepared plates.  Colonies were resuspended in sterile water, vortexed and 
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the cell density was adjusted spectrophotometrically to the transmittance of a 0.5 McFarland 
standard at 530 nm wavelength, to yield a stock suspension of 1 x 106 - 5 x 106 cells/ mL.  A 
working suspension was then made by diluting the stock 1:100 with RPMI 1640 broth media.  
The working stock was used for all drug studies.   The plates were incubated at 30-35oC for 48 h 
in a humid atmosphere and scored visually with the aid of a reading mirror and 
spectrophotometrically with an automatic plate reader set at 530 nm. MIC values are defined as 
the lowest concentration of agent that prevents any discernible growth, ~50% reduction of 
growth, as compared with drug-free control wells.  Control drugs used were Amphotericin B, 
and itraconazole, all diluted to 1.0 ug/mL concentrations (Sigma-Aldrich).  Controls were run 
parallel to each in vitro screening of the functionalized 2,3-steroid analogs. 
3.8.3 Preparation of spirostanes: 
Preparation of 5α-spirostan-3β-ol (tigogenin) (9):  A 2-Ethoxyethanol (10 mL) solution of 
hecogenin acetate  (18) (1 g; 2.12 mmol) and hydrazine hydrate (1 mL; 20 mmol) was stirred 
under nitrogen atmosphere for 20 minutes and refluxed for one hour.  Into the room temperature 
reaction mixture potassium hydroxide (1g; 17.8 mmol) was added and the reaction mixture was 
refluxed for an additional 3 hours. After cooling to room temperature, the reaction mixture was 
acidified by concentrated hydrochloric acid.  A white crystalline material precipitated and was 
separated by filtration, washed with water, and dried under reduced pressure to give 863 mg 
(98%) of pure product that has 1H NMR and 13C NMR consistent with literature data 31.  Selected 
1H NMR (400 MHz, CDCl3): δ 4.38 (q, J = 11.2 Hz, 1H), 3.58 (m, 1H), 3.47 (m, 1H), 3.37 (t, J = 
10.8 Hz, 1H), 0.96 (d, J = 3.4 Hz, 3H), 0.82 (s, 3H), 0.79 (d, J = 3.2 Hz, 3H), 0.76 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 109.5, 81.0, 71.5, 67.0, 62.3, 56.5,54.5, 45.0, 41.8, 40.7, 40.2, 
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38.4, 37.1, 35.7, 35.3, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 14.7 and 12.5 
ppm.  
 
Preparation of 5α-spirostan-3-one (23):  Tigogenin (9) (1 g, 2.40 mmol) was dissolved in 
acetone (50 mL) at 30°C. 8N chromic acid in 40% H2SO4 (2.5 mL) was added and the mixture 
was stirred for 30 minutes. Water (100 mL) was added and the resulting solid was filtered and 
washed with water and purified by flash column chromatography (1:2 ethyl acetate: hexanes) to 
give (3) as a white solid (930 mg, 93 % yield) which was used immediately in the next reaction. 
Selected 1H NMR (400 MHz, CDCl3): δ 4.39 (q, J = 11.2 Hz, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 
Hz, 1H), 1.02 (s, 3H), 0.96 (d, J = 3.6 Hz, 3H), 0.78 (s, 3H), 0.78 (d, J = 2.0 Hz, 3H) ppm. 13C 
NMR (100 MHz, CDCl3): δ 212.1, 109.4, 80.9, 67.0, 62.4, 56.3, 54.0, 46.8, 44.8, 41.8, 40.7, 
40.1, 38.7, 38.3, 35.9, 35.2, 32.0, 31.9, 31.5, 30.4, 29.0, 29.0, 21.4, 17.3, 16.6, 14.7 and 11.7 
ppm25. 
 
Preparation of 3-acetoxy-5α-spirost-2-ene (20):  An acetic acid (100 mL) suspension of 5α-
spirostan-3-one (23) (1g; 2.4 mmol) and montomorillonite clay (500 mg) was stirred at room 
temperature overnight.  The clay catalyst was separated by filtration and the filtrate was 
extracted with ether (3x30 mL).  The combined ether extracts were washed with saturated 
sodium bicarbonate (3x20 mL), brine (3x20 mL) and dried over anhydrous magnesium sulfate.  
The ether was evaporated under reduced pressure to give 1.0 g (90%) of white crystalline 
product (20). Selected 1H NMR (400 MHZ, CDCl3): δ 5.21 (d, 1H), 4.38 (q, J = 11.2 Hz, 1H), 
3.47 (m,1H), 3.37 (t, J = 10.8 Hz, 1H), 2.08 (s, 3H),   0.96 (d, J = 3.4 Hz, 3H), 0.82 (s, 3H), 0.79 
(d, J = 3.2 Hz,3H), and 0.76 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 165.2, 81.0, 71.5, 
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67.0, 62.3, 56.5,54.5, 45.0, 41.8, 40.7, 40.2, 38.4, 38.2, 37.1, 35.7, 35.3, 32.4, 31.9, 31.7, 31.5, 
30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 14.7 and 12.5 ppm. [The compound was previously prepared 
by Johns from (23) and isopropenyl acetate in the presence of sulfuric acid 26]. 
 
Preparation 2α-acetoxy-5α-spirostan-3-one (7):  Method A: A mixture of acetic acid (30 mL) 
and acetic anhydride (5 mL) was refluxed for ten minutes.  Into a room temperature cooled 
reaction mixture, 5α-spirostan-3-one (23) (830 mg; 2 mmol) and lead tetraacetate (1.1 g 3 mmol) 
was added and the resulting mixture was refluxed for 24 hours.  Into the room temperature 
cooled reaction mixture diethyl ether (150 mL) was added and the resulting mixture was washed 
with 5% hydrochloric acid (3x20 mL), saturated bicarbonate (3x30 mL) and brine (3x20 mL).  
The ether layer was dried over anhydrous magnesium sulfate and evaporated under reduced 
pressure to give (80%) of pure product (7).  Method B: An acetic anhydride solution (20 mL) of 
2α-acetoxy-2β,3α-epoxy-5α-spirostane (22) (950 mg; 2 mmol) and a catalytic amount of 
triethylamine (0.15 mL) was refluxed for 2 hours.  After cooling to room temperature, the 
reaction mixture was extracted with ether (3x20 mL).  The ether was evaporated giving pure 
product in 98% isolated yield.  Selected data: 1H NMR (400 MHz, CDCl3): δ 5.29 (dd, 1H), 4.38 
(q, J = 11.2 Hz, 1H), 3.47 (m,1H), 3.37 (t, J = 10.8 Hz, 1H), 2.08 (s, 3H), 0.96 (d, J = 3.4 Hz, 
3H), 0.82 (s, 3H), 0.79 (d, J = 3.2 Hz,3H), and 0.76 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 
165.2,162.5, 81.0, 71.5, 67.0, 62.3, 56.5,54.5, 45.0, 41.8, 40.7, 40.2, 38.4, 38.2, 37.1, 35.7, 35.3, 
32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 14.7, 12.5 ppm. [Physical properties of 
our compound are in agreement with ones previously published 27]. 
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Preparation 2α-acetoxy-2β ,3α-epoxy-5α-spirostane (22): A dichloromethane (20 mL) 
solution of 3-acetoxy-5α-spirost-2-ene (4) (910 mg; 2 mmol) and m-chloroperbenzoic acid (520 
mg; 3 mmol) was stirred at room temperature for 1 hour.  Into this reaction mixture 10% sodium 
sulfite (20 mL) was added and reaction mixture was stirred for additional 20 minutes.  The 
reaction mixture was extracted with ether (3x30 mL).  The combined ether extracts were washed 
with water (3x20 mL) dried over anhydrous magnesium sulfate and evaporated to give 800 mg 
(85%) pure epoxide 22.  Selected data: 1H NMR (400 MHz, CDCl3): δ 4.38 (q, J = 11.2 Hz, 1H), 
3.47 (m,1H), 3.37 (t, J = 10.8 Hz, 1H), 3.25 (d,1H), 2.08 (s, 3H), 3.25 (d,1H), 0.96 (d, J = 3.4 
Hz, 3H), 0.82 (s, 3H), 0.79 (d, J = 3.2 Hz,3H), and 0.76 ppm (s, 3H). 13C NMR (100 MHz, 
CDCl3): δ 165.2, 81.0, 71.5, 67.0, 62.3, 56.5,54.5, 45.0, 41.8, 40.7, 40.2, 38.4, 38.2, 37.1, 35.7, 
35.3, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 14.7, 12.5 ppm. 
 
Preparation of 2α-acetoxy-5α-spirostan-3β-ol (8): A tetrahydrofuran (10 mL) and methanol 
(5 mL) solution of 2α-acetoxy-5α-spirostan-3-one (23) (350 mg; 0.8 mmol) CeCl3x7H2O (373, 
1mmol) was stirred at room temperature for 10 minutes prior addition of sodium borohydride (60 
mg; 1.6 mmol).  The reaction mixture was stirred for additional 30 minutes following sodium 
borohydride addition.  The reaction mixture was acidified with 5% hydrochloric acid and 
extracted with ether (3x20 mL).  Combined ether extracts were dried over anhydrous magnesium 
sulfate and evaporated to give pure product in 90% isolated yield (8). Selected data: 1H NMR 
(400 MHz, CDCl3): δ 4.82 (1H, ddd, J =4.8, 9.4, 11.6 Hz, H-2b), 4.38 (q, J = 11.2 Hz, 1H), 3.59 
(1H, ddd, J = 4.7, 9.0, 11.5 Hz, 1H), 3.47 (m,1H), 3.37 (t, J = 10.8 Hz, 1H), 2.08 (s, 3H),  0.96 
(d, J = 3.4 Hz, 3H), 0.82 (s, 3H), 0.79 (d, J = 3.2 Hz,3H), 0.76 (s, 3H) ppm. 13C NMR (100 MHz, 
CDCl3): δ 165.2,162.5, 81.0, 71.5, 67.0, 62.3, 56.5,54.5, 45.0, 41.8, 40.7, 40.2, 38.4, 38.2, 37.1, 
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35.7, 35.3, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 14.7, 12.5 ppm. [Physical 
properties of our compound are in agreement with literature 28-31]. 
 
Preparation of 5α-spirostan-2α, 3β-diol (25):  A methanol (2 mL) and dichloromethane (10 
mL) solution of 2α-acetoxy-5α-spirostan-3β-ol (8) (475 mg; 1 mmol) and sodium hydroxide 
(0.12 g; 3 mmol) was stirred at room temperature overnight. Into the reaction mixture the acidic 
resin-dowex (1g) was added and this suspension was stirred at room temperature for 5 minutes.  
The resin was separated by filtration and the filtrate was evaporated to result in 368mg (85%) of 
pure product (25).  Selected data: 1H NMR (400 MHz, CDCl3): δ 4.38 (q, J = 11.2 Hz, 1H), 3.59 
(1H, ddd, J =4.7, 9.0, 11.5 Hz, 1H), 3.47 (m,1H), 3.40(1H, ddd, J = 5.1, 8.9, 10.9 Hz, 1H) 3.37 
(t, J = 10.8 Hz, 1H), 0.96 (d, J = 3.4 Hz, 3H), 0.82 (s, 3H), 0.79 (d, J = 3.2 Hz,3H), and 0.76 (s, 
3H) ppm. 13C NMR (100 MHz, CDCl3): δ 81.0, 72.5, 72.0, 71.5, 67.0, 62.3, 56.5,54.5, 45.0, 
41.8, 40.7, 40.2, 38.4, 38.2, 37.1, 35.7, 35.3, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 
16.7, 14.7 and 12.5 ppm. 
 
5α-Spirost-2-ene (10): NaH (5.8 mg, 0.24 mmol) was stirred in tetrahydrofuran (10 mL). 
Tigogenin (9) (100 mg, 0.24 mmol) was added and stirred at room temperature for 30 minutes.  
Carbon disulfide (130 mg, 1.7 mmol) was added and stirred another 2 hours.  3-Bromopropyne 
(140 mg, 1.2 mmol) was added and the mixture was stirred an additional 3 hours at room 
temperature. The reaction was quenched with saturated NH4Cl (40 mL), extracted with 
dichloromethane (3x50 mL), and the organic layers were combined and dried over sodium 
sulfate. The solvents were removed under reduced pressure and the residue was purified by flash 
column chromatography (1:1 ethyl acetate: hexanes) to give the propargyl 5α-spirostan-3β-yl 
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xanthate, which was used immediately in the following reaction. Selected 1H NMR of the 
xanthate (500 MHz, CDCl3): δ 5.50 (m, 1H), 4.40 (q, J = 11.3 Hz, 1H), 3.85 (s, 1H), 3.82 (s, 
1H), 3.48 (m, 1H), 3.38 (t, J = 11.0 Hz, 1H), 0.97 (d, J = 3.5 Hz, 3H), 0.88 (s, 3H), 0.80 (d, J = 
3.0 Hz, 3H), and 0.77 ppm (s, 3H). Trifluoromethanesulfonic acid (1.0 mL, 11 mmol) and 2,4,6-
trimethylpyridine (1.5 mL, 11 mL) were stirred at 0°C in diethyl ether (5 mL). A portion of the 
resulting sulfonate salt (7.0 mg, 0.02 mmol) was transferred to a solution of propargyl 5α-
spirostan-3β-yl xanthate (0.24 mmol) in toluene (10 mL). The reaction was refluxed 30 hours, 
cooled to room temperature, and the solvent was removed under reduced pressure. The resulting 
solid was purified by flash column chromatography (1:10 ethyl acetate: hexanes) to give 9 as a 
white solid (88 mg, 91 % yield over 2 steps from 2). Selected 1H NMR (400 MHz, CDCl3): δ 
5.56 (m, 2 H), 4.37 (q, J = 11.2 Hz, 1H), 3.45 (m, 1H), 3.35 (t, J = 10.4 Hz, 1H), 0.94 (d, J = 3.8 
Hz, 3H), 0.78 (s, 3H), 0.75 (s, 3H), and 0.75 (d, J = 3.2 Hz, 3H) ppm.  13C NMR (100 MHz, 
CDCl3): δ 126.0, 109.4, 81.0, 68.0, 67.0, 62.4, 56.5, 54.2, 41.8, 41.6, 40.6, 40.2, 39.9, 35.4, 34.9, 
32.2, 32.1, 31.9, 31.6, 30.5, 29.9, 29.0, 28.8, 20.9, 17.3, 16.6, 14.7 and 11.9 ppm. Alternatively, 
10 was also prepared from 9 via methyl 5α-spirostan-3β-yl xanthate.  Sodium hydride (10 mg, 
0.42 mmol) was suspended in tetrahydrofuran (10 mL).  Tigogenin (9) (100 mg, 0.24 mmol) was 
added and stirred at room temperature 30 minutes. Carbon disulfide (130 mg, 1.7 mmol) was 
added and stirred another 2 hours. Methyl iodide (170 mg, 1.2 mmol) was added and the mixture 
was stirred an additional 3 hours at room temperature. The reaction was quenched with saturated 
NH4Cl (40 mL), extracted with dichloromethane (3x50 mL), and the organic layers were 
combined and dried over sodium sulfate. The solvents were removed under reduced pressure and 
the residue was purified by flash column chromatography (1:15 ethyl acetate: hexanes) to give 
methyl 5α-spirostan-3β-yl xanthate, which was used immediately in the following reaction.  
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Selected 1H NMR of methyl 5α-spirostan-3β-yl xanthate (400 MHz, CDCl3): δ 5.47 (m, 1H), 
4.37 (q, J = 11.4 Hz, 1H), 3.45 (m, 1H), 3.35 (t, J = 10.8 Hz, 1H), 2.52 (s, 3H), 0.94 (d, J = 3.6 
Hz, 3H), 0.85 (s, 3H), 0.77 (d, J = 3.2 Hz, 3H), 0.74 (s, 3H) ppm. Methyl 5α-spirostan-3β-yl 
xanthate was heated at 200°C for 2 hours under reduced pressure. The resulting solid was 
purified by flash column chromatography (1:10 ethyl acetate: hexanes) to give (10) as a white 
solid (90 mg, 94 % yield). [Preparation was performed by modification of general procedures for 
preparation of olefins from alcohols 32]. 
 
Preparation of 2α ,3α-epoxy-5α-spirostane (11):  A dichloromethane solution of 5α-spirost-2-
ene (10) (4.44 g; 11.15 mmol) and m-chloroperbenzoic acid (2.12 g; 12.3 mmol) was stirred at 
room temperature for 30 minutes.  Aqueous (5%) sodium sulfite (100 mL) was added and the 
mixture was stirred for an additional 15 minutes.  The organic layer was separated and the 
aqueous phase was extracted with dichloromethane (3x100 mL).  Combined organic layers were 
washed with saturated sodium bicarbonate (3x30 mL), followed by brine (3x30 mL), and dried 
over anhydrous magnesium sulfate.  The solvent was removed under reduced pressure and the 
resulting solid was purified by flash column chromatography in hexane-ethyl acetate (5:1) to 
give 4.20 g (91 %) of white crystalline product.  Selected 1H NMR (400 MHz, CDCl3): δ 4.36 (q, 
J = 11.2 Hz, 1H), 3.45 (m, 1H), 3.35 (t, J = 10.8 Hz, 1H), 3.13 (br s, 1H), 3.09 (m, 1H), 0.94 (d, 
J = 3.6 Hz, 3H), 0.77 (d, J = 3.4 Hz, 3H), 0.75 (s, 3H), 0.73 (s, 3H) ppm.   13C NMR (100 MHz, 
CDCl3): δ 109.4, 80.9, 67.0, 62.3, 56.3, 53.8, 52.5, 51.1, 41.8, 40.5, 40.1, 38.4, 36.4, 35.4, 33.9, 
32.0, 31.9, 31.5, 30.4, 29.2, 29.0, 28.5, 20.8, 17.3, 16.5, 14.7 and 13.1 ppm. 
 
	   104	  
Preparation of 3α-hydroxy-5α-spirostan-2β-yl acetate (12) and 2β-hydroxy-5α-spirostan-
3α-yl acetate (13):  An acetic acid (10 mL) solution of epoxide 11 (100 mg; 0.24 mmol) was 
refluxed for 2 hours.  The solution was co-evaporated with toluene (3x5 mL) and the resulting 
solid was purified by gravity column chromatography in hexane- ethyl acetate (4:1) to give 12 
(70 mg; 64%) and 13 (19 mg; 17%). Selected 1H NMR for 12 (400 MHz, CDCl3): δ 4.87 (br s, 
1H), 4.38 (q, J = 11.2 Hz, 1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 2.04 (s, 
3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), and 0.75 ppm (s, 3H).   13C 
NMR (100 MHz, CDCl3): δ 170.5, 109.5, 81.0, 73.3, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 
40.2, 38.7, 37.3, 35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7, 
and 13.9 ppm. Selected 1H NMR for 13 (400 MHz, CDCl3): δ 4.78 (m, 1H), 4.39 (q, J = 11.2 Hz, 
1H), 4.10 (br s, 1H), 3.66 (m, 1H), 3.38 (t, J = 10.8 Hz, 1H), 2.09 (s, 3H), 1.06 (s, 3H), 0.96 (d, 
J=3.4Hz,3H), 0.79 (d, J=3.0Hz, 3H), 0.77 (s, 3H) ppm. 13CNMRof 12 (100 MHz, CDCl3): δ 
170.3, 109.4, 81.0, 75.7, 68.8, 67.0, 62.3, 56.3, 55.3, 45.6, 43.1, 41.7, 40.8, 40.1, 35.6, 34.6, 32.2, 
31.9, 31.5, 30.4, 28.9, 28.7, 28.2, 21.5, 21.2, 17.3, 16.7, 14.7 and 14.6 ppm. 
Preparation of 2β-acetoxy-5α-spirostan-3α-yl methylsulfonate (14):  A dichloromethane (15 
mL) solution of acetate 12 (474 mg; 1 mmol), methanesulfonyl chloride (0.15 mL; 1.5 mmol), 
and triethylamine (0.25 mL; 1.75 mmol) were stirred at 0°C under nitrogen atmosphere for 2 
hours.  Ice cold hydrochloric acid (1M, 50 mL) was added.  The organic layer was separated and 
the aqueous layer was extracted with dichloromethane. Combined organic layers were washed 
with water (3x20 mL), dried over anhydrous magnesium sulfate and evaporated under reduced 
pressure to give 458 mg (83%) of 14 that was used in next reaction without further purification. 
Selected 1H NMR (400 MHz, CDCl3): δ 4.99 (br s, 1H), 4.68 (br s, 1H), 4.40 (q, J = 11.6 Hz, 
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1H), 3.48 (m, 1H), 3.37 (t, J = 11.1 Hz, 1H), 3.08 (s, 3H), 0.96 (d, J = 3.5 Hz, 3H), 0.94 (s, 3H), 
0.79 (d, J = 3.2 Hz, 3H), and 0.76 (s, 3H) ppm. 
 
Preparation of 3β-hydroxy-5α-spirostan-2β-yl acetate (15) and 2β-hydroxy-5α-spirostan-
3β-yl acetate (16): A pyridine solution (20 mL) of sulfonate 14 (50 mg; 0.09 mmol) and water 
(5 mL) was refluxed for 7 hours.  The solvent was removed under reduced pressure and the 
product was co-evaporated with toluene (3x5 mL) and purified by silica gel flash column 
chromatography in hexane-ethyl acetate (4:1 → 1:1) to give 15 (87%) and 16 (10%) as white 
solids.  Selected 1H NMR of 15 (400 MHz, CDCl3): δ 5.14 (br s, 1H), 4.39 (q, J = 11.4 Hz, 1H), 
3.69 (m, 1H), 3.47 (m, 1H), 3.37 (t, J = 10.8 Hz, 1H), 2.10 (s, 3H), 0.96 (d, J = 3.4 Hz, 3H), 0.93 
(s, 3H), 0.79 (d, J = 3.0 Hz, 3H), 0.76 (s, 3H) ppm. Selected 1H NMR of 16 (400 MHz, CDCl3): 
δ 4.78 (m, 1H), 4.39 (q, J = 11.2 Hz, 1H), 4.10 (br s, 1H), 3.66 (m, 1H), 3.38 (t, J = 10.8 Hz, 
1H), 2.09 (s, 3H), 1.06 (s, 3H), 0.96 (d, J = 3.4 Hz, 3H), 0.79 (d, J = 3.0 Hz, 3H), 0.77 (s, 3H) 
ppm. 
 
Preparation of diluted compounds: None of the compounds tested over the course of these 
studies were soluble in water.  Therefore, DMSO was used to dilute each compound tested.  
Master stock concentrations of drugs were prepared to ensure that the maximum final 
concentration of DMSO in tested antifungal solutions was 1% or less.  Subsequent 2-fold serial 
dilutions were made using RPMI 1640 broth or sterile water to a final concentration of 1280-0.1 
ug/mL.  A final 10-fold dilution of each drug was made by aliquotting 0.1 mL of each dilution to 
0.9 mL of inoculating media (see preparation below), giving final drug concentrations tested in 
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the range of 128-0.01 ug/mL.  All drug controls used were diluted to 1.0 ug/mL concentrations, 
according to the manufacturer’s instructions. 
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CHAPTER-4: SYNTHESIS AND ANTIFUNGAL EVALUATION OF SPIROSTANE 
SAPONINS  
 
Spirostane saponins are an important class of natural products, which probably best 
known as starting materials for synthesis of various steroidal hormones. Spirostane saponins are 
composed of an aglycone moiety (also referred to as steroidal sapogenin) and a sugar chain of 
one or more monosaccharides. There are at least 90 plant families containing such compounds, 
particularly in monocotyledons1. The antifungal activity of spirostane saponins, particularly 
against agricultural pathogens has been known for long time2-4, while other reported activities of 
this class of compounds include antitumour, hypoglycemic, immunoregulatory, and 
cardiovascular disease prevention and treatment1. Saponins exist in the plants in such a 
complicated manner that one plant species normally contains more than several dozen 
structurally similar saponins. Isolation of a single pure saponin from plants, especially in 
considerable amounts, is extremely difficult. Consequently, many saponin extracts from herbs 
have been directly used to treat various human diseases without evaluation of the 
pharmacological activities of each component. Chemical synthesis would provide a realistic way 
to obtain homogeneous saponins and therefore opportunities for understanding the actions of a 
saponin on the human body. 
Our specific aim towards finding high potency antifungal saponin focused on synthesis of 
various saccharide drivatives of the most active steroid derivatives identified so far. In order to 
explore Structure Activity Relationship (SAR) study it was decided to synthesize mono-, di- and 
tri-saccharide saponins with a variety of sugar linkages. It was planed to synthesize linear as well 
as branched oligosaccharide in order to find out ideal linkage between sugar units for better 
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antifungal activity. Developed synthesis for glycoside derivatives of steroid could be used for 
total synthesis of various naturally occurring antifungal saponins including CAY-1.  
4.1 Synthesis of glycosides and saccharides:  
Glycoside syntheses in past years were initially focused mainly on the improvements of 
the well-known Koenigs-Knorr method, introduced in 1901, which requires an exchange of the 
anomeric hydroxyl group by bromine or chlorine as the first step (generation of glycosyl-group 
donor). The second step involves glycosyl group transfer to the glycosyl acceptor in the presence 
of a heavy metal ion promoter (Scheme-4.1, path B). Several inherent disadvantages associated 
with this method makes it often experimentally demanding and certainly unsuitable for large–
scale synthesis. For example it requires at least equimolar amounts of the heavy metal salt 
promoter, often incorrectly termed as “catalyst,” is a limiting factor5-7. Hence, alternative 
methods are of interest in order to overcome these shortcomings. 
The Fischer-Helferich method, as a direct anomeric-oxygen replacement reaction 
(Scheme-4.1, method A), has been very successfully applied for the synthesis of simple alkyl 
gluycosides. However, because of its reversibility, it has not gained general importance in the 
synthesis of complex oligosaccharides and glycoconjugates6-7.  
The requirements for glycoside syntheses, high chemical and stereochemical yield, and 
applicability to large-scale preparations were not effectively met by any of the methods just 
described. However, the general strategy for glycoside synthesis seemed to be reasonable. Only 
simple means of meeting these requirements will lead to a generally acceptable and useful 
methodology. Therefore, besides acid activation (Scheme-4.1, A and B), the simplest form of 
activation would be base activation generating first as anomeric alkoxide structure of pyranose or 
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furanose (Scheme-4.1, paths C and D). This method was very interesting as nature has a similar 
approach for generating glycosyl donors, namely glycosyl phosphate formation8, 9. 
 
 
Scheme 4.1 Synthesis of glycosides and saccharides9 
 
In beginning, direct anomeric O-alkylation seemed very unlikely to fulfill all the 
requirements for glycoside and saccharide synthesis. Although all remaining functional groups 
are protected, the ring-chain tautomerism between the anomeric forms and open side chain form 
(Schem-4.1, path C) already gives three possible sites for attack of the alkylating agent. Base 
catalyzed elimination in the open-chain form of the sugar could be a destructive side reaction. 
Therefore, the yield, regioselectivity and stereoselectivity of such direct anomeric O-alkylation 
would not be expected to be very good. 
O
OH
O
O-
O
OH
O
O
O
OR
O
Hal
O-H+
A BH
BaseAcid
ROH RX A B
ROH
MIld acid
ROH
Ag+
Hal-
Activation through 
retention of the 
anomeric oxygen
Glycosyl donors via 
anomeric-oxygen 
exchange reactions
O
H
A
B C
D
A. Fischer- Helferich (Acid Activation) 
B. Knonigs-Knorr; Br, Cl, (I) Activation
                                        F- Activation
                                     RS- Activation
C. Anomeric O-Alkylation: Base Activation
D. Trichloroacetimidate  (Imide Activation)
                                        SO2R-Activation
                                  PO(OR)2- Activation
	   114	  
The desired formation for the stable anomeric O-activated inetremediates via base 
catalysis requires system for reactivity in the subsequent glycosylation step. Therefore, after 
base-promoted trapping of anomeric O-activated inetermediates, mild acid treatment in the 
presence of acceptors, leads to formation of glycosides in an irreversible manner (Scheme-4.1, 
Path D) 5,9. Electron-deficient nitriles, such as trichloroacetonitrile and trifluoroactonitrile are 
known to undergo direct and reversible, base catalyzed addition of alcohols providing O-alkyl 
trichloroacetimidates10. This imidate synthesis has the advantage that the free imidates can be 
isolated as stable adducts, which are less sensitive to hydrolysis than corresponding salts. 
 
Scheme 4.2 Schmidt’s trichloroacetimidate method.11 
 
A detailed study of addition of trichloroacetonitrile to 2,3,4,6-tetra-O-benzyl-D-glucose 
revealed that from equatorial 1-oxide ion, the β-trichloroacetimidate is generated preferentially 
or even exclusively in a very rapid and reversible addition reaction (Schem-4.2) 5-7. However, 
this product anomerizes in a slow, base catalyzed reaction (via retroreaction, anomerization of 1-
oxide ion, and renewed trichloroacetonitrile addition) to the α-tricholoroactimidate having 
electron withdrawing 1-substituent in an axial position as favored by the thermodynamically 
operating anomeric effect11. Thus, with different bases for example K2CO3, Cs2CO3, NaH and 
1,8-diazobicyclo[5,4,0]undec-7-ene(DBU) both O-activated anomers may be isolated in pure 
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form and high yields via kinetic and thermodynamic reaction-control. Both anomers are 
commonly thermally stable and may be easily stored. Therefore if we wish to form 
thermodynamic product the base catalyzed reaction must go for longer period of time in order to 
anomerize kinetic product. 
 
4.2 Anomeric effect: Anomeric effect is defined as the preference of an electronegative 
substituent at the anomeric position of a carbohydrate to be axially rather than equatorially 
oriented. There are two most accepted explanations for anomeric effect being used over the 
years. 
 
Figure 4.1. The anomeric effect13 
 
One explanation for the anomeric effect is that there is less lone pair interaction between 
the substituent and the ring oxygen atom for gauche conformations (Figure 4.1).  
A second explanation is that the dipoles generated by the substituent and the ring oxygen 
atom is in opposing directions in the axial anomer and they are in similar directions in the 
equatorial anomer11, 12. Finally, the most widely accepted explanation for the anomeric effect is 
the stabilizing effect created by hyperconjugation between the axial lone pair on the ring oxygen 
atom and the σ* orbital of an axial heteroatom substituent on the anomeric carbon (Fig. 4.2). 
This type of stabilization by hyperconjugation is not possible when the substituent is equatorial. 
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Figure 4.2. Explanations for the anomeric effect12 
 
4.3 Glycosylation method for oligosaccharides: 
Many well-developed glycosylation methods for oligosaccharide synthesis follow the 
same general mechanism (Scheme 4.1), in the presence of a promoter; the leaving group of the 
glycosyl donor is freed from the molecule5,7, 13-14. The structure of the oxocarbenium 
intermediate formed depends on the nature of the C-2 substituent of the glycosyl donor. 
Participating groups, such as alkyl or aryl esters and amides, can help stabilize the intermediate 
and tend to favor the formation of 1,2-trans-glycosides (Scheme 4.3). It is important to note that 
in this case a side reaction occurs to form an orthoester. Even though orthoester formation is 
reversible, it can still have a deleterious effect on the glycosylation depending on the nature of 
the glycosyl donor and acceptor and the reaction conditions. 
Glycosyl donors with non-participating groups at C-2, such as ethers, called armed 
donors, react faster than those with participating groups at C-2 (disarmed donors). This is due to 
the fact that the C-2 substituent of an armed donor is less electron withdrawing than that of a 
disarmed donor and therefore the oxocarbenium intermediate forms faster (Scheme 4.3). In this 
case, the stereoselectivity of the glycosylation is largely solvent dependent. 
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Scheme 4.3. Generalized mechanism for glycosylation reactions5 
 
 
 
The trichloroacetimidate glycosylation method was selected due to the fact that it is 
generally high yielding and highly stereoselective even in complex oligosaccharide syntheses15-
18. The trichloroacetimidate donors are formed by the reaction of the anomeric alcohol with 
trichloroacetonitrile under basic conditions. Strong bases, such as sodium hydride, and longer 
reaction times favor the formation of the thermodynamically more stable α- trichloroacetimidate.  
The stereoselectivity of the donor is important for SN2 type glycosylations, which can be 
favored for the trichloroacetimidate method by using weaker promoters, such as BF3·OEt2.8 
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donors without a neighbouring group give mixture of the α- and β-anomeric glycosides.  
Yu et al. have reported synthesis of trifluoroacetimidate and demonstrated to be effective 
glycosyl donors in the presence of TMSOTf 20. Their method utilized 2,3,4,6-tetra-O-benzoyl-α-
D-glucopuranosyl trichloroacetimidate as glycosyl donor and a catalytic amount of trimethylsilyl 
trifluoromethanesulfonate (TMSOTf, 0.05equvalent) as a promoter that produces the 
corresponding saponin quantitatively. (Scheme 4.4) 
No benzoyl groups transfer products or ortho-esters were detected. The newly formed 
glycosidic bonds were proved to be exclusively 1,2-trans on the basis of their 1H NMR spectra19. 
They have also reported condensation of glycosyl trichloacetimidate with cholesterol in high 
yield and selectivity. The same methodology was applied to the synthesis of a trisaccharide 
saponin, dioscin.20 
 
 
Scheme 4.4. Glycosylation of sapogenins reported by Yu et al. 20 
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4.4 Synthesis of 2,3,4,6-tetra-O-benzoyl-α-D-glucopuranosyl trichloroacetimidate:  
Our synthesis of 2,3,4,6-tetra-O-benzoyl-α-D-glucopuranosyl trichloroacetimidate started 
with α-D-glucose, all hydroxyl groups were protected with benzoyl group with well-known 
esterification by benzoyl chloride in pyridine to get compound 7. The anomeric benzoyl group 
was selectively deprotected by mild base ethanolamine in ethylacetate and dimethylsulfoxie to 
get anomeric free hydroxyl group in compound 8 (Scheme 4.5) 21. Base catalysed activaton of 
anomeric oxygen in presence of trichloroacetonitrile in dichloromethane gave the desired 
compound in almost quantitative yield22, 23. The last step of reaction took 48hrs as we desired to 
make α-trichloroacetimidate which is the thermodynamic product, as was discussed previously 
that the kinetic product of this reaction β-tricholoacetimidate formed preferentially. However, 
this product anomerizes in a slow, base catalyzed reaction to the α-tricholoroactimidate having 
electron withdrawing 1-substituent in an axial position as favored by the thermodynamically 
operating anomeric effect. (Scheme 4.2) 
 
 
Scheme 4.5 Synthesis of 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl trichloroacetimidate: i) Pyridine, benzoyl 
chloride, reflux; ii) Ethanolamine, DMSO, EtOAc; iii) Trichloroacetonitrile, K2CO3, DCM, RT, 48hrs.  
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4.5 Retroanalysis of saccharide moiety of  saponin CAY-1: 
Synthesis of (1-3)-β linked disaccharide trichloroacetimidate was our first priority as 
CAY-1 oligosaccharide moiety has a (1-3)-β linked disaccharide attached to the central glucose. 
Retroanalysis of pentasaccharide moiety of CAY-1 was done in order to emphasize importance 
of having synthetic methodology for (1-3)-β linked disaccharide trichloroacetimidate, which 
could be attached directly to central sugar unit in its convergent synthesis (Scheme 4.6). The 
developed synthesis will give an edge over for the convergent synthetic approach for synthesis of 
branched oligosaccharides with similar skeleton as CAY-1 oligosaccharide moiety.  
 
Scheme 4.6 Retro-analysis of CAY-1 Pentasaccharide Moiety 
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4.6 Synthesis of (1→3)-β  linked disaccharide trichloroacetimidate: 
Synthesis of (1→3)-β linked disaccharide trichloroacetimidate utilizes glycosylation of 
2,3,4,6-tetra-O-benzoyl-α-D-glucopuranosyl trichloroacetimidate with diacetone-D-glucose, 9 in 
presence of acid catalyst BF3.OEt2 to give the coupled product 10.24 In presence of trifluoroactic 
acid and water the diacetone-protecting group was cleaved followed by rearrangement to give 
partially benzoyl protected disaccharide compound 11 (Scheme 4.7, step ii). Benzoyl protection 
of 11 was achieved by pyridine and benzoyl chloride under reflux conditions to get octa-
benzoylated disaccharide compound 12. Anomeric  benzoyl group was cleaved by mild base 
ethanolamine in ethyl acetate and DMSO to get compound 13 in 85% of isolated yield after 
column purification. Anomeric oxygen of 13 was then activated by base catalyzed reaction with 
tricholoroacetonitrile to give the disaccharide trichloroacetimidate compound 14 in quantitative 
yield. (Scheme 4.7)  
 
Scheme 4.7 Synthesis of (1-3)-β linked disaccharide trichloroacetimidate: i) BF3.OEt2, DCM; ii) TFA, THF/H2O; 
iii) pyridine, benzoyl chloride, reflux; iv) ethanolamine, DMSO, EtOAc;v) trichloroacetonitrile, K2CO3, DCM, room 
temperature, 48hrs.  
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4.7 Synthesis of various disaccharide trichloroacetimidates: 
After accomplishing the synthesis of mono and disaccharide trichloroacetimidate we 
utilized this methodology to synthesize various other disaccharide trichloroacetimidate starting 
from commercially available simple disaccharide molecules like maltose, lactose, cellobiose, and 
melibiose (Scheme 4.8). The idea behind synthesis of various disaccharide units and attach them 
to steroidal part in order to extensively explore SAR study and see what kind of linkage between 
two sugars would be needed to achieve best antifungal activity. Synthesis of a variety of 
disaccharide trichloroactimidate will also provides us an opportunity to synthesis a wide variety 
of branched oligosaccharide which might be needed for antifungal activity as in case of 
antifungal saponin CAY-1, which was not evident at this stage of project. 
 
Scheme 4.8 Synthesis of various disaccharide trichloroacetimidates : i) Pyridine, benzoyl chloride, reflux; ii) 
Ethanolamine, DMSO, EtOAc; iii) Trichloroacetonitrile, K2CO3, DCM, RT, 48hrs. 
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4.8 General methodology for Glycosylation: 
Glycosylation of trichloroacetimidates with various steroid derivatives synthesized 
previously was the next objective in our mind. Since we had no idea how many sugar units were 
optimum to achieve best antifungal activity, it was decided to start attaching one sugar unit first 
then two or three sugar units depending on the assay results. In order to have a fare SAR study 
and comparison between three different steroidal derivatives, it was decided that similar 
glycoside derivatives will be synthesized for all three steroids in order to comparative study of 
their antifungal activity.  
Glycosylation was achieved in general by TMSOTf catalyzed reaction in 
dichloromethane of activated sugar trichloroactimidate and steroidal derivative with free 
hydroxyl group at either C-2 or C-3 positions (Scheme 4.9). The benzoyl protection of sugar was 
removed after glycosylation reaction by sodium methoxide in methanol and dichloromethane 
mixture to get the desired saponin product after column purification. 
 
 
Scheme 4.9 Glycosylation for synthesis of Steroidal saponin: a general scheme.  
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4.9 Monosaccharide derivatives of steroids: 
 
Antifungal evaluation of glycosides linked steroid derivatives was initially done with 
monosaccharide derivatives and a significant increase in antifungal activity was observed 
compared to corresponding steroid derivatives. Monosaccahride derivatives of spirostane were 
far more active than corresponding cholestane and androstane derivatives. Of the eleven 
monosaccharide derivatives of various steroids tested, 21, 24, 27 and 28 were not significantly 
active against all four species tested, all other monosaccharide derivatives were active against at 
least two of the fungal strains. The C-2 substituted monosaccharide derivative 29 (with same 
steroidal unit as compound 28) was found to be active against C. albicans, C. glabrata and C. 
neoformans. (Table 4.1)   
 
Figure 4.3 Monosaccharide derivatives of steroids 
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Best acitivity among monosaccharide derivatives was observed with spirostane-based 
compound 22, 25, 26 and 30 ranging from 2 to 16 µg/mL (around 50% inhibition). Cholestane and 
androstane based monosaccharide derivatives were had lesser activity (32µg/mL and above-25 to 
50% inhibition) compared to corresponding spirostane derivatives (Table 4.1). Motivated by better 
activity with monosaccharide derivatives of steroids we decided to explore the effect of increased 
sugar chain length on efficacy of these series of compounds. The next step of our project at this 
moment was to synthesize various disaccharide derivatives of steroids and test them for antifungal 
activity against all the four pathogenic fungal strains. 
4.10 Disaccharide derivatives of steroids: 
Disaccharide derivatives of various steroid isomers were synthesized and evaluated 
against all four pathogenic fungal strains. Most of the disaccharide derivatives of steroids were 
more active than corresponding monosaccharide derivatives with exception of lactose based 
derivatives of steroids, which were having moderate activity and not much improvement from 
corresponding monosaccharide derivatives (Table 4.2). Probably the β- (1→4) linkage between 
galactose and glucose units in lactose didn’t provide the required orientation for interaction with 
fungal cell wall.  Out of five different disaccharide derivatives synthesized most of them were 
active against at least two of the fungal strains but maltose linked spirostane derivatives seemed to 
be the most potent molecules so far (Fig. 4.3). These sets of assay results did emphasized on the 
kind of linkage between sugar units needed for better antifungal activity.  
Maltose having α- (1→4) linkage between two glucose units seemed to be the best fit for 
antifungal activity amongst all other disaccharide derivatives synthesized and tested so far. Since 
we already had a bunch of very active antifungal maltose derivatives of various steroids, it was 
obvious to go a step further and see if attaching another sugar unit to maltose with α- (1→4) linkage 
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will increase the potency any further. In fact we were going in the right direction and it was 
amazing to find out that the four different derivatives of maltotriose synthesized (45, 46, 47 and 48) 
showed significant increase in antifungal activity (Table 4.3). There was a clear indication that the 
α- (1→4) linkage in these derivatives of steroids provided the desired orientation needed for 
interaction with fungal cell wall.  
 
Figure 4.4. Disaccharide and trisaccharide derivatives of steroids 
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After having the promising results from linear disaccharide and trisaccharide derivatives 
of various steroid isomers we were also aimed to explore possibility of exploring branched 
oligosacchride derivatives which would be quite similar to the branched oligosacchride in 
various naturally isolated saponins like CAY-1. That would give us an idea about how having 
linear versus branched oligosaccharide unit attached to steroids affects the antifungal activity in 
order to explore a critical part of SAR studies towards finding potent antifungal saponins. 
4.11 Synthesis of branched oligosacchairdes: 
Synthesis of branched oligosaccharides started from penta-O-Acetyl glucopyranose, 
which can be prepared from D-glucose in quantitative yield by acetic anhydride and pyridine 
reflux. Thioisopropyl group was introduced at anomeric position by acid catalyzed glycosylation 
with thioisopropanol. Acetyl group protection was cleaved by sodium hydroxide in methanol to 
yield compound 51 (step ii, Scheme 4.10). Dimethoxymethylbenzene under acidic conditions 
with camphor sulfonic acid in DMF leads to 4,6-diol protection to give the key intermediate 52 
in good yield25,26. At temperature below 0oC glycosylation of 52 with trichloroacetimidate 
activated monosaccharide sugar 1 with TMSOTf gave C-3 glycosylated disaccharide 53, which 
was glycosylated further using another mole of 1 at room temperature to get branched 
trisaccharide 54 (step iv, Scheme 4.10). Glycosylated 4, 6-O-benzylidene-1-thio-β-D-
glucopyranoside (54) could be coupled with another sugar27 or steroid28 having acceptor unit by 
N-iodosuccinimide (2.5eq) promoter and acid catalyst TMSOTf (0.1-0.2eq) in dichloromethane. 
These literatures reported coupling reaction could be used to get complex branched 
oligosaccharides and their derivatives with various steroids27, 28.  
There were some major issues with the glycosylation reaction (step iv, Scheme 4.10), 
which was the cause for low yield of reaction. The reaction was highly moisture sensitive, even 
	   128	  
after using molecular sieves and dry solvent for the reaction trichloroacetimidate activated sugar 
(1) was found to be hydrolyzing back to compound 8 in presence of trace of moisture. All three 
spots on TLC were isolated and confirmed by 1H-NMR to prove the observation. Use of freshly 
prepared trichloroacetimidate activated sugar and freshly purchased TMSOTf did improve the 
yield of reaction to certain extent but not much for this methodology to be effective for large-
scale synthesis of branched oligosaccharides. 
 
Scheme 4.10 Synthesis of 2,3-branched trisaccharide: (i) propane-2-thiol, BF3·OEt2, DCM, (ii) NaOH, 
MeOH/DCM, (iii) dimethoxymethylbenzene, CSA, DMF, 51% (3 steps), (iv) 1, TMSOTf, DCM, 23% (2 steps). 
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In order to simplify the synthesis of branched oligosaccharides and develop methodology, 
which can be useful for their large-scale synthesis it was decided to changed our strategy. We 
propose to design TAG molecules which would be attached to sugar and hence change the 
physical property of sugars in order to simply handling of intermediate and easier monitoring of 
reaction. Tag molecules are large aromatic molecules, which on attachment to sugars would 
make them less soluble in common organic solvents hence easy to re-crystallize and purify. The 
detailed of synthesis of tag molecules and their attachment of them to sugar will be discussed in 
details in chapter-5. 
4.12 Synthesis of fatty acid derivaties derivatives of steroids: 
We also synthesized some fatty acid derivatives derivatives of active molecules from 
steroid series in order to see the effect of having long chain aliphatic ring attached at C-3 
position of the steroids. This was inspired by the fact that there are some literature reports 
showing antifungal activity with the fatty acid derivatives of steroids29. Synthesis of fatty acid 
derivatives of various steroid isomers was achieved by two methods, Method-A30 involved 
coupling to corresponding acid chloride of a fatty acid to the steroid unit while Method-B29 
involved direct coupling of fatty acids by in situ activation of carboxylic acid group with DCC 
and base DMAP to steroid isomers (Scheme 4.11).  Two compounds 55 and 58 were synthesized 
by Method-A in almost quantitative yield whereas four other fatty acid derivatives were 
synthesized using Method-B. Most of these compounds were re-crystallized by polar solvents 
like ethanol and acetonitrile. 
It was not very surprising that most of the cholestane based fatty acid derivatives had 
solubility issue with our common solvent for micro-dilution, dimethylsolfoxide. The solubility 
issue was solved using a mixture of isopropyl alcohol and dimethylsulfoxide mixture as solvent 
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system for microdilution and compared with same solvent control. Only three out of six fatty 
acid derivative showed some antifungal activity, which was not very impressive. Compound 55 
and 59 were having 25% inhibition at 62µg/mL concentration for C. glabrata whereas 
compound 60 had 40% inhibition at 32µg/mL for the same pathogenic fungus. Overall there is a 
need for more fatty acid derivatives to be explored in order to achieve better antifungal activity 
of these series of compounds. Synthesis and antifungal evaluation of fatty acid derivatives of 
steroids will give a nice comparison with glycosidic derivatives, therefore hydrophilic versus 
hydrophobic substitution on steroids and their impact on antifungal activity could be studied in 
detailed for a complete SAR study. 
 
 
Scheme 4.11 Fatty acid derivatives of steroids 
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4.13 Antifungal assay of steroidal saponins 
 
The antifungal activity of the synthesized glycoside linked 2,3-spirostanes were evaluated 
in vitro using four species of fungi, including Candida albicans, Cryptococcus neoformans, 
Candida glabrata, and the filamentous fungus Aspergillus fumigatus. The results of these 
screenings are summarized in Table 4.1, 4.2 and 4.3.  Of the eleven monosaccharide derivatives of 
various steroids tested, 21, 24, 27 and 28 were the compounds that showed no significant antifungal 
activity against all four species tested, other all other five monosaccharide derivatives were active 
against at least two of the fungal strains. The C-2 substituted monosaccharide derivative with same 
steroid 29 was found to be active against C. albicans, C. glabrata and C. neoformans  (where more 
than 25% inhibition was observed in the highest dose tested 125µg/mL –Table 4). Best acitivity 
among monosaccharide derivatives was observed with spirostane-based compounds 22, 25, 26 and 
30 ranging from 2 to 16 µg/mL (around 50% inhibition). Cholestane and androstane based 
monosaccharide derivatives had lesser activity (32µg/mL about-25 to 50% inhibition) compared to 
corresponding spirostane derivatives (Table-4.1).  
Disaccharide derivatives of steroids with lactose did not improve the antifungal activity for 
almost all of the steroids, which forced us to look for some other disaccharide units to be attached 
to the steroids to improve their activity more than the monosaccharide units. We have synthesized 
other disaccharide-like maltose, cellobiose, melibiose- based derivatives of active series of steroids. 
Among these disaccharide derivatives maltose seemed to gave the best antifungal activity, for 
example compound 34 have an activity 8µg/mL for C. glabrata and 16µg/mL for C. albicans 
(100% inhibition). Among maltose derivatives of steroids spirostane based compounds are more 
active than corresponding cholestane and androstane compounds, for instance cholestane compound 
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33 have 25% inhibition at 125µg/mL with C. albicans and at 16µg/mL with C. glabrata (Table 
4.2). Androstane based maltose derivative, 31 is only active with C. albicans at 62µg/mL (25% 
inhibition) and had no activity with C. glabrata. It was very interesting to find out that maltose 
derivative of commercially available diosgenin (39) also had moderate activity at 16µg/mL (25% 
inhibition) with C. albicans and 32µg/mL (50%inhibition) with C. glabrata.  
Among the fatty acid derivatives of steroids three out of six had moderate activity, 
compound 55 and 59 had 25% inhibition at 62µg/mL for Candida glabrata. Fatty acid derivative of 
cholestane compound 60 was having 40% inhibition at 32µg/mL for C. galbrata (Table 4.3). The 
low to moderate activity of fatty acid derivatives might be due to their solubility issues, so there is 
need for more fatty acid derivatives to be synthesized and explored against pathogenic fungal 
strains in order to get a potent antifungal agent in this series of steroid derivatives.  
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Table 4.1 Antifungal activities of novel steroid monosaccharide analogs (MIC in µg/mL) 
MIC50 (µg/mL)a,f  
Compound C. albicans b C. glabrata c C. neoformans d A. fumigatus e 
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  aMIC values are reported only for compounds displaying 1) a prominent decrease in turbidity by visual comparison to the control 
wells containing no antifungal and 2) a >50% reduction in fungal growth compared to controls containing no antifungal, as 
measured spectroscopically by absorption at 530 nm. 
bATCC no. 10231;cATCC no. 48435;dATCC no. 36556;eATCC no. 16424 
fAll values were determined after incubation at 35°C for 48 h. 
*denotes compounds that had 1) a slight reduction in turbidity to no change and 2) had less than a 25% reduction in growth 
compared to controls, as measured spectroscopically by absorption at 530 nm. 
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Table 4.2 Antifungal activities of novel steroids disaccharide analogs (MIC in µg/mL) 
MIC50 (µg/mL)a,f  
Compound C. albicans b C. glabrata c C. neoformans d A. fumigatus e 
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Table 4.3 Antifungal activities of steroid trisaccharide and fatty acid analogs (MIC in µg/mL) 
MIC50 (µg/mL)a,f  
Compound C. albicans b C. glabrata c C. neoformans d A. fumigatus e 
 
 
NC* 
 
16 
 
8 
 
NC* 
 
 
NC* 
 
NC* 
 
32 
 
NC* 
 
 
NC* 
 
>125 
 
>125 
 
NC* 
 
 
NC* 
 
NC* 
 
32 
 
16 
 
 
NC* 
 
62  
 
NC* 
 
NC* 
 
 
NC* 
 
 
NC* 
 
NC* 
 
NC* 
 
 
NC* 
 
NC* 
 
NC* 
 
NC* 
 
 
NC* 
 
NC* 
 
NC* 
 
NC* 
 
 
NC* 
 
62  
 
NC* 
 
NC* 
 
 
NC* 
 
32  
 
NC* 
 
NC* 
	  	  aMIC values are reported only for compounds displaying 1) a prominent decrease in turbidity by visual comparison to the control 
wells containing no antifungal and 2) a >50% reduction in fungal growth compared to controls containing no antifungal, as 
measured spectroscopically by absorption at 530 nm. 
bATCC no. 10231;cATCC no. 48435;dATCC no. 36556;eATCC no. 16424 
fAll values were determined after incubation at 35°C for 48 h. 
*denotes compounds that had 1) a slight reduction in turbidity to no change and 2) had less than a 25% reduction in growth 
compared to controls, as measured spectroscopically by absorption at 530 nm. 
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4.14 Conclusions 
We have developed a synthesis for glycoside linked steroid derivatives from mono, di 
and trisaccharides. Antifungal assay of all synthesized derivatives against four pathogenic fungal 
strains was performed. Most of the monosaccharide derivatives were found to have better 
activity than corresponding un-substituted steroid units with the exception of compound 28, 20 
which were not active against any of the tested fungal strains. Compound 22 among cholestane 
and 26 among spirostane monosaccharide derivatives were found to be most potent.  
Disaccharide based saponins were found to have better antifungal activity than 
corresponding monosaccharide derivatives with an exception of lactose based derivatives (36,37 
and 38), which were not active against any of the four fungal strains. Among the active 
disacchride saponins the maltose derivatives (31-35 and 39) were found to be most potent 
compounds in this series so far for all the four fungal strains tested. Maltose derivative of 2,3-
spirostane had best activity across the board and with 0.5µg/mL activity for Cryptococcus 
neoformans.  
Maltotriose derivatives showed a loss in activity over the corresponding disaccharide 
derivative (Maltose). Further studies are required in order to find the optimum number of sugar 
units needed in the saponin for the best antifungal activity. Synthesis and coupling of branched 
oligosaccharides with steroid isomers need to be explored in future works, to see the effect of 
branching in oligosaccharide unit on the antifungal activity of various saponins.  
Fatty acid derivatives of active steroid isomers were also synthesized and assayed for 
antifungal activity. Out of six derivatives synthesized only three (55, 59 and 60) had mild 
antifungal activity. There is a need for a more extensive study of other possible fatty acid 
derivatives in order to find a potent antifungal molecule in this series of compounds. 
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4.15 Experimental 
 
4.15.1 Synthesis of monosaccharide and disaccharide trichloroacetimidate: Synthesis of 
monosaccharide trichloroacetimidate was achieved starting from commercially available D-
glucose in three steps in 75 to 80% of isolated yield. Our synthesis of 2,3,4,6-tetra-O-benzoyl-α-
D-glucopuranosyl trichloroacetimidate started with α-D-glucose, all hydroxyl groups were 
protected with benzoyl group with well-known esterification by benzoyl chloride in pyridine to 
get compound 7. The anomeric benzoyl group was selectively deprotected by mild base 
ethanolamine in ethylacetate and dimethylsulfoxie to get anomeric free hydroxyl group in 
compound 8. Base catalysed activaton of anomeric oxygen in presence of trichloroacetonitrile in 
dichloromethane gave the desired monosaccharide trichloroactimidate compound 1 in almost 
quantitative yield. 
Penta-O-benzoyl-β-D-glucopyranose (7): D-glucose 6 (5.0 g, 28 mmol) was refluxed in 
pyridine (100 mL) for 1 hour. The solution was then added to benzoyl chloride (20 mL) which 
had been heated to 65°C. After the mixture was cooled to room temperature, water (400 mL) was 
added and stirred until the product solidified, approximately 30 minutes. The solid was filtered 
and washed with water and recrystallized from ethyl acetate to give 7 as a white solid (11 g, 56 
% yield). 1H NMR (400 MHz, CDCl3): δ 8.01 (d, J = 4.0 Hz, 4H), 7.89 (d, J = 3.8 Hz, 4H), 7.84 
(d, J = 3.9 Hz, 2H), 7.53 – 7.21 (m, 15 H), 6.28 (d, J=3.9 Hz, 1H), 6.02 (t, J = 9.3 Hz, 1H), 5.83 
(q, J=12.9 Hz, 2H), 4.64 (dd, J1= 6.0 Hz, J2= 1.4 Hz, 1H), 4.49 (dd, J1 = 8.1 Hz, J2 = 2.1 
Hz, 1H), 4.394 (m, 1H). 13C NMR (400 MHz, CDCl3): δ 166.3, 165.8, 165.30, 165.28, 164.8, 
134.0, 133.7, 133.6, 133.5, 133.3, 130.4, 130.0, 129.99, 129.96, 129.7, 128.9, 128.84, 128.82, 
128.7, 128.62, 128.59, 128.5, 92.9, 73.3, 73.0, 71.0, 69.2, 62.8. 
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2,3,4,6-Tetra-O-benzoyl-D-glucopyranose (8): Pentabenzoyl-δ-D-glucopyranose 7 (10 g, 14 
mmol) and freshly distilled 2-aminoethanol (2.0 g, 36 mmol) were stirred at room temperature in 
ethyl acetate (150 mL) and DMSO (2 mL) overnight, during which time the initial suspension 
formed a solution. The resulting solution was washed with water (3 x 150 mL) and the organic 
layer was dried over sodium sulfate and concentrated. The residue was purified by flash column 
chromatography (CH2Cl2 followed by Et2O) to give 8 as a white solid (6.0 g, 70 % yield). 100 
mg of the product was recrystallized from diethyl ether/hexanes for 1H and 13C NMR analysis. 
1H NMR (400 MHz, CDCl3) : δ 8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 
5.72 (m, 2H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 
Hz, 1H), 3.12 (d, J=1.3 Hz, 1H). 13C NMR of 3 (CDCl3): δ 166.6, 166.1, 166.1, 165.5, 133.6, 
133.5, 133.3, 130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 
128.4, 90.6, 72.5 and 70.4 ppm. 
 
O–(Tetra-O-benzoyl-α-D-glucopyranosyl)-trichloroacetimidate (1): Tetrabenzoyl- D-
glucopyranose 8 (2.0 g, 3.3 mmol), K2CO3 (1.1 g, 8.2 mmol), and trichloroacetonitrile (5 mL) 
were stirred at room temperature in dichloromethane (20 mL) for 48 hours. The resulting 
suspension was filtered through silica gel using a 1:1 mixture of CH2Cl2 and Et2O (150 mL). The 
filtrate was concentrated to give 1 as a pale yellow solid (2.0 g, 83 % yield). 1H NMR (400 MHz, 
CDCl3): δ 8.62 (s, 1H) 8.02 (d, J = 3.9 Hz, 2H), 7.93 (br d, J = 5.7 Hz, 4H), 7.85 (d, J = 4.2 Hz, 
2H), 7.56 – 7.25 (m, 12H), 6.82 (d, J = 2.0 Hz, 1H), 6.25 (t, J = 9.9 Hz, 1H), 5.79 (t, J=9.9 Hz, 
1H), 5.60 (dd, J1 = 5.1 Hz, J2 = 1.8 Hz, 1H), 4.62(brd,J=5.1Hz,2H),4.46(dd,J1 =6.5Hz,J2 
=3.0Hz,1H). 13C NMR (400 MHz, CDCl3): δ 166.2, 165.8, 165.6, 165.4, 160.7, 133.7, 133.5, 
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133.4, 130.1, 129.91, 129.86, 129.7, 129.0, 128.7, 128.6, 128.6, 128.5, 128.5, 93.3, 90.9, 70.9, 
70.3, 68.8 and 62.6 ppm. 
Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-1,2,5,6-di-O-isopropylidene-α-D-glucofuranose 
(5): Trichloroacetimidate 1 (2.0 g, 2.7 mmol) and diacetone D- glucose 9 (650 mg, 2.5 mmol) 
were stirred under an atmosphere of nitrogen in anhydrous dichloromethane (20 mL) with 3Ǻ 
molecular sieves for 1 hour. The solution was cooled in an ice bath for 30 minutes before 
BF3·OEt2 (2 mL) was added and stirred for 1 hour in the ice bath followed by 1 hour at room 
temperature. The solution was added to an ice- cold saturated aqueous sodium bicarbonate 
solution (100 mL) with vigorous stirring and then extracted with ether (2 x 75 mL). The organic 
layers were combined and dried over sodium sulfate. The solvent was removed under reduced 
pressure and the residue was purified by flash column chromatography (CH2Cl2:THF 9:1 to 0:1) 
to give 10 as a white solid (1.1 g, 53 % yield). 1H NMR (400 MHz, CDCl3): δ 8.03 (d, J = 4.4 
Hz, 2H), 7.91 (t, J = 9.8 Hz, 4H), 7.80 (d, J = 4.4 Hz, 2H), 7.57 – 7.26 (m, 12H), 5.89 (m, 2H), 
5.66 (t, J=8.0Hz,1H),5.51(t,J=8.8Hz,1H),4.90(d,J=3.8Hz,1H),4.73(dd,J1 =6.2Hz, J2 = 1.4 Hz, 
1H), 4.42 (m, 2H), 4.28 (d, J = 1.4 Hz, 1H), 4.16 (m, 1H), 4.07 (m, 2H), 4.01 (dd, J1= 3.4 Hz, 
J2= 1.2 Hz, 1H), 3.84 (q, J = 9.2 Hz, 1H), 1.36 (s, 6H), 1.26 (s, 6H). 13C NMR (400 MHZ, 
CDCl3): δ 166.5, 166.0, 165.6, 165.4, 133.8, 133.7, 133.6, 130.1, 130.0, 129.6, 129.2, 128.9, 
128.7, 128.6, 112.0, 105.3, 102.0, 85.2, 79.7, 75.8, 72.84, 72.77, 72.5, 72.2, 69.5, 69.4, 62.8, 27.0 
and 26.4 ppm. 
 
Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-D-glucopyranose (11): Disaccharide 10 (3.2 g, 
3.8 mmol) was stirred at 40oC in THF (10 mL) and a 1:1 mixture of trifluoroacetic acid and 
water (40 mL) for 24 hours. The solution was then added slowly to water (400 mL) with stirring. 
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The resulting solid was filtered and washed with water to give 11 as a white solid (2.5 g, 86 % 
yield). 1H NMR (400 MHz, CDCl3): δ 7.99 – 7.86 (m, 6H), 7.80 (d, J = 3.8 Hz, 2H), 7.47 – 7.21 
(m, 12H), 5.90 (t, J = 9.6 Hz, 1H), 5.71 (t, J = 9.6 Hz, 1H), 5.52 (t, J = 9.2 Hz, 1H), 5.05 (d, J = 
1.6 Hz, 1H), 4.94 (d, J = 4.0 Hz, 1H), 4.69 (t, J = 12.8 Hz, 1H), 4.41 (m, 1H), 4.14 (m, 2H), 3.94 
(m, 1H), 3.80 (m, 1H), 3.69 (t, J = 9.6Hz, 1H), 3.41 (m, 1H), 3.31 (m, 1H). 13C NMR (400 MHz, 
CDCl3): δ 166.6, 166.0, 165.7, 165.3, 133.6, 133.5, 133.4, 130.0, 129.9, 129.5, 129.2, 129.2, 
129.2, 129.0, 129.0, 128.6, 128.5, 128.4, 128.4, 102.0, 101.9, 96.6, 92.5, 77.4, 76.4, 75.2, 74.7, 
73.6, 73.1, 72.3, 72.2, 72.1, 70.8, 70.6, 70.4, 70.1, 69.9, 69.7 and 63.1 ppm.  
 
Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-tetra-O-benzoyl-D-glucopyranose (12): 
Disaccharide 11 (2.5 g, 3.3 mmol) was refluxed in pyridine (50 mL) for 30 minutes. The solution 
was added to benzoyl chloride (10 mL) that had been heated to 65°C. After the mixture was 
cooled to room temperature, water (200 mL) was added. The resulting syrup was separated from 
the aqueous layer and dissolved in CH2Cl2 (50 mL). The solution was washed with water (3 x 50 
mL), dried over sodium sulfate, and the solvent was removed under reduced pressure. The 
residue was crystallized from CH2Cl2/hexanes to give 12 as a white solid (3.0 g, 78 % yield). 1H 
NMR of 12 (400 MHz, CDCl3): δ 8.12 – 7.77 (m, 32H), 7.62 – 7.15 (m, 48H), 6.69 (d, J = 1.8 
Hz, 1H), 6.19 (t, J = 10.0 Hz, 1H), 6.14 (d, J = 4.2 Hz, 1H), 5.92 (m, 2H), 5.71 – 5.41 (m, 7H), 
5.08 (d, J = 3.8 Hz, 1H), 5.00(d,J=4.0Hz,1H), 4.58(dd,J1 =6.0Hz,J2 =1.6Hz,1H),4.51–4.37(m, 
5H), 4.23 (m, 1H), 4.18 – 3.99 (m, 5H), 3.94 (dd, J1 = 6.2 Hz, J2 = 3.0 Hz, 1H), 3.86 (dd, J1 = 
6.4 Hz, J2 = 3.0 Hz, 1H). 13C NMR of 7(400 MHz, CDCl3): δ 172.0, 166.3, 166.0, 165.8, 165.4, 
164.9, 134.0, 133.6, 133.5, 133.4, 133.3, 130.4, 130.22, 130.16, 130.1, 130.0, 129.8, 129.5, 
129.4, 129.0, 128.9, 128.8, 128.7, 128.6, 128.51, 128.48, 128.4, 101.1, 100.5, 92.9, 90.1, 75.4, 
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73.2, 73.0, 72.9, 72.4, 72.1, 71.9, 71.0, 70.6, 70.4, 69.9, 69.4, 69.1, 67.5, 67.1 and 63.2 ppm.  
 
Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-2,4,6-tri-O-benzoyl-D-glucopyranose (13): 
Disaccharide 12 (3.4 g, 2.9 mmol) was stirred with freshly distilled 2-aminoethanol (500 mg, 8.2 
77mmol) and DMSO (0.5 mL) in ethyl acetate (50 mL) for 24 hours at room temperature. The 
mixture was washed with water (3 x 50 mL), dried over sodium sulfate, and concentrated. The 
resulting syrup was purified by flash column chromatography (CH2Cl2 followed by Et2O) to give 
13 as a white solid (1.2 g, 40 % yield). 1H NMR of 13 (400 MHz, CDCl3): δ 8.08 – 7.77 (m, 14 
H), 7.53 – 7.26 (m, 21 H), 6.11 (t, J = 10.0 Hz, 1H), 5.90 (t, J = 9.6 Hz, 1H), 5.69 (t, J = 9.6 Hz, 
1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H),5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 
=1.8Hz,1H),4.95(d,J = 3.8 Hz, 1H), 4.71 (dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H), 4.62 (m, 1H), 4.49 
(m, 1H), 4.39 (dd, J1 = 6.0 Hz, J2 = 2.2 Hz, 1H), 4.13 (m, 2H). 13C NMR of 13 (400 MHz, 
CDCl3): δ 166.5, 166.0, 165.9, 165.7, 165.4, 138.9, 133.7, 133.6, 133.5, 133.4, 133.3, 130.4, 
130.1, 130.1, 130.0, 130.0, 130.0, 129.8, 129.7, 129.6, 129.4, 129.3, 129.0, 128.8, 128.7, 128.6, 
128.5, 128.4, 102.5, 90.4, 77.4, 72.8, 72.6, 72.4, 72.3, 70.2, 69.9, 69.5, 69.0 and 63.0 ppm.  
 
O-(Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-tri-O-benzoyl-α-D-glucopyranosyl)- 
trichloroacetimdate (14): Disaccharide 13 (1.2 g, 1.2 mmol), potassium carbonate (0.42 g, 3.0 
mmol), and trichloroacetonitrile (4 mL) were stirred 48 hours in CH2Cl2 (20 mL) at room 
temperature. The resulting suspension was filtered through silica gel using a 1:1 mixture of 
CH2Cl2 and Et2O (150 mL). The filtrate was concentrated to give 14 as a pale yellow solid (1.3 
g, 94 % yield) which was used immediately in the next reaction without further purification. 1H 
NMR of 14 (400 MHz, CDCl3): 8.36 (s, 1H), 7.98 – 7.73 (m, 14H), 7.51 – 7.26 (m, 21H), 6.64 
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(d, J = 2.0 Hz, 1H), 6.14 (t, J = 9.8 Hz, 1H), 5.88 (t, J = 10.1 Hz, 1H), 5.63 – 5.32 (m, 4H), 4.98 
(d, J = 4.1 Hz, 1H), 4.40 – 4.61 (m, 3H), 4.13 (m, 2H), 3.84 (m, 1H). 13C NMR of 14 (400 MHz, 
CDCl3): δ 166.5, 166.0, 165.9, 165.7, 165.4, 138.9, 133.7, 133.6, 133.5, 133.4, 133.3, 130.4, 
130.1, 130.1, 130.0, 130.0, 130.0, 129.8, 129.7, 129.6, 129.4, 129.3, 129.0, 128.8, 128.7, 128.6, 
128.5, 128.4, 102.5, 90.4, 77.4, 72.8, 72.6, 72.4, 72.3, 70.2, 69.9, 69.5, 69.0 and 63.0 ppm.  
 
General procedure for glycosylation:  
Glycosylation was achieved in general by TMSOTf catalyzed reaction in 
dichloromethane of activated sugar trichloroactimidate and steroidal derivative with free 
hydroxyl group at either C-2 or C-3 positions (Scheme-below). The benzoyl protection of sugar 
was removed after glycosylation reaction by sodium methoxide in methanol and 
dichloromethane mixture to get the desired saponin product after column purification. 
4.15.2 General Procedure for monosaccharide derivatives: 
Synthesis of Tigogenyl-3β-glucose (25):  Trichloroacetimidate glucosyl donor 1 (200 mg, 0.27 
mmol) and steroidal acceptor tigogenin  (100 mg, 0.27 mmol) were stirred under an atmosphere 
of nitrogen in anhydrous CH2Cl2 (10 mL), with 3Å molecular sieves for 1 hour. The mixture was 
cooled to 0°C before TMSOTf (15 µL, 0.1 mmol) was added. The reaction was stirred for 3 
hours at 0°C to room temperature, quenched with triethylamine, and extracted with 
dicholomethane. The solvents were removed under reduced pressure and the resulting syrup was 
purified by gravity column chromatography (15% ethyl acetate: hexane) to give 175mg of 
benzoylated saccharide-coupled tigogenin(65% isolated yield). 1H NMR (400 MHz, CDCl3): δ 
8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 2H), 5.30 (dd, J1=6.45 
Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, J=11.2,1H), 
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3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 (s, 3H), 0.95 
(d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  (CDCl3): δ 
166.6, 166.13, 166.10, 165.5, 133.6, 133.5, 133.3, 130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 
129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.46, 109.5, 90.6, 81.0, 73.3, 72.5, 70.4, 67.7, 67.0, 
62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 
21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
Benzoylated monosaccharide coupled tigogenin (175mg,0.18mmols) was dissolved in Methanol 
and dichloromethane mix (1:1, 10ml) and freshly prepared sodium methoxide solution in 
methanol was added dropwise untill pH 9-11 was achieved. Reaction mixture was stirred at room 
temperature for one hour. On completion of reaction the reaction mixture was neutralized by 
acidic dowex resin to neutral PH and filtered off resin. Solvent was removed under reduced 
pressure and crude product was purified by column chromatography 
(Methanol:Dichloromethane:: 1:6) to get the 91mg of desired product 25 (90%-yield).1H NMR 
(400 MHz, CDCl3): δ 5.72 (m, 2H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.46 
(dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 
10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, 
J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  (CDCl3): δ119.6, 109.8, 82.9, 81.5, 81.0, 78.7, 76.8, 
74.1, 71.5, 67.0, 66.3, 62.3, 56.5, 54.5, 45.0, 41.8, 40.7, 40.2, 38.4, 37.1, 35.9, 35.5, 32.4, 31.9, 
31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 14.7 and 12.5 ppm.  
 
Synthesis of Androstanyl-2α-hydroxy-3β-glucose (20): Benzoyl protected 20: 1H NMR (400 
MHz, CDCl3): δ 8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 2H), 
4.82 (1H, ddd, J = 4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, J = 4.7, 9.0, 11.5 Hz, H-2b), 2.12 (3H, 
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s, CH3CO), 0.90 (3H, d, J = 6.5 Hz, CH3-21), 0.87 (6H, two d, J = 6.5 Hz, CH3-26 and CH3-27), 
and 0.82 (3H, s, CH3-19) ppm. 13C NMR δ: 171.6,166.6, 166.13, 166.10, 165.5, 133.6, 133.5, 
133.3, 130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 
109.5, 73.0, 68.1, 56.3, 56.2, 44.1, 42.5, 41.7, 39.9, 39.4, 39.3, 36.7, 36.1, 35.8, 34.7, 32.2, 31.7, 
28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 21.4, 20.9,18.6, 12.5 and 12.0 ppm. 
 
Androstanyl-2α-hydroxy-3β-glucose (20): 1H NMR (400 MHz, CDCl3): δ 5.03, 4.82 (1H, ddd, 
J = 4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, J = 4.7, 9.0, 11.5 Hz, H-2b), 0.90 (3H, d, J = 6.5 Hz, 
CH3-21), 0.87 (6H, two d, J = 6.5 Hz, CH3-26 and CH3-27), and 0.82 (3H, s, CH3-19) ppm. 13C 
NMR δ: 109.5, 73.0, 68.1, 56.3, 56.2, 44.1, 42.5, 41.7, 39.9, 39.4, 39.3, 36.7, 36.1, 35.8, 34.7, 
32.2, 31.7, 28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 21.4, 20.9, 18.6, 12.5 and 12.0 ppm. 
 
Synthesis of Androstanyl-3β-glucose (21): Benzoyl protected 21: 1H NMR (400 MHz, CDCl3): 
δ 8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 2H), 4.82 (1H, ddd, J 
= 4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, J = 4.7, 9.0, 11.5 Hz, H-2b), 0.90 (3H, d, J = 6.5 Hz, 
CH3-21), 0.87 (6H, two d, J = 6.5 Hz, CH3-26 and CH3-27), and 0.82 (3H, s, CH3-19) ppm. 13C 
NMR δ: 171.6, 166.6, 166.1, 166.1, 133.6, 133.5, 133.3, 130.1, 130.0, 129.8, 129.7, 129.6, 
129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.46, 109.5, 73.0, 68.1, 56.3, 56.2, 44.1, 42.5, 
41.7, 39.9, 39.4, 39.3, 36.7, 36.1, 35.8, 34.7, 32.2, 31.7, 28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 
21.3, 20.9,12.5 and 12.0 ppm. 
 
Androstanyl-3β-glucose (21): 1H NMR (400 MHz, CDCl3): δ 5.03, 4.82 (1H, ddd, J = 4.8, 9.4, 
11.6 Hz, H-2b), 3.59 (1H, ddd, J = 4.7, 9.0, 11.5 Hz, H-2b), 0.90 (3H, d, J = 6.5 Hz, CH3-21), 
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0.87 (6H, two d, J = 6.5 Hz, CH3-26 and CH3-27), and 0.82 (3H, s, CH3-19) ppm. 13C NMR δ: 
109.5, 73.0, 68.1, 56.3, 56.2, 44.1, 42.5, 41.7, 39.8, 39.4, 39.3, 36.7, 36.1, 35.8, 34.7, 32.2, 31.7, 
28.2, 27.9, 27.4, 24.1, 23.8, 22.8, 22.5, 21.4, 20.9, 18.6,12.5 and 12.0 ppm. 
 
Synthesis of Cholestanyl-2α-hydroxy-3β-glucose (22): Synthesis of benzoylated 22: 1H NMR 
(400 MHz, CDCl3): δ 8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 
2H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.82 (1H, ddd, J=4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, 
ddd, J=5.4, 9.5, 11.1 Hz, H-3a), 2.08 (3H, s, CH3CO), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, 
CH3-27), and 0.64 ppm (3H, s, CH3-18). 13C-NMR (CDCl3): δ171.6, 166.6, 166.1, 166.1, 165.5, 
133.6, 133.5, 133.3, 130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 
128.5, 128.4, 76.4, 73.5, 56.2, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.4, 37.2, 36.1, 35.9, 35.7, 34.7, 
31.7, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.0 and 12.0 ppm.  
 
Cholestanyl-2α-hydroxy-3β-glucose (22): 1H NMR (400 MHz, CDCl3): δ 5.72 (m, 2H), 5.30 
(dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 
(1H, ddd, JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 
0.64 ppm (3H, s, CH3-18). 13C-NMR (CDCl3): δ 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 
39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.3, 18.6, 
13.1 and 12.0 ppm.  
 
Synthesis of Cholestanyl-3β-glucose (23): Synthesis of benzoylated 23: 1H NMR (400 MHz, 
CDCl3): δ 8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 2H), 5.30 
(dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, 
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JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm 
(3H, s, CH3-18). 13C-NMR (CDCl3): δ171.59, 166.6, 166.1, 166.1, 165.5, 133.5, 133.3, 130.1, 
130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 76.5, 73.5, 
56.3, 56.2, 54.1, 44.4, 42.5, 42.1, 39.8, 39.4, 37.2, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 
24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.1 and 12.0 ppm.  
 
Cholestanyl-3β-glucose (23): 1H NMR (400 MHz, CDCl3):  δ 5.72 (m, 2H), 5.30 (dd, J1=6.45 
Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, 
JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm 
(3H, s, CH3-18). 13C-NMR (CDCl3): δ 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 
37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.3, 18.6, 13.0 and 
12.0 ppm.  
 
Synthesis of Cholesteryl-3β-glucose (24): Synthesis of benzoylated 24: 1H NMR (400 MHz, 
CDCl3): δ 8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 2H), 5.38(d, 
1H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, 
ddd, JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 
ppm (3H, s, CH3-18). 13C-NMR (CDCl3): δ171.6, 166.6, 166.1, 166.1, 165.5, 133.5, 133.3, 
130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 76.5, 
73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.2, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 
27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.0 and 12.0 ppm.  
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Cholesteryl-3β-glucose (24): 1H NMR (400 MHz, CDCl3): δ 5.72 (m, 2H), 5.38(d, 1H), 5.30 
(dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 
(1H, ddd, JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 
0.64 ppm (3H, s, CH3-18). 13C-NMR (CDCl3): δ 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 
39.8, 39.5, 37.2, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 
13.0 and 12.0 ppm.  
 
Synthesis of Diosgenyl-3β-glucose (26): Synthesis of benzoylated 26: 1H NMR (400 MHz, 
CDCl3): δ 8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 2H), 5.38(d, 
1H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.87 (br, s,1H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 
1H), 4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 
Hz, 1H), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 
3H). 13C NMR of  (CDCl3): δ 170.5, 166.6, 166.13, 166.10, 165.5, 133.6, 133.5, 133.3, 130.1, 
130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.5, 109.5, 90.6, 
81.0, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 34.8, 32.2, 
32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7, 13.9. 
 
Diosgenyl-3β-glucose (26): 1H NMR (400 MHz, CDCl3): δ 5.72 (m, 2H), 5.38 (d, 1H) 5.30 (dd, 
J1=6.45 Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, 
J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 
(s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  
(CDCl3): δ119.6, 109.8, 82.9, 81.5, 81.0, 78.7, 76.8, 74.1, 71.5, 67.0, 66.3, 62.3, 56.5, 54.5, 45.0, 
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41.8, 40.7, 40.2, 38.4, 37.1, 35.9, 35.5, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.6, 20.8, 17.3, 
16.7, 14.7, 13.9 ppm. 
  
Synthesis of Tigogenyl-2α--hydroxy-3β-glucose (27): Synthesis of benzoylated 27: 1H NMR 
(400 MHz, CDCl3): δ 8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 
2H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 
4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 
1H), 2.12(3H,s, CH3CO), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 
3H), 0.75 (s, 3H). 13C NMR of  (CDCl3): δ 166.6, 166.1, 166.10, 165.5, 133.6, 133.5, 133.3, 
130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 109.5, 
90.6, 81.0, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 34.8, 
32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7, 13.9. 
 
Tigogenyl-2α--hydroxy-3β-glucose (27): 1H NMR (400 MHz, CDCl3): δ 5.72 (m, 2H), 5.30 
(dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, 
J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 
(s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  
(CDCl3): δ119.6, 109.8, 82.9, 81.5, 81.0, 78.7, 76.8, 74.1, 71.5, 67.0, 66.3, 62.3, 56.5, 54.5, 45.0, 
41.8, 40.7, 40.2, 38.4, 37.1, 35.9, 35.5, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 
14.7 and 12.5 ppm.  
 
Synthesis of Tigogenyl-2β--hydroxy-3α-glucose (28):  Synthesis of benzoylated 28: 1H NMR 
(400 MHz, CDCl3): δ 8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 
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2H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.87 (br, s,1H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 
1H), 4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 
Hz, 1H), 2.12(3H,s, CH3CO), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 
Hz, 3H), 0.75 (s, 3H). 13C NMR of  (CDCl3): δ 170.5,166.6, 166.13, 166.10, 165.5, 133.6, 133.5, 
133.3, 130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 
109.5, 90.6, 81.0, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 
34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
 
Tigogenyl-2β--hydroxy-3α-glucose (28): 1H NMR (400 MHz, CDCl3): δ 5.72 (m, 2H), 5.30 
(dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, 
J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 
(s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  
(CDCl3): δ119.6, 109.8, 82.9, 81.5, 81.0, 78.7, 76.8, 74.1, 71.5, 67.0, 66.3, 62.3, 56.5, 54.5, 45.0, 
41.8, 40.7, 40.2, 38.4, 37.1, 35.9, 35.5, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.6, 20.8, 17.3, 
16.7, 14.7 and 13.9 ppm.  
 
Synthesis of Tigogenyl-3β--hydroxy-2α-glucose (29): Synthesis of benzoylated 29: 1H NMR 
(400 MHz, CDCl3): δ 8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 
2H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.87 (br, s,1H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 
1H), 4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 
Hz, 1H), 2.12(3H,s, CH3CO), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 
Hz, 3H), 0.75 (s, 3H). 13C NMR of  (CDCl3): δ 170.5,166.6, 166.13, 166.10, 165.5, 133.6, 133.5, 
133.3, 130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 
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109.5, 90.6, 81.0, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 
34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9ppm. 
 
Tigogenyl-3β--hydroxy-2α-glucose  (29): 1H NMR (400 MHz, CDCl3): δ 5.72 (m, 2H), 5.30 
(dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, 
J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 
(s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  
(CDCl3): δ119.6, 109.8, 82.9, 81.5, 81.0, 78.7, 76.8, 74.1, 71.5, 67.0, 66.3, 62.3, 56.5, 54.5, 45.0, 
41.8, 40.7, 40.2, 38.4, 37.1, 35.9, 35.5, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.6, 20.8, 17.3, 
16.7, 14.7 and 13.9ppm.  
 
Synthesis of Tigogenyl-3β--hydroxy-2β-glucose (30): Synthesis of benzoylated 30: 1H NMR 
(400 MHz, CDCl3): δ 8.19- 7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 
2H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.87 (br, s, 1H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 
1H), 4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 
Hz, 1H), 2.12(3H,s, CH3CO), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 
Hz, 3H), 0.75 (s, 3H). 13C NMR of  (CDCl3): δ 170.5,166.6, 166.13, 166.10, 165.5, 133.6, 133.5, 
133.3, 130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.46, 
109.5, 90.6, 81.0, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 
34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
 
Tigogenyl-3β--hydroxy-2β-glucose (30): 1H NMR (400 MHz, CDCl3): δ 5.72 (m, 2H), 5.30 
(dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, 
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J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 
(s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  
(CDCl3): δ119.6, 109.8, 82.9, 81.5, 81.0, 78.7, 76.8, 74.1, 71.5, 67.0, 66.3, 62.3, 56.5, 54.5, 45.0, 
41.8, 40.7, 40.2, 38.4, 37.1, 35.9, 35.5, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.6, 20.8, 17.3, 
16.7, 14.7 and 13.9 ppm.  
 
4.15.3 General Procedure for disaccharide derivatives: Synthesis of Compound Tigogenyl-
3β-maltose (35) Trichloroacetimidate glucosyl donor (476mg, 0.39 mmol) and steroidal 
acceptor tigogenin  (163mg, 0.39 mmol) were stirred under an atmosphere of nitrogen in 
anhydrous CH2Cl2 (10 mL), with 3Å molecular sieves for 1 hour. The mixture was cooled to 0°C 
before TMSOTf (15 µL, 0.1 mmol) was added. The reaction was stirred for 3 hours at 0°C to 
room temperature, quenched with triethylamine, and extracted with dicholomethane. The 
solvents were removed under reduced pressure and the resulting syrup was purified by gravity 
column chromatography (15% ethyl acetate: hexane) to give 385mg of benzoylated disaccharide-
coupled tigogenin 35 (67% isolated yield).  
Tigogenyl-3β-maltose (35): Benzoylated disaccharide coupled tigogenin (375mg, 0.25mmols) 
was dissolved in Methanol and dichloromethane mix (1:1, 10ml) and freshly prepared sodium 
methoxide solution in methanol was added dropwise untill pH 9-11 was achieved. Reaction 
mixture was stirred at room temperature for one hour. On completion of reaction the reaction 
mixture was neutralized by acidic dowex resin to neutral PH and filtered off resin. Solvent was 
removed under reduced pressure and crude product was purified by column chromatography 
(Methanol:Dichloromethane:: 1:6) to get the 160mg of desired product 35 (85%-yield).  
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Synthesis of Androstanyl-2α-hydroxy-3β-maltose (31): Synthesis of benzoylated 31: 1H 
NMR (400 MHz, CDCl3): 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 
(t, J = 9.6 Hz, 1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 
1.8Hz,1H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 
3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, H-3a), 2.08 (3H, s, CH3CO), and 0.64 ppm (3H, s, CH3-18). 
13C-NMR (CDCl3): δ171.6, 166.6, 166.13, 166.10, 165.5, 133.6, 133.5, 133.3, 130.1, 130.0, 
129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 76.5, 73.5, 56.3, 56.1, 
54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 22.5, 21.4, 13.0 and 12.0 
ppm.  
Cholestanyl-2α-hydroxy-3β-maltose (32): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 
(t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 
5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.82 (1H, ddd, 
JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, 
CH3-21, CH3-26, CH3-27), and 0.64 ppm (3H, s, CH3-18). 13C-NMR (DMSO): δ 76.5, 73.5, 
56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.8, 
24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.0 and 12.0 ppm.  
 
Synthesis of Cholestanyl-2α-hydroxy-3β-maltose (32): Synthesis of benzoylated 32: 1H NMR 
(400 MHz, CDCl3): 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J = 
9.6 Hz, 1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 
1.8Hz,1H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 
3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, H-3a), 2.08 (3H, s, CH3CO), 0.84-0.90 (12H, CH3-19, CH3-
21, CH3-26, CH3-27), and 0.64 ppm (3H, s, CH3-18). 13C-NMR (CDCl3): δ171.6, 166.6, 166.1, 
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166.1, 165.5, 133.6, 133.5, 133.3, 130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 
128.8, 128.6, 128.5, 128.4, 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 
35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.8, 22.8, 22.5, 21.4, 18.6, 13.1 and 12.0 ppm.  
 
Cholestanyl-2α-hydroxy-3β-maltose (32): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 
(t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 
5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.82 (1H, ddd, 
JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, 
CH3-21, CH3-26, CH3-27), and 0.64 ppm (3H, s, CH3-18). 13C-NMR (DMSO): δ 76.5, 73.5, 
56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 
24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.0 and 12.0 ppm.   
 
Synthesis of Cholestanyl-3β-maltose (33): Synthesis of benzoylated 33: 1H NMR (400 MHz, 
CDCl3): 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J = 9.6 Hz, 
1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 
5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, 
JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm 
(3H, s, CH3-18). 13C-NMR (CDCl3): δ171.6, 166.6, 166.13, 166.10, 165.5, 133.6, 133.5, 133.3, 
130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.5, 76.5, 
73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.2, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 
27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.0 and 12.0 ppm.  
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Cholestanyl-3β-maltose (33): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 
1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz, 1H), 5.28(t,J=10.4Hz,1H),5.10(dd,J1 
=5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.82 (2H,s), 3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, 
H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm (3H, s, CH3-18). 13C-
NMR (DMSO): δ 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 
34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.0 and 12.0 ppm.  
 
Synthesis of Tigogenyl-2α-hydroxy-3β-maltose (34): Synthesis of benzoylated 34: 1H NMR 
(400 MHz, CDCl3): δ 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J 
= 9.6 Hz, 1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 
1.8Hz,1H),5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 
(dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, 
J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 
1H),2.12(3H,s, CH3CO), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 
3H), 0.75 (s, 3H). 13C NMR of  (CDCl3): δ 166.6, 166.13, 166.10, 165.9,165.7,165.5,165.4, 
138.9, 133.7, 133.6, 133.5, 133.4, 133.3, 130.4,130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 
129.0, 128.9, 128.8, 128.6, 128.5, 128.46, 102.5, 90.6, 81.0, 77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 
62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 
21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
Tigogenyl-2α-hydroxy-3β-maltose (34): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 (t, 
J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 
5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 (dd, J1 = 
6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, J=11.2,1H), 
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3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 (s, 3H), 0.95 
(d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  (DMSO): δ 
119.1,102.5, 90.6, 81.0, 77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 
37.3, 35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 
ppm. 
Synthesis of Tigogenyl-3β-maltose (35): Benzoyl protected 35: 1H NMR (400 MHz, CDCl3): δ 
8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J = 9.6 Hz, 1H), 5.72 
(m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 
1.8Hz,1H),5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 
(dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, 
J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 
(s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  
(CDCl3): δ 166.6, 166.13, 166.10, 165.9,165.7,165.5,165.4, 138.9, 133.7, 133.6, 133.5, 133.4, 
133.3, 130.4,130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 
128.46, 102.5, 90.6, 81.0, 77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 
38.7, 37.3, 35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 
13.9 ppm. 
Tigogenyl-3β-maltose (35): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 
1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 5.28(t,J=10.4Hz,1H),5.10(dd,J1 
=5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 (dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 
2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 
3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 
3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  (DMSO): δ 119.1,102.5, 90.6, 81.0, 
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77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 34.8, 32.2, 
32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
Synthesis of Tigogenyl-3β-cellobiose (36): Synthesis of benzoylated Compound 36: 1H NMR 
(400 MHz, CDCl3): δ 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J 
= 9.6 Hz, 1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 
1.8Hz,1H),5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 
(dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, 
J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 
(s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  
(CDCl3): δ 166.6, 166.1, 166.1, 165.9, 165.7, 165.5, 165.4, 138.9, 133.7, 133.6, 133.5, 133.4, 
133.3, 130.4, 130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 
128.4, 102.5, 90.6, 81.0, 77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 
37.3, 35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 
ppm. 
 
Tigogenyl-3β-cellobiose (36): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 
1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 5.28(t,J=10.4Hz,1H),5.10(dd,J1 
=5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 (dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 
2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 
3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 
3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  (DMSO): δ 119.1,102.5, 90.6, 81.0, 
77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 34.8, 32.2, 
32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
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Synthesis of Cholestanyl-3β-cellobiose (37): Synthesis of benzoylated 37: 1H NMR (400 MHz, 
CDCl3): 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J = 9.6 Hz, 
1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 
5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, 
JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm 
(3H, s, CH3-18). 13C-NMR (CDCl3): δ171.6, 166.6, 166.2, 166.1, 165.5, 133.6, 133.5, 133.3, 
130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 76.5, 
73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 
27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.1 and 12.0 ppm.  
 
Cholestanyl-3β-cellobiose (37): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 (t, J = 9.6 
Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz, 1H), 5.28(t,J=10.4Hz,1H),5.10(dd,J1 
=5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.82 (2H,s), 3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, 
H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm (3H, s, CH3-18). 13C-
NMR (DMSO): δ 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 
34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.0 and 12.0 ppm.  
 
Synthesis of Cholestanyl-2α-hydroxy-3β-maltose (38): Synthesis of benzoylated Compound 
38: 1H NMR (400 MHz, CDCl3): 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 
1H), 5.90 (t, J = 9.6 Hz, 1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 
5.39 (d, J = 1.8Hz,1H), 5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 
Hz, H-2b), 3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, H-3a), 2.08 (3H, s, CH3CO), 0.84-0.90 (12H, 
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CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm (3H, s, CH3-18). 13C-NMR (CDCl3): δ171.6, 
166.6, 166.2, 166.1, 165.5, 133.6, 133.5, 133.3, 130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 
129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 
37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.0 and 
12.0 ppm.  
 
Cholestanyl-2α-hydroxy-3β-maltose (38): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 
(t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 
5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.82 (2H,s), 
3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), 
and 0.64 ppm (3H, s, CH3-18). 13C-NMR (DMSO): δ 76.4, 73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 
42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 
18.6, 13.0 and 12.0 ppm.  
 
Synthesis of Diosgenyl-3β-maltose (39): Synthesis of benzoylated Compound 39: 1H NMR 
(400 MHz, CDCl3): δ 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J 
= 9.6 Hz, 1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 
1.8Hz,1H),5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 
(dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, 
J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 
(s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  
(CDCl3): δ 166.6, 166.1, 166.1, 165.9,165.7,165.5,165.4, 138.9, 133.7, 133.6, 133.5, 133.4, 
133.3, 130.4,130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 
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128.4, 102.5, 90.6, 81.0, 77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 
37.3, 35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 
ppm. 
Diosgenyl-3β-maltose (39): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 
1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 5.28(t,J=10.4Hz,1H),5.10(dd,J1 
=5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 (dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 
2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 
3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 
3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  (DMSO): δ 119.1,102.5, 90.6, 81.0, 
77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 34.8, 32.2, 
32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
Synthesis of Tigogenyl-3β-cellobiose (40): Synthesis of benzoylated 40: 1H NMR (400 MHz, 
CDCl3): 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J = 9.6 Hz, 
1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 
5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, 
JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm 
(3H, s, CH3-18). 13C-NMR (CDCl3): δ171.6, 166.6, 166.1, 166.1, 165.5, 133.6, 133.5, 133.3, 
130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 76.5, 
73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 
27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.1 and 12.0 ppm.  
 
Tigogenyl-3β-cellobiose (40): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 
1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 5.28(t,J=10.4Hz,1H),5.10(dd,J1 
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=5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.82 (2H,s), 3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, 
H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm (3H, s, CH3-18). 13C-
NMR (DMSO): δ 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.2, 36.1, 35.9, 35.7, 
34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.1 and 12.0 ppm.  
 
Synthesis of Tigogenyl-3β-laminaribiose (41): Synthesis of benzoylated 41: 1H NMR (400 
MHz, CDCl3): 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J = 9.6 
Hz, 1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 
5.30 (dd, J1=6.45 Hz, J2=1.2 Hz, 1H), 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, 
JZ5.4, 9.5, 11.1 Hz, H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm 
(3H, s, CH3-18). 13C-NMR (CDCl3): δ171.6, 166.6, 166.13, 166.10, 165.5, 133.6, 133.5, 133.3, 
130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 76.5, 
73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 
27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.1 and 12.0 ppm. 
  
Tigogenyl-3β-laminaribiose (41): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 (t, J = 9.6 
Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz,1H), 5.28(t,J=10.4Hz,1H),5.10(dd,J1 
=5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.82 (2H,s), 3.59 (1H, ddd, JZ5.4, 9.5, 11.1 Hz, 
H-3a), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), and 0.64 ppm (3H, s, CH3-18). 13C-
NMR (DMSO): δ 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 
34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 21.4, 18.6, 13.1 and 12.0 ppm.  
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Synthesis of Cholestanyl-3β-cellobiose (42): Synthesis of benzoylated 42: 1H NMR (400 MHz, 
CDCl3): δ 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J = 9.6 Hz, 
1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 
5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 (dd, J1 = 
6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, J=11.2,1H), 
3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 (s, 3H), 0.95 
(d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  (CDCl3): δ 
166.6, 166.1, 166.10, 165.9,165.7,165.5,165.4, 138.9, 133.7, 133.6, 133.5, 133.4, 133.3, 
130.4,130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 
102.5, 90.6, 81.0, 77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 
35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
Cholestanyl-3β-cellobiose (42): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 (t, J = 9.6 
Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 
4.95(d,J = 3.8 Hz, 1H), 4.71 (dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 2H), 4.46 (dd, J1=8.6 
Hz, J2=2.4 Hz, 1H), 4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 
3.12 (d, J=1.3 Hz, 1H), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 
3H), 0.75 (s, 3H). 13C NMR of  (DMSO): δ 119.1,102.5, 90.6, 81.0, 77.4, 73.3, 72.5, 70.4, 67.7, 
67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 
28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
Synthesis of Cholestanyl-3β-melibiose (43):  Synthesis of benzoylated 43: 1H NMR (400 MHz, 
CDCl3): δ 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J = 9.6 Hz, 
1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 
5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 (dd, J1 = 
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6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, J=11.2,1H), 
3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 (s, 3H), 0.95 
(d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  (CDCl3): δ 
166.6, 166.13, 166.10, 165.9, 165.7, 165.5, 165.4, 138.9, 133.7, 133.6, 133.5, 133.4, 133.3, 
130.4,130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 
102.5, 90.6, 81.0, 77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 
35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
Cholestanyl-3β-melibiose (43): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 (t, J = 9.6 
Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 
4.95(d,J = 3.8 Hz, 1H), 4.71 (dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 2H), 4.46 (dd, J1=8.6 
Hz, J2=2.4 Hz, 1H), 4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 
3.12 (d, J=1.3 Hz, 1H), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 
3H), 0.75 (s, 3H). 13C NMR of  (DMSO): δ 119.1,102.5, 90.6, 81.0, 77.4, 73.3, 72.5, 70.4, 67.7, 
67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 
28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
Synthesis of Tigogenyl-3β-melibiose (44): Synthesis of benzoylated 44: 1H NMR (400 MHz, 
CDCl3): δ 8.08- 7.77 (m, 14H), 7.57-7.26 (m, 21H), 6.13 (t, J=9.9 Hz, 1H), 5.90 (t, J = 9.6 Hz, 
1H), 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 
1.8Hz,1H),5.28(t,J=10.4Hz,1H),5.10(dd,J1 =5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 
(dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, 
J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 
(s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  
(CDCl3): δ 166.6, 166.13, 166.10, 165.9,165.7,165.5,165.4, 138.9, 133.7, 133.6, 133.5, 133.4, 
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133.3, 130.4,130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 
128.46, 102.5, 90.6, 81.0, 77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 
38.7, 37.3, 35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 
13.9 ppm. 
Tigogenyl-3β-melibiose (44): 1H NMR (400 MHz, DMSO): δ 5.72 (m, 2H), 5.69 (t, J = 9.6 Hz, 
1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 1.8Hz, 1H), 5.28(t,J=10.4Hz,1H),5.10(dd,J1 
=5.2Hz,J2 =1.8Hz,1H), 4.95(d,J = 3.8 Hz, 1H), 4.71 (dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H),4.66 (m, 
2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 4.38(q, J=11.2,1H), 3.84 (br s, 1H), 3.46 (m, 1H), 
3.36 (t, J = 10.8 Hz, 1H), 3.12 (d, J=1.3 Hz, 1H), 2.04 (s, 3H), 0.95 (d, J = 3.4 Hz, 3H), 0.92 (s, 
3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H). 13C NMR of  (DMSO): δ 119.1,102.5, 90.6, 81.0, 
77.4, 73.3, 72.5, 70.4, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 37.3, 35.9, 34.8, 32.2, 
32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7 and 13.9 ppm. 
Cholestanyl-3β-deca-benzoyl-maltotriose:  1H NMR of benzoylated 45 (400 MHz, CDCl3): δ 
8.04 (d, J = 3.6 Hz, 2H), 7.92 – 7.74 (m, 12H), 7.52 – 7.23 (m, 21H), 5.92 (t, J = 9.6 
Hz,1H),5.78(t,J=9.6Hz,1H),5.66(t,J=9.6Hz,1H),5.53(dd,J1 =4.9Hz,J2 =4.2Hz, 1H), 5.39 (m, 2H), 
5.28 (m, 2H), 4.65 (d, J = 4.0 Hz, 1H), 4.64 (d, J = 4.8 Hz, 1H), 4.47 (dd, J1 = 6.1 Hz, J2 = 2.4 
Hz, 1H), 4.17 (m, 1H), 4.04 – 3.92 (m, 4H), 3.84 – 3.80 (m, 3H), 3.63 – 3.56 (m, 2H), 1.12( 3H, 
s, CH3-19), 0.85, 0.91 (9H, CH3-21, Ch3-26 and CH3-27), 0.67 (3H, s, CH3-18) ppm 13C NMR 
of 45 (400 MHz, CDCl3): δ 166.8, 166.5, 165.9, 165.7, 165.5, 165.4, 133.8, 133.7, 133.5, 130.1, 
130.0, 129.9, 129.7, 129.4, 128.9, 128.7, 128.6, 128.5, 101.6, 101.2, 92.9, 77.4, 75.1, 74.7, 74.4, 
73.4, 72.6, 72.5, 72.0, 71.9, 70.4, 70.2, 69.9, 69.8, 69.1, 67.9, 63.2, 56.1, 56.0, 53.8, 47.8, 44.8, 
43.6, 42.5, 39.7, 39.5, 37.2, 36.1, 35.7, 34.7, 31.6, 28.4, 28.2, 27.9, 24.1, 23.8, 22.8, 22.5, 21.6, 
20.8, 18.6, 12.7 and 12.0 ppm. 
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Cholestanyl-2α-hydroxy-3β-deca-benzoyl-maltotriose:  1H NMR of benzoylated 46 (400 
MHz, CDCl3): δ 8.04 (d, J = 3.6 Hz, 2H), 7.92 – 7.74 (m, 12H), 7.52 – 7.23 (m, 21H), 5.92 (t, J 
= 9.6 Hz,1H),5.78(t,J=9.6Hz,1H),5.66(t,J=9.6Hz,1H),5.53(dd,J1 =4.9Hz,J2 =4.2Hz, 1H), 5.39 (m, 
2H), 5.28 (m, 2H), 4.65 (d, J = 4.0 Hz, 1H), 4.64 (d, J = 4.8 Hz, 1H), 4.47 (dd, J1 = 6.1 Hz, J2 = 
2.4 Hz, 1H), 4.17 (m, 1H), 4.04 – 3.92 (m, 4H), 3.84 – 3.80 (m, 3H), 3.63 (m, 1H), 3.41(m, 1H), 
1.12( 3H, s, CH3-19), 0.85, 0.91 (9H, CH3-21, Ch3-26 and CH3-27), 0.67 (3H, s, CH3-18) ppm 
13C NMR of Benzoylated 46 (400 MHz, CDCl3): δ 166.8, 166.5, 165.9, 165.7, 165.5, 165.4, 
133.8, 133.7, 133.5, 130.1, 130.0, 129.9, 129.7, 129.4, 128.9, 128.7, 128.6, 128.5, 101.6, 101.2, 
92.9, 77.4, 75.1, 74.7, 74.5, 73.4, 72.6, 72.5, 72.0, 71.9, 70.4, 70.2, 69.9, 69.8, 69.1, 67.9, 63.2, 
56.1, 56.0, 53.8, 47.8, 44.8, 43.6, 42.5, 39.7, 39.4, 37.2, 36.1, 35.7, 34.6, 31.5, 28.4, 28.2, 27.9, 
24.1, 23.8, 22.8, 22.5, 21.6, 20.8, 18.6, 12.7 and 12.0 ppm. 
 
Tigogenyl-3β-deca-benzoyl-maltotriose:  1H NMR of benzoylated 47 (400 MHz, CDCl3): δ 
8.04 (d, J = 3.6 Hz, 2H), 7.92 – 7.74 (m, 12H), 7.52 – 7.23 (m, 21H), 5.92 (t, J = 
9.6Hz,1H),5.78(t,J=9.6Hz,1H),5.66(t,J=9.6Hz,1H),5.53(dd,J1 =4.9Hz,J2 =4.2Hz, 1H), 5.39 (m, 
2H), 5.28 (m, 2H), 4.65 (d, J = 4.0 Hz, 1H), 4.64 (d, J = 4.8 Hz, 1H), 4.47 (dd, J1 = 6.1 Hz, J2 = 
2.4 Hz, 1H), 4.38 (q, J = 11.2 Hz, 1H), 4.17 (m, 1H), 4.04 – 3.92 (m, 4H), 3.84 – 3.80 (m, 3H), 
3.63 – 3.56 (m, 2H), 3.47(m, 1H), 3.37(m, 1H), 0.96( d, J = 3.4Hz, 3H), 0.82 (s, 3H), 0.76(s, 3H) 
ppm. 13C NMR of benzoylated 47 (400 MHz, CDCl3): δ 166.8, 166.5, 165.9, 165.7, 165.5, 
165.4, 133.8, 133.7, 133.5, 130.1, 130.0, 129.9, 129.7, 129.4, 128.9, 128.7, 128.6, 128.5, 109.5, 
101.6, 101.2, 92.9, 81.0, 77.4, 75.1, 74.7, 73.4, 72.6, 72.5, 72.0, 71.9, 71.5, 70.4, 70.2, 69.9, 69.8, 
69.1, 67.9, 67.0, 63.2, 62.3, 56.5,54.5, 45.0, 41.8, 40.7, 40.2, 38.4, 37.1, 35.7, 35.3, 32.4, 31.9, 
31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 14.7 and 12.5 ppm. 
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Tigogenyl-2α-hydroxy-3β-deca-benzoyl-maltotriose:  1H NMR of benzoylated 48 (400 MHz, 
CDCl3): δ 8.04 (d, J = 3.6 Hz, 2H), 7.92 – 7.74 (m, 12H), 7.52 – 7.23 (m, 21H), 5.92 (t, J = 
9.6Hz,1H),5.78(t,J=9.6Hz,1H),5.66(t,J=9.6Hz,1H),5.53(dd,J1 =4.9Hz,J2 =4.2Hz, 1H), 5.39 (m, 
2H), 5.28 (m, 2H), 4.65 (d, J = 4.0 Hz, 1H), 4.64 (d, J = 4.8 Hz, 1H), 4.47 (dd, J1 = 6.1 Hz, J2 = 
2.4 Hz, 1H), 4.38 (q, J = 11.2 Hz, 1H), 4.17 (m, 1H), 4.04 – 3.92 (m, 4H), 3.84 – 3.80 (m, 3H), 
3.63 – 3.56 (m, 2H), 3.47(m, 1H), 3.37(m, 1H), 0.96( d, J = 3.4Hz, 3H), 0.82 (s, 3H), 0.76(s, 3H) 
ppm. 13C NMR of benzoylated 48 (400 MHz, CDCl3): δ 166.8, 166.5, 165.9, 165.7, 165.5, 
165.4, 133.8, 133.7, 133.5, 130.1, 130.0, 129.9, 129.7, 129.4, 128.9, 128.7, 128.6, 128.5, 109.5, 
101.6, 101.2, 92.9, 81.0, 77.4, 75.1, 74.7, 73.4, 72.6, 72.5, 72.0, 71.9, 71.5, 70.4, 70.2, 69.9, 69.8, 
69.1, 67.9, 67.0, 63.2, 62.3, 56.5,54.5, 45.0, 41.8, 40.7, 40.2, 38.4, 37.1, 35.7, 35.3, 32.4, 31.9, 
31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 14.7 and 12.5 ppm. 
 
Penta-O-acetyl-D-glucopyranose (49): D-glucose (20 g, 110 mmol) was refluxed in pyridine 
(150 mL) for 1 hour. Acetic anhydride (100 mL) was added and the mixture was refluxed an 
additional 2 hours. The resulting solution was cooled to room temperature, poured over ice (300 
mL) and stirred until the product solidified, about 2 hours. The solid was filtered, washed with 
water, and recrystallized from ethyl acetate/hexanes to give 49 as a white solid (36 g, 83 % 
yield). 1H NMR of 49 (400 MHZ, CDCl3): δ 5.72 (d, J = 4.0 Hz, 1H), 5.26 (t, J = 9.2 Hz, 1H), 
5.14(t,J=8.8Hz,1H),5.13(t,J=10.0Hz,1H),4.30(dd,J1 =6.2Hz,J2 =2.2Hz,1H), 4.12 (dd, J1 = 6.3 Hz, 
J2 = 1.0 Hz, 1H), 3.84 (m, 1H), 2.12 (s, 3H), 2.09 (s, 3H), 2.04 (s, 6H), 2.01 (s, 3H).13C NMR of 
49 (400 MHz, CDCl3): δ 170.7, 170.3, 169.8, 169.5, 168.9, 89.1, 69.9, 69.2, 67.9, 61.5, 20.9, 
20.8, 20.7, 20.6 and 20.5ppm. 
 
Isopropyl tetra-O-acetyl-1-thio-β-D-glucopyranoside (50): Penta-O-acetyl-β-D-glucopyranose 
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78 (3.7 g, 9.4 mmol) and propane-2-thiol (1.0 mL, 13 mmol) were stirred at room temperature in 
CH2Cl2 with 3 Å molecular sieves for 30 minutes under an atmosphere of nitrogen. BF3·OEt2 (3.5 
mL) was added and the mixture was stirred an additional 2 hours. The molecular sieves were 
filtered and the filtrate was added to 5 % NaHCO3 (50 mL) with vigorous stirring. The organic 
layer was separated, washed with 5 % NaHCO3 (3 x 50 mL), and dried over sodium sulfate. The 
solvent was removed under reduced pressure and the resulting solid was used immediately in the 
next reaction without further purification.1H NMR (400 MHz, CDCl3): δ 5.11 (t, J = 9.6 Hz, 
1H), 4.94(t,J=9.6Hz,1H),4.86(t,J=9.6Hz,1H),4.49(d,J=5.2Hz,1H),4.11(dd,J1 = 6.2Hz,J2 
=2.8Hz,1H),4.00(dd,J1 =6.0Hz,J2 =1.2Hz,1H),3.61(m,1H),3.05(m, 1H), 1.94 (s, 3H), 1.92 (s, 
3H), 1.90 (s, 3H), 1.88 (s, 3H), 1.19 (d, J = 2.2 Hz, 3H), 1.17 (d, J = 2.2 Hz, 3H). 13C NMR (400 
MHz, CDCl3): δ 170.6, 170.2, 169.4, 169.3, 83.3, 75.6, 73.9, 70.1, 68.4, 62.2, 35.6, 24.0, 23.7, 
20.7, 20.7 and 20.5 ppm. 
 
Isopropyl 1-thio-β-D-glucopyranoside (51): Thioglucopyranoside 50 was dissolved in 2:1 
MeOH: CH2Cl2 (45 mL). Sodium hydroxide (1N) was added to a pH ~ 9-10. The solution was 
stirred at room temperature 6 hours, neutralized with acidic Dowex resin, and filtered. The 
solvents were removed under reduced pressure and the resulting solid was co-evaporated with 
toluene (3 x 10 mL) and used immediately in the following reaction without further purification. 
1H NMR (400 MHz, DMSO- D6): δ 4.31 (d, J = 4.8 Hz, 1H), 3.65 (dd, J1= 5.9 Hz, J2= 0.6 Hz, 
1H), 3.40 (dd, J1 = 5.9 Hz, J2= 2.9 Hz, 1H), 3.18 – 2.93 (m, 5H), 1.22 (dd, J1 = 3.4 Hz, J2 = 2.1 
Hz, 6H). 13C NMR (400 MHz, DMSO-D6): δ 84.5, 80.9, 78.3, 73.3, 70.1, 61.3, 33.4, 23.9 and 
23.8 ppm. 
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Isopropyl (R)-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (52): Thioglucopyranoside 51 
and dimethoxymethylbenzene (1.7 g, 11 mmol) were dissolved in DMF (15 mL). The solution 
was cooled to 0°C and CSA was added to a pH ~ 2-3. After the mixture was stirred at room 
temperature overnight, it was neutralized with triethylamine. Ethyl acetate (100 mL) was added 
and the resulting solution was washed with brine (2 x 100 mL), dried over sodium sulfate. The 
solvents were removed under reduced pressure and the product was purified by flash column 
chromatography (1:1 ethyl acetate: petroleum ether) to give 52 as a white solid (1.6 g, 51 % yield 
in 3 steps from 49). 1H NMR (400 MHz, CDCl3): δ 7.55 – 7.36 (m, 5H), 5.55 (s, 2H), 4.54 (d, J 
= 5.0 Hz, 1H), 4.35 (dd, J1 = 5.2 Hz, J2 = 2.3 Hz, 1H), 3.88 – 3.75 (m, 2H), 3.62 – 3.45 (m, 3H), 
3.24 (m, 1H), 1.36 (d, J = 3.3 Hz, 6H). 13C NMR (400 MHz, CDCl3): δ 129.4, 128.5, 126.6, 
126.5, 102.1, 86.5, 81.2, 72.3, 72.3, 68.9, 63.6, 36.5, 24.4 and 23.8 ppm. 
 
Isopropyl tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-[tetra-O-benzoyl-β-D- 
glucopyranosyl-(1→2)]-(R)-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (54): 
Trichloroacetimidate donor 1 (3.7 g, 5.0 mmol) and thioglucopyranoside 52 (1.5 g, 4.5 mmol) 
were co-evaporated with toluene (3 x 10 mL), dried under reduced pressure overnight, and then 
stirred under an atmosphere of nitrogen in anhydrous CH2Cl2 (50 mL), with 3Å molecular sieves 
for 1 hour. The mixture was cooled to 0°C before TMSOTf (91 μL, 0.5 mmol) was added. The 
reaction was stirred at 0°C for 5 hours, neutralized with triethylamine (0.3 mL), and filtered. The 
solvents were removed under reduced pressure and the product was purified by gravity column 
chromatography (2:3 ethyl acetate: petroleum ether) to give isopropyl tetra-O-benzoyl-β-D-
glucopyranosyl- (1→3)-(R)-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (53), which was 
used immediately in the following reaction. 1H NMR of 53 (400 MHz, CDCl3): δ 8.14 – 7.82 (m, 
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10H), 7.23 – 7.57 (m, 15 H), 5.92 (t, J = 9.2 Hz, 1H), 5.71 (t, J = 9.2 Hz, 1H), 5.57 (s, 2H), 
5.56(dd,J1 =3.6Hz,J2 =1.0Hz,1H),5.22(d,J=4.0Hz,1H),4.49(dd,J1 =5.9 Hz, J2 = 1.8 Hz, 1H), 
4.44 (d, J = 5.0 Hz, 1H), 4.33 (t, J = 12.0 Hz, 1H), 4.32 (t, J = 12.4 Hz, 1H), 3.94 (m, 1H), 3.90 
(t, J = 8.4 Hz, 1H), 3.77 (t, J = 10.8 Hz, 1H), 3.71, (t, J = 9.6 Hz, 1H), 3.49 – 3.44 (m, 2H), 3.14 
(m, 1H), 1.24 (d, J = 2.9 Hz, 6H). Disaccharide 53 and trichloroacetimidate donor 1 (3.0 g, 4.0 
mmol) were co-evaporated with toluene (3 x 10 mL), dried under reduced pressure overnight, 
and then stirred under an atmosphere of nitrogen in anhydrous CH2Cl2 (50 mL), with 3Å 
molecular sieves for 1 hour. The mixture was cooled to 0°C before TMSOTf (91 μL, 0.5 mmol) 
was added. The reaction was stirred at 0°C for 3 hours, neutralized with triethylamine (0.5 mL), 
and filtered. The solvents were removed under reduced pressure and the product was purified by 
gravity column chromatography (2:3 ethyl acetate: petroleum ether) and then recrystallized from 
methanol to give 54 (1.6 g, 23 % yield in 2 steps from 52). 1H NMR (400 MHz, CDCl3): δ 8.29 
– 7.21 (m, 45H), 5.83 (t, J = 9.2 Hz, 1H), 5.79 (t, J = 9.6 Hz, 1H), 5.61 – 5.52 (m, 3H), 5.51 (s, 
2H), 5.43 (t, J = 10.0 Hz, 1H), 4.97 (d, J = 3.8 Hz, 1H), 4.80 (d, J = 4.2 Hz, 1H), 
4.49(d,J=4.8Hz,1H),4.37(dd,J1 =5.9Hz,J2 =1.6Hz,1H),4.28–4.18(m, 4H), 4.00 (t, J = 8.8 Hz, 1H), 
3.90 (t, J = 9.6 Hz, 1H), 3.69 (t, J = 10.8 Hz, 1H), 3.62 (t, J = 9.2 Hz, 1H), 3.30 (m, 1H), 3.07 
(m, 1H), 2.79 (m, 1H), 2.67 (m, 1H), 1.22 (d, J = 3.2 Hz, 3H), 1.09, (d, J = 3.4 Hz, 3H).13C NMR 
(400 MHz, CDCl3): δ 166.5, 166.1, 166.0, 165.5, 165.4, 165.3, 163.9, 133.8, 133.7, 133.6, 
133.5, 133.3, 130.3, 130.2, 130.1, 130.0, 129.9, 129.8, 129.7, 129.7, 129.6, 129.6, 129.5, 129.4, 
129.4, 129.3, 129.2, 129.1, 129.0, 128.9, 128.9, 128.7, 128.6, 128.5, 128.5, 128.3, 128.3, 126.2, 
101.4, 100.0, 99.6, 96.1, 92.1, 84.0, 80.9, 78.6, 77.4, 76.7, 73.1, 72.5, 71.5, 71.3, 70.8, 69.2, 68.7, 
63.6, 62.2, 34.3, 23.8 and 23.6 ppm. 
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Synthesis of Diosgenyl-3β-hexanoate (55):   
1H NMR (400 MHz, CDCl3): δ 4.82 (1H, ddd, J =4.8, 9.4, 11.6 Hz, H-2b), 4.38 (q, J = 11.2 Hz, 
1H), 3.59 (1H, ddd, J = 4.7, 9.0, 11.5 Hz, 1H), 3.47 (m, 1H), 3.37 (t, J = 10.8 Hz, 1H), 2.08 (s, 
3H),  0.96 (d, J = 3.4 Hz, 3H), 0.82 (s, 3H), 0.79 (d, J = 3.2 Hz,3H), 0.76 (s, 3H) ppm. 13C NMR 
(100 MHz, CDCl3): δ 165.2,162.5, 81.0, 71.5, 67.0, 62.3, 56.5,54.5, 45.0, 41.8, 40.7, 40.2, 38.4, 
38.2, 37.1, 35.7, 35.3, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 14.7 and 12.5 
ppm.  
 
Synthesis of Tigogenyl-2α-acetoxy-3β- tetradecanoate (56):   
1H NMR (400 MHz, CDCl3): δ 4.82 (1H, ddd, J =4.8, 9.4, 11.6 Hz, H-2b), 4.38 (q, J = 11.2 Hz, 
1H), 3.59 (1H, ddd, J = 4.7, 9.0, 11.5 Hz, 1H), 3.47 (m, 1H), 3.37 (t, J = 10.8 Hz, 1H), 2.08 (s, 
3H),  0.96 (d, J = 3.4 Hz, 3H), 0.82 (s, 3H), 0.79 (d, J = 3.2 Hz,3H), 0.76 (s, 3H) ppm. 13C NMR 
(100 MHz, CDCl3): δ 165.2,162.5, 81.0, 71.5, 67.0, 62.3, 56.5,54.5, 45.0, 41.8, 40.7, 40.2, 38.4, 
38.2, 37.1, 35.7, 35.3, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 14.7 and 12.5 
ppm.  
 
Synthesis of Tigogenyl-2α-acetoxy-3β-hexadecanoate (57):   
1H NMR (400 MHz, CDCl3): δ 4.82 (1H, ddd, J =4.8, 9.4, 11.6 Hz, H-2b), 4.38 (q, J = 11.2 Hz, 
1H), 3.59 (1H, ddd, J = 4.7, 9.0, 11.5 Hz, 1H), 3.47 (m,1H), 3.37 (t, J = 10.8 Hz, 1H), 2.08 (s, 
3H),  0.96 (d, J = 3.4 Hz, 3H), 0.82 (s, 3H), 0.79 (d, J = 3.2 Hz,3H), 0.76 (s, 3H) ppm. 13C NMR 
(100 MHz, CDCl3): δ 165.2,162.5, 81.0, 71.5, 67.0, 62.3, 56.5, 54.5, 45.0, 41.8, 40.7, 40.2, 38.4, 
38.2, 37.1, 35.7, 35.3, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 21.2, 17.3, 16.7, 14.7 and 12.5 
ppm.  
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Synthesis of Cholestanyl-2α-acetoxy-3β-hexanoate (58):   
1H NMR (400 MHz, CDCl3): δ 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, JZ5.4, 
9.5, 11.1 Hz, H-3a), 2.08 (3H, s, CH3CO), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), 
and 0.64 ppm (3H, s, CH3-18). 13C-NMR (CDCl3) δ: 171.6, 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 
42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 
21.4, 18.6, 13.0 and 12.0 ppm.  
 
Synthesis of Cholestanyl-2α-acetoxy-3β-tetradecanoate (59):   
1H NMR (400 MHz, CDCl3): δ 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, JZ5.4, 
9.5, 11.1 Hz, H-3a), 2.08 (3H, s, CH3CO), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), 
and 0.64 ppm (3H, s, CH3-18). 13C-NMR (CDCl3) δ: 171.6, 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 
42.5, 42.1, 39.8, 39.5, 37.3, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 
21.4, 18.6, 13.0 and 12.0 ppm.  
 
Synthesis of Cholestanyl-2α-acetoxy-3β-hexadecanoate (60):   
1H NMR (400 MHz, CDCl3): δ 4.82 (1H, ddd, JZ4.8, 9.4, 11.6 Hz, H-2b), 3.59 (1H, ddd, JZ5.4, 
9.5, 11.1 Hz, H-3a), 2.08 (3H, s, CH3CO), 0.84-0.90 (12H, CH3-19, CH3-21, CH3-26, CH3-27), 
and 0.64 ppm (3H, s, CH3-18). 13C-NMR (CDCl3) δ: 171.6, 76.5, 73.5, 56.3, 56.1, 54.1, 44.4, 
42.5, 42.1, 39.8, 39.4, 37.2, 36.1, 35.9, 35.7, 34.7, 31.8, 28.2, 27.9, 27.7, 24.1, 23.7, 22.8, 22.5, 
21.4, 18.6, 13.1 and 12.0 ppm.  
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CHAPTER-5: TAG MOLECULE BASED APPROACH FOR SYNTHESIS OF 
BRANCHED OLIGOSACCHARIDE 
Glycoproteins, glycolipids, and glycophospholipids are major components of 
membranes.1 The oligosaccharide residues are responsible for intercellular recognition and 
interaction and they also act as receptors for proteins, hormones, and viruses and regulate 
immune reactions.2 These significant activities have attracted significant research interest in 
oligosaccharides and glycoconjugates.3 Unlike peptides and nucleotides, in which the 
information content is determined solely by the number and sequence of different monomer 
units, the information content of oligosaccharides is also determined by the site of coupling, the 
configuration of glycosidic linkage (α or β), and by the occurrence of branching. Thus, polymers 
made by carbohydrates can carry considerably more information per building block than proteins 
and nucleic acids. Therefore, the chemical synthesis of oligosaccharides is more complicated 
than that of other biopolymers.4 A major source of branched oligosaccharides is still isolated 
from natural resources. Unfortunately, the amplification methods—such as the polymerase chain 
reaction (PCR) for nucleic acids or bacterial expression systems for protein production—do not 
exist for glycoconjugates. Therefore, the overall progress in glycobiology has suffered from a 
lack of tools that would quickly provide a diverse library of oligosaccharides in a similar fashion 
to ones that are currently available for nucleic acids and amino acids. Classically all solution- 
phase carbohydrate synthetic methodologies5 are relatively complicated and time- consuming, 
therefore oligosaccharide synthesis requires more expertise and has been mostly performed in 
specialized laboratories. There have been some recent advances in the development of modern 
sequencing methods6 such as the development of protocols toward solution-phase and solid-
phase oligosaccharide synthesis. However, more advances in the oligosaccharide synthesis are 
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necessary to drive the development of diagnostic tests, vaccines and carbohydrate therapeutics7. 
The synthesis of carbohydrates has been pursued for more than a century, and many 
oligosaccharides can now be synthesized, albeit with considerable effort8. This tremendously 
hampers the exploration of oligosaccharide biological studies. One can argue that a fully 
automated oligosaccharide synthesis process must be developed.9 However for an efficient 
automated synthesis there is a need for a large number of oligosaccharide building blocks 
(monomers) and the methodology to connect them to the oligomers. Applying polymer-
supported syntheses in the preparation of oligosaccharides has its drawbacks. For 
oligosaccharide synthesis, the main problem is associated with use of an excess of the expensive 
carbohydrate building blocks that are required to drive the heterogeneous reaction to completion, 
and it is very difficult to monitor the sugar–sugar coupling process by normal characterization 
methods such as TLC, NMR and mass spectrometry. Furthermore, the heterogeneous nature of 
the insoluble polymers and restricted reaction conditions often result in non-linear reaction 
kinetics, unequal distribution, difficult access to the reaction sites, improper solvation and 
inefficient coupling rates to name a few.10  
In order to overcome some of these problems, new synthetic methodology with TAG 
molecules11 was proposed that would take into account the advantages of both polymer supported 
reactions (such as easy purification) and all solution chemistry (such as easy reaction 
monitoring). Since the preparation of branched oligosaccharides is a difficult task, we have 
employed the use of a tagged glucose that can be used as a key building block for various 
branched oligosaccharides (Fig. 1). Once we synthesize the oligosaccharide building block, other 
saccharide units can be added in positions 1, 2, and 3 selectively.12 (Fig. 5.1) 
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Figure 5.1 Proposed tagged glucose as a synthone for preparation of branched oligosaccharide. 
 
The tag attachment should give the tagged saccharide desirable physical properties 
that saccharide by itself does not have, such as low moisture sensitivity, solubility in low polarity 
organic solvents, easy purification, and easy reaction monitoring and structure elucidation. In 
addition the tag attachment should be stable under reaction conditions required to prepare 
oligosaccharides, and at the same time easily removed once the final reaction is completed and 
the product is purified.  
In general, a tag is a group of atoms or a molecular fragment that is attached to a 
molecule for identification13. However in some instances a tag is used to give a particular nature 
to a molecule. Several types of tags, such as affinity tags and fluorescent tags have been widely 
used in field of chemistry and biochemistry. A tag that facilitates phase separation is called a 
phase tag. A phase tag is a functional group attached to a molecule to control the favorable phase 
of the parent molecule in phase separation. In other words a phase tag changes the natural phase 
affinity of the molecule, which makes it easy to separate tagged molecule, that have strong 
interaction to a phase determined by the tag, from other untagged molecule which have natural 
phase affinity. 
O
HO OH
OH
O
O
TAG
3 2
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Scheme 5.1 Monophasic reaction and biphasic separation  
Generally, a monophasic system is advantageous for reactions although a biphasic (or 
multiphasic) system is essential for phase separation (Scheme 5.1). Heterogeneous reactions 
usually proceed less effectively than the homogeneous counterparts. The most popular way of 
solving this problem is the use of a solvent that disssolves both tagged compound and untagged 
compounds. After reaction is finished, the solvents are changed to form a biphasic system. 
Sometimes temperature-dependent miscibilities or solubilities are used to switch from 
monophasic to biphasic system.14-16 
Substrate tags should meet the following requirements17: 
• It should be easily introduced to a starting molecule (tagging). 
• It should be stable under the conditions of desired chemical transformations. 
• It should not interfere with the desired chemical transformations. 
• It should effectively change the phase affinity of the molecule to ensure 
effective phase separation. 
• After the transformation is completed, a tag should be removable from the 
product without affecting other functional groups in the molecule (detagging). 
 
TAG
B
A TAG
B
A
Reaction Stage Separation Stage
MONOPHASIC
(high reactivity)
BIPHASIC
(easy separation)
B
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5.1: Synthesis of TAG molecules: 
5.1.1 Synthesis of phthalimides and naphthalimides: Microwave-assisted preparation of 
several cyclic imides was performed with four different cyclic anhydrides. All the reactions are 
significantly faster and the isolated yields are significantly higher compared to conventionally 
heated reactions. Cyclic imides18 play an important role in organic syntheses and in medicinal 
chemistry. For instance, cyclic imides, particularly phthalimides, have been widely used as 
amino acid protection groups19 and have attracted considerable attention in medicinal chemistry.20 
Maleimides are important constituents of peptide-conjugate haptens, antibody–antibody 
conjugates, immune conjugates, and enzyme inhibitors.21Recently, a solvent-free procedure using 
TaCl5-silica gel as a catalyst was described for the preparation of imides under microwave 
irradiation.22 Sandhu and co-workers advocated the use of a more eco-friendly solvent-free 
system, involving the reaction of equal amounts of anhydride and amines or amino acids in the 
absence of a solvent in a domestic oven without any catalyst.23 In the case of the reaction of the 
anhydride with amino acids, a reaction between two solids was involved, for example between 
phthalic anhydride and glycine. Unfortunately, no temperature measurements were reported.23 
In order to address these limitations we have developed microwave-assisted preparation 
of cyclic imides in polar solvents such as DMF and pyridine from cyclic anhydrides and 
corresponding amines. In the course of our microwave-assisted reaction studies, we explored the 
preparation of phthalimides from phthalic anhydride and the corresponding amine in DMF as a 
solvent. The magnetron power for microwave was adjusted for gentle solvent refluxing. After the 
reaction was completed, the product was isolated by ice-water precipitation from the hot reaction 
mixture. The reaction time and isolated yields are presented in Table 5.1.  Using conventional 
reaction methods, time taken for transformation into the corresponding imides ranged from 12 to 
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16 h (Table 5.1). However, utilizing the new microwave-assisted method of preparation gave 
quantitative yields of product in no more than 1 h (Table 5.1). 26 
Table 5.1 Preparation of phthalimides24 
 
Compound Imide Time (min) Power (W) Yield (%) Timea (hr) Yielda (%) 
1 
 
60 300 94 16 85 
2 
 
60 300 95 16 65 
3 
 
30 300 97 12 65 
4 
 
60 450 85 16 60 
5 
 
40 450 95 16 60 
6 
 
40 450 90 16 63 
a Conventional heating in toluene as a solvent catalytic amount of TEA 
O
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O
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1: R = 4-CH3C6H4,      2: R = C6H5
3: R = 3-BrC6H4,         4: R = 2-C6H5-C6H4
5: R = CH3(CH2)4CH2, 6: R = CH3(CH2)15CH2
phthalic anhydride
N
O
O
N
O
O
N
O
O
Br
N
O
O Ph
N
O
O
CH2 CH3
5
N
O
O
CH2 CH3
16
	   181	  
For conventional preparation of 1 toluene is the superior solvent in comparison to DMF 
in regards to both the reaction time and isolated yield. For instance, after refluxing the DMF 
solution for two days the isolated yield of 1 was only 45%. This is not an unusual finding 
because the preparation of aromatic and aliphatic phthalimides under conventional heating 
usually requires prolonged time in solvents such as toluene, acetic acid, .26 There are also reports 
of microwave-assisted synthesis without solvent.26 However, the no-solvent approach can only 
be successful if one of the reactants absorbs microwave irradiation and has relatively low melting 
point. On the other hand, our procedure is applicable to broad range of amines regardless of their 
physical state or microwave radiation absorption because our solvent (DMF) is an excellent 
microwave reaction media, as it was demonstrated on the examples of aromatic amines (1-4) and 
aliphatic amines (5 and 6, Table 5.1) and microwave-assisted reaction is superior to conventional 
reaction. 
In general, five-membered cyclic anhydrides are more reactive than six-membered cyclic 
anhydrides. Therefore, it does not come as a surprise that microwave-assisted reaction conditions 
used for the preparation of cyclic imides with 1,8-naphthalic anhydride are more demanding than 
those with phthalic anhydride, where the reaction time is more than quadruples. However by 
replacing DMF as the solvent with pyridine, the isolated yield was higher and the reaction time 
was shortened (Table 5.2). The isolation of the product requires quenching the reaction with 
water or with aqueous hydrochloric acid followed by crystallization of the product. As 
demonstrated in Table 5.2, the isolated yields are higher and the reaction times are shortened by 
10–20 times in the case of microwave-assisted preparation. 
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Table 5.2 Synthesis of 1,8-naphthylimides26 
 
Entry Imide Time (hr) Power (W) Yield (%) Timea (hr) Yielda (%) 
1 7 4 300 70 48 55 
2 7 2 450 90 20 70 
3 8 4 300 65 48 50 
4 8 2 450 95 24 75 
5 9 1 450 93 24 50 
Note- different power for DMF and pyridine is required for reflux due to difference in their polarity. 
a With conventional heating 
 
5.1.2 Synthesis of Succinimides: 
We were not able to prepare succinimide by simple microwave heating in either DMF or 
pyridine solution of succinic anhydride and the corresponding amine. The major product was the 
corresponding open amide acid that, upon continued microwave heating, decomposed. Even 
when the DMF reaction mixture was microwaved for 8hrs, only traces of the product were 
detected with substantial amount of decomposition material. However, if the DMF reaction 
mixture was first microwaved for a short time and then a water-removing reagent, such as DCC 
was added followed by short microwave irradiation, then the corresponding succinimide was 
successfully prepared. 
To simplify the isolation and purification of the product, acetic anhydride was used as a 
dehydration reagent instead of DCC. The reaction was practically completed in 20 min. To 
eliminate the excess of the acetic anhydride, water was added and the reaction mixture was 
microwaved for an additional 20 min (Table 5.3). Considering the  nature of the reaction   
N R
O
O
N
O
O
N
O
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7: R = H; 8: R = CH3
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media (DMF + Ac2O + H2O), the product can be isolated by ice-water precipitation and purified 
by simple washing with water or aqueous hydrochloride. If necessary, further purification can be 
accomplished by column chromatography. The reaction conditions and isolated yields for some 
of the prepared succinimides are presented in Table 5.3. 
Table 5.3 Synthesis of succinimides26 
 
Entry Imide Yielda (%) Timeb (hr) Yieldb (%) 
1 
 
91 24 45 
2 
 
84 16 35 
3 
 
85 16 35 
4 
 
92 24 40 
5 
 
88 24 35 
a All microwave reactions were performed with a power of 300W and reaction time 30+30+20 minutes. 
b For conventional method only heating with acetic anhydride was reported. 
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5.1.3 Synthesis of Maleimides: 
The described procedure that was so successful for the preparation of both aliphatic and 
aromatic succinimides cannot be accepted as a general procedure for the preparation of 
maleimides. In many instances, using this preparation approach generated a complex mixture 
with majority (more than 60%) of the maleimide as a product. Unfortunately, the formed 
byproducts make the isolation and purification of the maleimide difficult. However this approach 
is still applicable for the preparation of simple aromatic maleimides such as phenyl and naphthyl 
maleimides (Table 5.4). In the case of aliphatic maleimides, the conversion of the amine into 
maleimide was around 60% therefore a new microwave-assisted preparation strategy was 
required. 
Maleic anhydride followed by the ring closure in acetic anhydride with a catalytic 
amount of acetic acid. Isolated yields of the maleimides range around 50%. 26 In our microwave-
assisted preparation approach we also applied the two-step synthesis (Method B Table 10). In the 
first step, tetrahydrofuran (THF) solutions of the corresponding amine and maleic anhydride 
were mixed at room temperature. The reaction was completed after a few minutes. The formed 
precipitate was mixed with acetic anhydride and a catalytic amount of sodium acetate and then 
microwaved at 450 W. The reaction conditions and isolated yields are presented in Table 5.4. 
 
 
 
 
 
 
	   185	  
Table 5.4 Synthesis of Maleimides26 
 
Entry Method Imide Time (min) Power (W) Yield (%) 
1 A 
 
70 450 91 
2 A 
 
70 450 84 
3 B 
 
30 450 93 
4 B 
 
30 450 95 
5 B 
 
30 450 93 
6 B 
 
30 450 85 
 
O
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RH2N+ N
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Microwave
A or B
15: R = Phenyl;    16: R = 1-naphthyl 
17: R = 4-methylphenyl; 
18: R = bis(4-phenylene)methane
Method A: DMF, Ac2O, H2O
Method B: a) THF b) Ac2O-AcONa
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We have explored the effects of microwave irradiation on the preparation of cyclic 
imides. Given the possibility to control the power of microwave radiation, it was possible to use 
microwave irradiation for the preparation of cyclic imides that require microwave radiation in 
the range of a few minutes to a few hours. This approach is superior to conventional synthetic 
approach in both isolated yield of the product and required reaction time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   187	  
5.2 Microwave-assisted NBS bromination of p-iminotoluenes:  
A simple, efficient, and rapid microwave-assisted method for the preparation of protected 
p-bromomethyl and p-dibromomethylanilines was developed as new alcohol, thiol, and amine 
protection groups.  The procedure involves microwave-assisted NBS radical bromination of 
readily available N-protected p-toluidine.  The microwave-assisted radical bromination was 
found to be superior to the conventional NBS radical bromination. 
We selected cyclic imides of p-aminobenzyl and p-aminobenzylidene bromides as ideal 
protection groups for the purposes of our natural product syntheses. Cyclic imides are 
compounds that crystallize well and are relatively stable in acid, neutral, and dry basic reaction 
media. When these groups are part of the protected compound either in the ether, thioether, or 
amine form, they are relatively stable in the above mentioned reaction conditions.  The major 
advantage of these benzyl based protection groups over others that their acid sensitivity can be 
significantly increased by removal of imides protection using hydrazine or a base. The resulting 
p-amino benzyl ethers, thioethers, or amines are easily cleaved with moderate acids.  For 
alcohols, the corresponding phenylmethyl bromide A is an ideal protection group, while for 1, 2- 
and 1, 3-diols the phenylmethylene dibromide B is the ideal protection group and finally, for 
thiols and amines, the triphenylmethyl bromide C is the ideal protection group (Figure 5.2). 26-28 
 
 
Figure 5.2 New alcohol, thiol, and amino protection groups 
N
O
O
CHyBrz
x
A: x=z=1; y=2 for alcohol protection
B: x=y=1; z=2 for 1,2- and 1,3-diols protection
C:x=3, y=0, z=1 for thiol and amino group protection
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 One of the requirements for broad use of these protection groups in natural product synthesis 
is that they be available in large amounts either commercially or through simple preparation 
procedures.  The classical approach to prepare benzyl bromides and benzylidene dibromides is 
through the direct bromination of the benzylic methyl, or through deoxybromination of benzylic 
alcohol or benzaldehyde derivatives. 29 The latter route implies a multistep synthesis, which is 
often time consuming.  Alternatively, the two-step bromination method, via the generation of the 
methyl anion developed by Fraser, 30, 31 appears attractive. However, this method is incompatible 
with the presence of nucleophile sensitive functional groups on the molecule, such as an ester 
group. 
Radical mediated bromination is frequently used to achieve selective activation of the benzyl 
and allyl positions of an organic molecule.32 Using N-bromosuccinimide (NBS) in 
tetrachloromethane with various radical initiators normally carries out the reaction.33 However, 
tetrachloromethane presents a relatively high toxicity and carcinogenicity, which restricts its use 
in general synthesis.34 Other solvents, such as methyl acetate, in light and some microwave-
assisted benzylic brominations,35 replaced tetrachloromethane but to avoid using it, Golding and 
coworkers36 used (trifluoromethyl) benzene as a solvent in the benzylic bromination with NBS. 
Subsequently, Ulrich and coworkers found that dichloromethane and benzene are better solvents 
for radical bromination than carbontetrachloride.37 
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5.2.1 Microwave-assisted NBS mono-bromination of p-iminotoluenes:  
Our microwave-assisted NBS bromination was performed in benzene as solvent instead 
of tetrachloromethane with only one equivalent of NBS.   The reaction is basically over in less 
than two hours and the isolated yields are higher than 80% (Table 11).  By comparison, if the 
reaction is performed under conventional methods (refluxing of benzene) then the reaction 
requires a reaction time 3-10 times longer.  Longer reaction times generate more byproducts that 
hamper the isolation and purification of the final product, resulting in lower isolated yields.  In 
addition, for conventional NBS bromination, more than one equivalent (1.3-1.5 eq.) of NBS is 
required for full conversion (disappearance of starting material).   
On the other hand if carbon tetrachloride is used as a solvent, then the required reaction 
time is more than doubled in comparison with benzene as a solvent.  For instance, seventeen 
hours is required for the preparation of 19 in benzene (Table 5.5).  For example, to shorten 
reaction times to two hours for compound 19 (Table 5.5) using more conventional reaction 
conditions, a combination of both carbon tetrachloride refluxing and ultraviolent radiation was 
used.40 These examples only emphasize superiority of microwave-assisted NBS benzyl 
bromination in benzene as solvent (Table5.5). 
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Table 5.5 Preparation of benzyl bromides24 
Microwave Conventional Product 
Time 
(min.) 
Yield (%) Time (min.) Yield (%) 
 
30 85 190 72 
 
40 83 300 75 
 
60 87 180 65 
 
40 80 240 67 
 
90 82 300 78 
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5.2.2 Microwave-assisted NBS di-bromination of p-iminotoluenes:  
Microwave-assisted NBS dibromination is as effective as monobromination (Table 12) 
and this method again is superior, considering that the usual isolated yields for dibromination are 
between 5-40%.38  Furthermore, using conventional methods, the reaction mixture always 
contains mixture of dibromo and monobromo products and require more than one day to 
complete and at least three equivalents of NBS.  In the case of the conventional heating, the 
benzene solution was refluxed for at least 12 hours and a small amount of monobrominated 
product was still present.  The isolated yields are somewhere between 60-70%.39   
Microwave-assisted reaction requires only a few hours with more than 95% conversion 
into dibromo product and the isolated yields are between 80 and 90% (Table 5.6).  This is the 
cleanest, simplest, shortest, and the highest yielding procedure for preparation of 
dibromomethylarene derivatives from methylarenes. 
Finally, benzyl NBS bromination can be performed in environmentally friendly solvents 
such as ethyl acetate and diethyl carbonate25. For instance, if NBS radical bromination was 
performed in ethyl acetate instead of benzene for 24 (Table 5.6), then the required reaction time 
was slightly longer (one hour) and the isolated yield moderately lower (75%).  However, if the 
NBS bromination was performed in DMF as a reaction media, then the reaction was completed 
in 10 minutes but isolated yield is only 60%. 
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Table 5.6. Isolated yields of benzylidine bromides24 
Microwave Conventional Product 
Time (hrs) Yield (%) Time (hrs) Yield (%) 
 
1 88 12 70 
 
3 83 24 65 
 
3 92 24 66 
 
In conclusion, it can be stated that with using this new NBS radical benzyl bromination 
method, desirable bromomethyl and dibromomethylarenes can be prepared from readily 
available methylarenes in high quantities and short reaction times coupled with almost 
quantitative isolated yields.  This synthetic approach was proven to be superior to conventional 
NBS bromination. 
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5.3 Synthesis of aldehyde based tag molecules:  
Dibromomethylarenes were also key precursor for synthesis other tag molecules which 
could be used for 1,3-diol protection, for instance corresponding aldehyde and dimethyl acetals. 
They were hydrolyzed by pyridine/water to corresponding aldehyde in quantitative yield 
(Scheme5.2). 
 
Scheme 5.2 Synthesis of aldehyde based tag molecules 
Aldehyde based tag molecules were also transformed into corresponding methyl acetal in 
presence of cobalt chloride, which could be used as potential tag molecule for sugars as 4,6-
acetal protection(Scheme 3). Its well known that 4,6-bezylacetal prtection of sugars are done by 
dimethoxylbenzaldehyde in presence of camphor sulfonic acid. We wanted to use similar 
strategy to attaché tag molecules to sugar hence synthesizing dimethoxy acetals seemed obvious. 
 
 
Scheme 5.3 Synthesis of dimethoxyactal tag molecules 
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5.4 Tagged glucose for the synthesis of branched oligosaccharides 
The tag attachment to the sugar our next step which should give the tagged saccharide 
desirable physical properties that saccharide by itself does not have, such as solubility in low 
polarity organic solvents, easy purification, and easy reaction monitoring and structure 
elucidation. In addition the tag attachment should be stable under reaction conditions required to 
prepare oligosaccharides, and at the same time easily removable once the final reaction is 
completed and the product is purified.  
 Several variations of these types of tag molecules were explored and phthalimide 
derivatives of p-toluidine (Fig. 5.3) have proven to be the best in compliance with these required 
conditions. These compounds are crystalline and are easily purified by crystallization; they are 
stable in acidic media, which is commonly required for glycosylation38, but not stable in a base 
and can be removed from newly formed oligosaccharide at the same time when ester groups (OH 
protection) of oligosaccharides are hydrolyzed. Additionally, the remaining part of the tag (p-
aminobenzyl group) can easily be removed upon neutralization of the reaction mixture. The 
thiophenyl group in position 1 is also a protection group that upon oxidation becomes a good 
leaving group and the whole molecule is now a good glycoside donor.39 
There are two very promising sites to attach tag molecule to sugar molecule, First being 
the anomeric position which the most reactive center and second is 4,6-diol protection utilizing 
selectivity towards reaction to primary alcohol group (Fig.5.3). We need to have 1, 4 and 6-
hydroxy groups protected in order to have possibility to do glycosylation at 2 and 3 position for 
the synthesis of branched oligosacchrides. 
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Figure 5.3 Possible attachment sites for tag molecule 
Since we have developed synthesis of 1-thioisopropanol-glucopyranose in our initial 
attempt for synthesis of branched oligosaccharides it was decided that 4,6-diol protections by our 
tag molecule could be very easy way to attach it to sugar. However our initial attempts to attach 
tag molecule to sugar using acid catalyzed reaction by camphor sulfonic acid by 27-28 and 30-31 
were not successful. In case of coupling of 27-28 no attachment with sugar was observed even 
after 18hrs of reaction while in case of 30-31 the hyrdolysis of tag molecule to corresponding 
aldehyde to give 27-28 was observed. Our failure with acid catalyzed attachment of tag 
molecules to sugar had forced us to look for alternative strategy and we decided to go with based 
catalyzed coupling using dibromomethylarenes itself. There is literature report of such kind of 
reaction with not very impressive yield. We were able to attach tag molecule to sugar by 
refluxing with pyridine but with not more than 40% of isolated yield, the major product of the 
reaction was the hydrolyzed tag to corresponding aldehyde (Note- this is one of the way to make 
aldehyde based tag molecules). It was speculated that moisture content in pyridine was the cause 
behind the major side reaction hence we decided to use freshly distilled pyridine for the reaction. 
It did help to improve the yield a little bit but not good enough for synthesizing these tagged 
sugars in large-scale. The reaction yield was down to 20% in case of naphthyl based tag 
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molecules compared to 40% in phthalyl based tag molecules, probably because of poor reactivity 
of former towards base catalyzed coupling to the sugar. 
Our focus changed after several failure attempts towards other point of attachment which 
is the anomeric position. Thiol based tag molecule was synthesized by reacting chlorosulfonic 
acid and phosphorus pentachloride to cyclic imide 2 to get corresponding para-substituted 
sufonyl chlorides (32), which could be reduce to corresponding thiols 33 by zinc metal catalyzed 
acidic reduction (Scheme 5.4).  
 
Scheme 5.4 Synthesis of thiol based tag molecule 
Thiol based tag molecule 33 could be to attached to the anomeric position of sugar in a 
similar fashion as thioisopropyl group was introduced (Scheme 4.10) by Lewis acid catalyst 
BF3.OEt2 in dry dichloromethane. However, we were not successful in attaching our tag 
molecule to the sugar may be because it was not reactive enough to attack the nucleophilic 
anomeric carbon, as there was no reaction even after 8 hrs of stirring at room temperature by 
BF3.OEt2 in dry dichloromethane. 
Starting with D-glucose (34) all hydroxyl groups were protected with an acetyl group.41 
The anomeric acetyl group of 35 was substituted by thiophenol in methylene dichloride using 
borontrifloride acidic catalyst to get compound 36 in 96% yield.42 Acetyl protection groups were 
removed in almost quantitative yields with sodium methoxide in dry methanol to give compound 
37.43 Same compound was also prepared from D-glucose and thiophenyl in aqueous media by 
using 2-chloro-1,3-dimethylimidazolinium chloride as catalyst.44 
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There are several classic methods for benzaldehyde protection of monosaccharide.43 It is 
now common to use dimethyl acetals of benzaldehyde derivatives in DMF and camphorsulfonic 
acid as the catalyst.45 A similar procedure to introduce our tag molecules with dimethyl acetals of 
aldehyde 27 was not successful. The main product of the reaction was the free aldehyde 27. To 
avoid this problem, a study for preparation of tagged monosaccharide 38 from 37 and benzyl 
dibromides 24 in pyridine as reaction media was used. Although there is some literature evidence 
that supports this synthetic approach46 in our case isolated yields were around 40% at best. 
Therefore, this approach was not applicable to large-scale preparation of tagged 
monosaccharides. Considering that in the process of tagging 37 with dimethylacetal of 27, the 
corresponding aldehyde 27 was detected, we developed a method of monosaccharide tagging 
with the aldehyde 27 (Scheme 5.5). To simplify and make the reaction more economic, p-
toluenesulfonic acid monohydrate was used as an acid catalyst with a minimal amount of DMF 
to make the benzene solution homogeneous. The reaction was carried with benzene reflux and a 
Soxhlet extraction apparatus filled with anhydrous calcium chloride for the removal of water 
from azeotropically distilled benzene–water mixture. The reaction was completed after 3–4 h 
with isolated yield of tagged monosaccharide between 80% and 90%. The prepared tagged 
glucose corresponded to the properties that were initially sought after. 
	   198	  
 
Scheme 5.5 Synthesis of activated and tagged glucose. Reagents and conditions:(i) (CH3CO)2O, Pyridine; (ii) 
C6H5SH/CH2Cl2/BF3.OEt2;(iii) CH3ONa/CH3OH; (iv) TAG-38,39,40/p-CH3C4H4SO3H/DMF-benzene; (v) 
C6H5SH+2-chloro-1,3-dimethylimidacolinium chloride in (C2H5)3N/H2O/CH3CN. 
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To demonstrate the efficiency of our tag approach in the preparation of oligosaccharides, 
the simplicity of the reaction conditions, and the recyclability of tag aldehydes, we have 
demonstrated as example preparations, the synthesis of compounds 42, 43, and 44 (Scheme 5.6). 
All reactions were performed in a common organic solvent (dichloromethane). 
 
Scheme 5.6 Glycosylation, Oligosaccharide deprotection, and tag molecule removal. Reagents and conditions: (i) 
(CH3)3SiOSO2CF3/ CH2Cl2/(0oC to room temperature in 2hrs) 75%; (ii) NaOCH3/CH3OH/CH2Cl2 (room 
temperature), yield 93%; (iii) CF3COOH/CH2Cl2 (room temperature), yield 95%. 
 
The glycosylation was selectively performed with 41 in the C-3 position of the tagged 
monosaccharide 40 and our isolated yield was 75% using standard glycosylation procedures.47 
Product 42 was purified by filtration of the reaction mixture through a short silica gel column 
using dichloromethane–ethyl acetate (3/1) as an elutent. Selective benzoate hydrolysis was 
started at 0 °C with sodium methoxide in a dichloromethane–methanol solution. The solution 
was allowed to stir at room temperature for 4 h, was evaporated and mixed with 
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dichloromethane–ethyl acetate and filtered through short column of silica gel. The tag molecule 
was removed with trifluroacetic acid in dichloromethane. The formed precipitate was an 
oligosaccharide solution containing the tag aldehyde 27. 
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5.5 Conclusions 
In conclusion, we have developed synthetic procedures for the preparation of tag 
reagents based on phthalimide of p-toluidine. Syntheses for cyclic imides were explored for a 
broad range of substrates including aliphatic and aromatic derivatives. The developed methods 
have potential to be used in large-scale industrial synthesis of cyclic imides very efficiently in a 
short period of time using microwave conditions. 
Benzylic mono and di-bromination was successfully achieved under microwave 
condition using benzene as solvent which is a much better option compared to carbon 
tetrachloride, which is carcinogenic. The possibility to use environment friendly organic solvents 
like ethyl acetate and diethylcarbonate were also explored and found to be very effective for 
benzylic bromination by N-bromosuccinimide.  All procedures are simple and materials can be 
obtained in large quantities.  
Tagging monosaccharides with aldehyde based tag molecules is simple, and requires 
refluxing the DMF/benzene solution of the corresponding tag aldehyde and monosaccharide 
under Soxhlet extraction apparatus. Tagged monosaccharides can be glycosylated first in 
position 3, then 2, and finally 1 with the same or different saccharide building blocks. In the last 
step of the synthesis, the tag molecule can be selectively deprotected, isolated as an aldehyde, 
and reused in new oligosaccharide syntheses. Recyclibility of aldehyde tag molecules gives an 
advantage over other tag molecules we explored so far and seems to be best one among various 
other tag molecules synthesized. Model reactions to prove the applicability of tag strategy is 
amazing and we could selectively remove protecting groups on the tagged sugar depending on w 
the next step in the synthesis. Over all we have developed very nice synthesis of tag molecules, 
their coupling to sugar (tagging) and selective removal (detagging). 
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5.6 Experimental 
5.6.1 General Consideration. Chemicals were purchased from Sigma-Aldrich, Acros, and 
Merck. Co., The 1H and 13C NMR spectra were run on Varian 400 MHz Unity in CDCl3 or 
DMSO-d6, as solvent and internal standards.  Our laboratory microwave reactor was made by 
using magnetron (700W) from domestic microwave.  The microwave cavity was reduced to 21.6 
cm in height, 17.30 cm wide, and 25.4 cm deep with two 2.54 cm.  The bottom of the microwave 
cavity was replaced with brass and magnetic stirrer was installed. On the top of the microwave 
two openings of one inch in diameter were made on onside cavity and on the outside cover of the 
microwave reactor.  The test performed shows the there is no microwave radiation above the 
openings.  The power of the microwave radiation was controlled by direct wiring of variable 
autotransformer for control of the microwave magnetron.  The power was monitored wit ECM 
meter.  The composition of the reaction mixture influence change of the ECM power.  When 
reaction is completed the power measured with ECM meter become constant.  Detail electronic, 
and mechanic schemes of the microwave reactor will be available in our new patent. 
5.6.2 General procedure for synthesis of phthalimides (1-6): 
In round bottom flask (100 ml) phthalic anhydride (1.5 g; 0.01 mol), corresponding amine (0.01) 
and N,N-dimethyformaamide (20 ml) are mixed together.  The round bottom flask with reaction 
mixture was put in our microwave reactor equiped with condense and magnetic stirrer.  The 
reaction mixture stirred under microwave radiation with mild solvent refluxing (magnetron 
power between 300 and 450 W).  After reaction was completed reaction mixture was poured 
onto crushed ice (~200 g).  Formed white precipitate was separated by filtration, washed with 
water and dried under reduced pressure.  According to the NMR spectra compounds are more 
than 96% pure.  IF higher purity is required further purification can be performed by column 
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chromatography.  The 1H-NMR and 13C-NMR spectra were recorded in CDCl3 or in DMSO-d6 
and they are identical to authentic samples. 
4-methylphenylphthalimide (1):  1H NMR (400 MHz, CDCl3): δ 7.98 (d, 2H), 7.80 (d, 2H), 
7.35(s, 4H), 2.41(s, 3H) ppm. 13C NMR δ: 168.0, 138.2, 134.5, 132.0, 130.0, 129.5, 127.1 124.0, 
and 21.5 ppm.  
 
Phenylphthalimide (2):  1H NMR (400 MHz, CDCl3): δ 7.98 (d, 2H), 7.80 (d, 2H), 7.35-7.60(m, 
5H) ppm. 13C NMR δ: 168.0, 136.1, 134.5, 132.0, 129.5, 128.1, 126.5, and 124.0 ppm.  
 
3-Bromophenylphthalimide (3):  1H NMR (400 MHz, CDCl3): δ 7.98 (d, 2H), 7.80 (d, 2H), 
7.62(s, 1H), 7.55(d, 1H), 7.40(dd, 2H) ppm. 13C NMR δ: 168.0, 136.1, 134.0, 132.2, 132.0, 
131.5, 131.0, 127.1 124.0, and 122.0 ppm.  
 
2-Phenylphenylphthalimide (4):  1H NMR (400 MHz, CDCl3): δ 7.82 (dd, 2H), 7.70 (dd, 2H), 
7.5- 7.6(m, 2H), 7.40-7.52 (m, 2H), 7.21-7.38(m, 2H), 6.85(t, 1H), 6.80 (d, 2H) ppm. 13C NMR 
δ: 168.0, 140.1, 134.0, 132.1,130.8, 130.5, 128.8, 128.5, 128.0, 127.1 124.0, 118.5 and 116.0 
ppm.  
 
Hexylphthalimide (5):  1H NMR (400 MHz, CDCl3): δ 7.85 (dd, 2H), 7.65 (dd, 2H), 3.62(t, 2H), 
1.62(m, 2H), 1.20-1.24(s, 6H), 0.85 (t, 3H) ppm. 13C NMR δ: 168.0, 134.0, 132.1, 123.5, 38.0, 
32.0, 28.5, 26.1, 22.2 and 14.0 ppm.  
	   204	  
Hexadecylphthalimide (6):  1H NMR (400 MHz, CDCl3): δ 7.82 (dd, 2H), 7.65 (dd, 2H), 3.62(t, 
2H), 1.62(m, 2H), 1.20-1.35(s, 11H), 0.82 (t, 3H) ppm. 13C NMR δ: 168.0, 134.1, 132.1, 123.5, 
38.0, 32.1, 30.0, 30.0, 30.0, 29.9, 29.8, 29.7, 29.5, 29.0, 28.5, 28.0, 27.0, 23.1 and 14.0 ppm.  
 
5.6.3 General Procedure for synthesis of 1,8-naphthalimides (7, 8 and 9): 
Pyridine (100 ml) solution of anhydride (5mmol for 1,8-naphthalic anhydride and 2.5 mmol for 
dianhydride) and corresponding amine (8mmol) were microwave heated at magnetron power of 
450W with gentile solvent refluxing.  Cold reaction mixture was poured over crushed ice and 
formed white precipitate was separated by filtration and washed with water (3x20ml).  Solid 
material was dissolved in dichloromethane (100 ml), this solution was washed with 10% 
hydrochloric acid (3x50 ml), water (3x50 ml), and dried over anhydrous sodium sulfate.  After 
evaporated of dicloromethane 96% pure product was obtained. 
Phenylnaphthalimide (7):  1H NMR (400 MHz, CDCl3): δ 8.65 (d, 2H), 8.24 (d, 2H), 7.80 ( t, 
2H), 7.42-7.60(m, 3H), 7.35(d, 2H) ppm. 13C NMR δ: 164.1, 136.1, 134.5, 132.0, 130.1, 129.2, 
128.2, 128.1, 128.0, 127.5 and 123.5 ppm.  
 
4-Methlyphenylnaphthalimide (8):  1H NMR (400 MHz, CDCl3): δ 8.65 (d, 2H), 8.24 (d, 2H), 
7.80(t, 2H), 7.20(d, 2H), 2.42(s, 3H) ppm. 13C NMR δ: 164.1, 128.1, 125.5, 125.0, 124.0, 123.1, 
122.0, 121.1, 119.5, 118.0, 116.1 and 31.1 ppm.  
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2,7-dip-tolylbenzo[3,8]phenanthroline-1,3,6,8-tetraone (9):  1H NMR (400 MHz, CDCl3): δ 
8.82 (s, 4H), 7.38(d, 4H), 7.20(d, 4H), 2.42(s, 6H) ppm. 13C NMR δ: 164.1, 140.2, 132.1, 131.8, 
130.4, 128.2, 128.0, 127.2 and 22.1 ppm.  
 
5.6.4 General method for synthesis of succinimidess (10-14) 
DMF (20 ml) solution of succinic anhydride (2 g; 0.02 mol) and corresponding amine (0.02 mol 
for 11 and 13; 0.01 mol for 10, 12 and 14) was heated in microwave reactor with slow solvent 
refloxing for 30 minutes.  Reaction mixture was cooled to room temperature and acetic 
anhydride (5.7 ml; 6.13 g; 0.06 mol) and gently refluxed in microwave oven for 20 minutes.  Into 
room temperature cooled reaction mixture water (5 ml) was added and reaction mixture was 
gently refluxed in microwave oven for additional 20 minutes.  Resulting reaction mixture was 
deluted with dichloromethane (100 ml). Resulting dichloromethane solution was washed with 
saturated water solution of sodium bicarbonate (3x50 ml), water (3x50ml) and dried over 
anhydrous sodium sulfate.  After solvent was evaporated crude product was purified by column 
chromatography with ethylacetate-hexane (5:1) as an eluent. 
Benzylsuccinimide (10):  1H NMR (400 MHz, CDCl3): δ 7.21-7.40 (m, 5H), 2.61(s, 4H) ppm. 
13C NMR δ: 176.5, 135.05, 128.7, 128.5, 127.8, 44.2 and 28.1 ppm. 
 
Hexyl-1,6-disuccinimide (11):  1H NMR (400 MHz, CDCl3): δ 7.21-7.40 (m, 5H), 2.61(s, 4H) 
ppm. 13C NMR δ: 176.5, 135.05, 128.7, 128.5, 127.8, 44.2 and 28.1 ppm. 
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4-methylphenylsuccinimide (12):  1H NMR (400 MHz, CDCl3): δ 7.30 (d, 2H), 7.15(d, 2H), 
2.91(s, 4H), 2.38 (s, 3H) ppm. 13C NMR δ: 176.9, 138.1, 130.2, 129.1, 126.0, 28.5 and 21.3 ppm. 
 
4, 4’- Methanediphenyldisuccinimide (13):  1H NMR (400 MHz, CDCl3): δ 7.36 (d, 4H), 7.21( 
d, 4H), 4.02 (s, 2H), 2.75(s, 8H) ppm. 13C NMR δ: 177.5, 141.0, 130.8, 129.1, 127.1, 40.2, 39.9, 
39.7, 39.5, 39.3, 39.1 and 28.4 ppm. 
 
1-Naphthylsuccinimide (14):  1H NMR (400 MHz, CDCl3): δ 8.01-8.06 (t, 2H), 7.81( d, 1H), 
7.51-7.65( m, 3H), 7.42 (d, 1H), 2.80- 3.08(m, 4H) ppm. 13C NMR δ: 177.5, 137.7, 129.7, 129.6, 
129.2, 128.2, 126.8, 126.6, 126.5, 125.6, 122.87, 39.7, 39.5, 39.2 and 28.9 ppm. 
 
5.6.5 General Procedure for synthesis of maleimides (15-18).  Thetrahydrofuran (20 ml) 
solution of maleic anhydride (1g; 0.01 mol) and tetrahydrofuran solution (20 ml) of 
corresponding amine (1.1 equivalent for monoamine and 0.55 equivalent for diamine) was mixed 
together at room temperature.  Immediately precipitate was formed.  Reaction mixture was 
stirred at room temperature for 15 minutes, solvent was decanted and solid dried under nitrogen 
flow.  Acetic anhydride (21 ml) and sodium acetate (1g) ware added to the solid material.  
Reaction mixture was heated for 30 minutes in microwave oven with magnetron power of 450W.  
Cooled to room temperature, reaction mixture was in water (300 ml).  Resulting mixture was 
extracted with ether (3x50 ml).  Ether was dried over anhydrous sodium sulfate and evaporated 
to solid residue.  Product was purified by column chromatography with 5% ethylacetate in 
dichloromethane. 
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Phenylmaleimide (15):  1H NMR (400 MHz, CDCl3): δ 7.30-7.51 (m, 5H), 6.85(s, 2H) ppm. 13C 
NMR δ: 170.1, 132.5, 131.1, 130.0, 128.1 and 126.0 ppm. 
 
1-Naphthylmaleimide (16):  1H NMR (400 MHz, CDCl3): δ 7.81-8.02 (m, 2H), 7.45-7.60(m, 
4H), 7.41(d, 1H), 6.98(s, 2H) ppm. 13C NMR δ: 170.15, 134.5, 130.5, 130.10, 129.0, 127.8, 
127.1, 126.6, 126.1, 125.0 and 122.5 ppm. 
 
4-MethlyPhenylmaleimide (17):  1H NMR (400 MHz, CDCl3): δ 7.30(d, 2H), 7.21(d, 2H), 
6.85(s, 2H), 2.42(s, 3H) ppm. 13C NMR δ: 169.9, 138.3, 134.4, 130.04,128.7, 126.2 and 21.3 
ppm. 
 
4, 4’- Methanediphenyldimaleimide (18):  1H NMR (400 MHz, CDCl3): δ 7.20-7.32(m, 8H), 
6.85(s, 4H), 4.02(s, 2H)ppm. 13C NMR δ: 169.9, 140.1, 134.2, 130.2, 129.8, 126.2 and 40.8 ppm. 
 
5.6.6 Typical procedure for preparation of monobromoarene (19-23):  Benzene (10 ml) 
solution of methyl benzene derivative (5 mmol), N-bromosuccinamide (0.89 g; 5 mmol), and 
benzoylperoxide (0.12 g; 0.5 mmol) was refluxed under microwave heating (magnetron power 
600 W).  After reaction was completed (See Table 1) solvent was evaporated; solid residue was 
dissolved in dichloromethane (100 ml) and washed with saturated water solution of sodium 
bicarbonate (3x15 ml) and water (3x15 ml).  Dichloromethane was evaporated and the solid 
residue was purified by silica gel column chromatography with hexane-dichloromethane as an 
eluent. 
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4-(Bromomethyl)phenylphthalimide (19): Isolated yield (85%). 1H-NMR (CDCl3): 7.98 (2H, 
m), 7.80 (2H, m), 7.55 (2H, d, J = 8Hz), 7.45 (2H, d, J = 8Hz), and 4.55 (2H, s) ppm. 13C-NMR  
(CDCl3): 167.1, 140.0, 138.2, 135.1, 132.0, 130.2, 127.5, 124.3 and 33.0 ppm. C15H10BrNO2 
(MW 316.15). MS (m/z) 317.99 (10%), 314.99 (100%), and 316.99 (95%). 
 
4-(Bromomethyl)phenylsuccinimide (20): Isolated yield 83%. 1H-NMR (CDCl3): 7.51 (2H, d, J 
= 7.6 Hz), 7.32 (2H, d, J = 7.6Hz), 4.48 (2H, s) ppm. 13C-NMR (CDCl3): 176.0, 138.2, 130.2, 
127.5, 126.1, 33.0 and 28.1 ppm. C11H10BrNO2 (MW 268.11). MS (m/z) 269.99 (8%), 268.99 
(95%), 266.99 (100%). 
 
4-(Bromomethyl)phenylnaphthalimide (21): Isolated yield (87%). 1H-NMR (CDCl3): 8.65 
(2H, d, J = 7.2 Hz), 8.27 (2H, d, J = 8.4 Hz), 7.80 (2H, t, J = 7.2 Hz), 7.58 (2H, d, J = 8.4 Hz), 
7.30 (2H, d, J = 8.4 Hz), and 4.57 (2H, s) ppm. 13C-NMR (CDCl3) 164.1 , 138.2, 135.0, 134.3, 
131.2, 130.2, 129.5, 127.1, 123.0, and 33.0 ppm. C19H12BrNO2 (MW 366.21) m/z: 368.01 (15%), 
367.00 (100%), 365.01 (100.0%), 366.01 (10%) 
 
4-(Bromomethyl)-N-benzoyl-N-methylaniline (22): Isolated yield (80%).  1H-NMR (CDCl3):  
7.28 (2H, d, J = 7.8Hz), 7.25 (7H, m), 7.02 (2H, d, J = 7.8Hz), 4.40 (2H, s), and 3.47 (3H, s) 
ppm.  13C-NMR (CDCl3): 171.0, 145.2, 136.1, 135.5, 130.2, 129.1, 128.0, 127.6, 39.4, and 33.0 
ppm. C15H14BrNO (MW 304.18). MS (m/z) 306.03 (10%) 305.02 (90%), 303.03 (100). 
 
2-(Bromomethyl)phenylphthalimide (23):  Isolated yield (82%).  1H-NMR (CDCl3): 7.98 (2H, 
m), 7.80 (2H, m), 7.30 (4H, m), and 4.46 (2H) ppm. 13CNMR (CDCl3): 167.0, 136.1, 135.2, 
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132.0, 131.3, 130.2, 129.5, 128.2, 124.1 and 30.0 ppm. C15H10BrNO2 (Mw 316.15). MS (m/z) 
317.99 (10%), 316.99 (95%), 314.99 (100%)  
 
5.6.7 Typical procedure for preparation of dibromoarene 24-26:  Benzene (10 ml) mixture of 
the methylbenzene derivative (3.3 mmol), N-bromsucinimide (1.8 g; 10 mmol), and 
benzoylperoxide (75 mg; 0.31 mmol) was refluxed for three hours under microwave radiation 
(magnetron power 600W).  The solvent was evaporated under reduced pressure and the solid 
residue was dissolved in dichloromethane (100 ml).  Dichloromethane solution was washed with 
saturated sodium bicarbonate (3x15 ml), water (3x20 ml) and dried over anhydrous sodium 
sulfate.  The solvent was evaporated and residue purified by filtration through short silica gel 
column with hexane-dichloromethane as solvent. 
 
4,4’-(dibromomethyl)phenylphthalimide (24):  Isolated yield (88%).  1H-NMR (CDCl3): 7.98 
(2H, m), 7.82 (2H, m), 7.72 (2H, d, J = 8.0 Hz), 7.51 (2H, d, J = 8.0 Hz), and 6.68 (1H, s) ppm. 
13C-NMR (CDCl3): 167.1, 141.0, 135.3, 133.2, 131.0, 128.5, 127.1, 124.0 and 40.2 ppm. 
C15H9Br2NO2 (MW 395.05). MS (m/z) 396.90 (50%), 395.90 (10%), 394.90 (100%), 392.90 
(50%). 
 
4,4’-(dibromomethyl)phenylsuccinimide (25):  Isolated yield (83%).  1H-NMR (CDCl3): 7.68 
(2H, d, J = 7.4 Hz), 7.32 (2H, d. J = 7.4 Hz), 6.64 (1H, s), and 2.99 (4H, s) ppm.  13C-NMR 
(CDCl3): 178.1, 133.0, 128.5, 127.2, 126.3, 40.0 and 28.1 ppm.  C11H9Br2NO2 (MW 347.00) m/z 
348.90 (50%), 347.90 (10%), 346.90 (100%), 344.90 (50%). 
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4,4’-(dibromomethyl)phenylnaphthalimide (26):  Isolated yield (92%).   1H-NMR (CDCl3): 
8.82 (2H, t, J = 8 Hz), 8.48 (2H, d, J = 8 Hz), 7.83 (2H, t, J = 8 Hz), 7.75 (2H, d, J = 7.8 Hz), 
7.36 (2H, d, J = 7.8 Hz), and 6.72 (1H, s) ppm. 13C-NMR (CDCl3, 400 MHz) 164.2, 142.0, 
137.5, 135.1, 132.0, 129.3, 128.1, 127.0, 123.2 and 40.0 ppm. C19H11Br2NO2 (MW 445.10). MS 
(m/z) 447.91 (10%), 446.9 (50%) 445.9 (20%), 444.9 (100%), 443.9 (10%). 442.9 (50%). 
5.6.8 Penta-O-acetyl-D-glucopyranose (35): D-glucose (20 g, 110 mmol) was refluxed in 
pyridine (150 mL) for 1 hour. Acetic anhydride (100 mL) was added and the mixture was 
refluxed an additional 2 hours. The resulting solution was cooled to room temperature, poured 
over ice (300 mL) and stirred until the product solidified, about 2 hours. The solid was filtered, 
washed with water, and recrystallized from ethyl acetate/hexanes to give 35 as a white solid (36 
g, 83 % yield).: 1H NMR of 35 (400 MHZ, CDCl3): δ 5.72 (d, J = 4.0 Hz, 1H), 5.26 (t, J = 9.2 
Hz, 1H), 5.14(t,J=8.8Hz,1H),5.13(t,J=10.0Hz,1H),4.30(dd,J1 =6.2Hz,J2 =2.2Hz,1H), 4.12 (dd, 
J1 = 6.3 Hz, J2 = 1.0 Hz, 1H), 3.84 (m, 1H), 2.12 (s, 3H), 2.09 (s, 3H), 2.04 (s, 6H), 2.01 (s, 3H). 
13C NMR of 35 (400 MHz, CDCl3): δ 170.7, 170.3, 169.8, 169.5, 168.9, 89.1, 69.9, 69.2, 67.9, 
61.5, 20.9, 20.8, 20.7, 20.6 and 20.5 ppm. 
5.6.9 Phenyl tetra-O-acetyl-1-thio-β-D-glucopyranoside (36): Penta-O-acetyl-β-D- 
glucopyranose 35 (3.7 g, 9.4 mmol) and thiophenol (1.0 mL, 13 mmol) were stirred at room 
temperature in CH2Cl2 with 3 Å molecular sieves for 30 minutes under an atmosphere of 
nitrogen. BF3·OEt2 (3.5 mL) was added and the mixture was stirred an additional 2 hours. The 
molecular sieves were filtered and the filtrate was added to 5 % NaHCO3 (50 mL) with vigorous 
stirring. The organic layer was separated, washed with 5 % NaHCO3 (3 x 50 mL), and dried over 
sodium sulfate. The solvent was removed under reduced pressure and the resulting solid was 
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used immediately in the next reaction without further purification. 1H NMR (400 MHz, CDCl3): 
δ 7.48-7.32 (m, 5H), 5.11 (t, J = 9.6 Hz, 1H), 
4.94(t,J=9.6Hz,1H),4.86(t,J=9.6Hz,1H),4.49(d,J=5.2Hz,1H),4.11(dd,J1 = 6.2Hz,J2 
=2.8Hz,1H),4.00(dd,J1 =6.0Hz,J2 =1.2Hz,1H),3.61(m,1H),3.05(m, 1H), 1.94 (s, 3H), 1.92 (s, 
3H), 1.90 (s, 3H), 1.88 (s, 3H). 13C NMR (400 MHz, CDCl3): δ 170.6, 170.2, 169.4, 169.3, 
120.1, 118.3, 115.0, 105.2, 83.3, 75.6, 73.9, 70.1, 68.4, 62.2, 24.0, 23.7, 20.7 and 20.7 ppm. 
5.6.10 Phenyl-1-thio-β-D-glucopyranoside (37): Thioglucopyranoside 36 was dissolved in 2:1 
MeOH: CH2Cl2 (45 mL). Sodium methoxide  was added to a pH ~ 9-10. The solution was stirred 
at room temperature 6 hours, neutralized with acidic Dowex resin, and filtered. The solvents 
were removed under reduced pressure and the resulting solid was co-evaporated with toluene (3 
x 10 mL) and used immediately in the following reaction without further purification. 1H NMR 
(300 MHz, DMSO- D6): δ 7.48-7.32 (m, 5H), 4.31 (d, J = 4.8 83Hz, 1H), 3.65 (dd, J1 = 5.9 
Hz, J2 = 0.6 Hz, 1H), 3.40 (dd, J1 = 5.9 Hz, J2 = 2.9 Hz, 1H), 3.18 – 2.93 (m, 5H). 
13C NMR (400 MHz, DMSO-D6): δ120.1, 118.3, 115.0, 105.2, 84.5, 80.9, 78.3, 73.3, 70.1 and 
61.3 ppm.  
5.6.11 Synthesis of naphthylimide-4-benzaldehyde (28): Dibromo tag molecule 25 (1gm) was 
refluxed in pyridine (15ml) for two hours and then poured over crushed ice and stirred for 30 
minutes. Filtered off the white precipitate (840mg) as our product. 1H NMR of 28 (400 MHZ, 
CDCl3): δ 10.1 (s, 1H), 8.1 (d, 2H), 8.0 (dd ,2H), 7.8 (dd, 2H),7.65 (d, 2H). 13C NMR of 28 (400 
MHz, CDCl3): δ 169.0, 162.4, 138.2, 134.5, 132.1, 130.2, 127.1 and 124.0 ppm. 
5.6.12 Synthesis of 2-[4-(7,8-Dihydroxy-6-phenylsulfanyl-hexahydro-pyrano[3,2-
d][1,3]dioxin-2-yl)-phenyl]-isoindole-1,3-dione (38) : Dissolved  4-(1,3-Dioxo-1,3-dihydro-
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isoindol-2-yl)-benzaldehyde (400mg, 1.59mmols) and 2-Hydroxymethyl-6-phenylsulfanyl-
tetrahydro-pyran-3,4,5-triol ( 450mg, 1.65mmols) in dry N,N-dimethyl formamide  (8ml) and 
added benzene (25ml) to the mixture. Added  p-Toluene sulfonic acid (15mg) to the reaction 
mixture. Stirred the reaction at 500C under vacuum and condenser with chilled water condenser 
which is attached through Din-Stark’s apparatus  (half filled with calcium chloride anhydrous) 
for 3hrs and 30minutes.On completion of reaction diluted reaction mixture with dichloromethane 
and washed twice with saturated sodium bicarbonate solution (30ml X 2). Concentrated organic 
portion on rotavapour to get crude product which was then purified by column chromatography 
on silica-gel (20% EtOAc: DCM elution concentration to get out product from column) to get 
685mg white solid as desired product. Product was confirmed by 1H and 13C –NMR in CDCl3.( 
isolated yield 85%) 1H NMR of 38 (400 MHZ, CDCl3): δ 7.98 (dd, 2H), 7.8 (dd, 2H), 7.6 (d 
,2H), 7.48 (m, 2H),7.42 (d, 2H). 7.27 (m, 3H), 5.6 (s, 1H), 4.62(d, 1H), 4.4 (dd, 1H), 3.8(m, 1H), 
3.58-3.40( m, 2H) 13C NMR of 38 (400 MHz, CDCl3): δ 167.2, 141.1, 135.0, 133.2, 131.3, 
128.0, 127.1, 124.0, δ120.1, 118.3, 115.0, 105.2, 84.5, 80.9, 78.3, 73.3, 70.1, 61.3 and 40.0 ppm. 
 5.6.13 Synthesis of 2-[4-(7,8-Dihydroxy-6-phenylsulfanyl-hexahydro-pyrano[3,2-
d][1,3]dioxin-2-yl)-phenyl]-benzo[f]isoindole-1,3-dione (39) : Dissolved  4-(1,3-Dioxo-1,3-
dihydro-benzo[f]isoindol-2-yl)-benzaldehyde (222mg, 1.59mmols) and 2-Hydroxymethyl-6-
phenylsulfanyl-tetrahydro-pyran-3,4,5-triol (200mg, 1.65mmols) in dry N,N-dimethyl 
formamide  (8ml) and added benzene (25ml) to the mixture. p-Toluene sulfonic acid (15mg) was 
added to the reaction mixture. Stirred the reaction at 600C under vacuum and condenser with 
chilled water condenser which is attached through Din-Stark’s apparatus  (half filled with 
calcium chloride anhydrous) for 3hrs and 30minutes.On completion of reaction diluted reaction 
mixture with dichloromethane and washed twice with saturated sodium bicarbonate solution 
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(30ml X 2 ). Concentrated organic portion on rotavapour to get crude product which was then 
purified by column chromatography on silica-gel (20% EtOAc: DCM elution concentration to 
get out product from column) to get 335mg white solid as desired product. Product was 
confirmed by 1H and 13C –NMR in CDCl3. (isolated yield 82%)1H NMR of 39 8.52 (s, 2H), 8.15 
(m, 2H), 7.68 (m, 4H), 7.62(dd, 2H), 7.5-7.45( m, 4H), 7.28( m, 3H) 5.6 (s, 1H), 4.62(d, 1H), 4.4 
(dd, 1H), 3.8(m, 1H), 3.58-3.40( m, 2H) 13C NMR of 39 (400 MHz, CDCl3): δ 168.2, 138.0, 
136.1, 134.2, 131.0, 129.6, 129.5, 129.4, 129.0, 128.1, 126.5, 126.0, 102.0, 89.5, 80.9, 75.3, 72.5, 
71.1 and 68.2 ppm. 
5.6.14 Synthesis of 2-[4-(7,8-Dihydroxy-6-phenylsulfanyl-hexahydro-pyrano[3,2-
d][1,3]dioxin-2-yl)-phenyl]-benzo[de]isoquinoline-1,3-dione (40) : Dissolved  4-(1,3-Dioxo-
1H,3H-benzo[de]isoquinolin-2-yl)-benzaldehyde (100mg, 0.33mmols) and 2-Hydroxymethyl-6-
phenylsulfanyl-tetrahydro-pyran-3,4,5-triol ( 90mg, 0.33mmols) in dry N,N-dimethyl formamide  
(5ml) and added benzene (25ml) to the mixture. p-Toluene sulfonic acid (10mg) was added to 
the reaction mixture. Stirred the reaction at 700C under vacuum and condenser with chilled water 
condenser which is attached through Din-Stark apparatus  (half filled with calcium chloride 
anhydrous) for 4hrs and 30minutes.On completion of reaction diluted reaction mixture with 
dichloromethane and washed twice with saturated sodium bicarbonate solution (30ml X 2). 
Concentrated organic portion on rotavapour to get crude product which was then purified by 
column chromatography on silica-gel (30% EtOAc: DCM elution concentration to get out 
product from column) to get 67mg white solid as desired product. Product was confirmed by 1H 
and 13C –NMR in CDCl3. ( isolated yield 80%)1H NMR of 40 8.82 (2H, t, J = 8 Hz), 8.48 (2H, d, 
J = 8 Hz), 7.83 (2H, t, J = 8 Hz), 7.75 (2H, d, J = 7.8 Hz), 7.36 (2H, d, J = 7.8 Hz), and 6.72 (1H, 
s), 5.6 (s, 1H), 4.62(d, 1H), 4.4 (dd, 1H), 3.8(m, 1H), 3.58-3.40( m, 2H) 13C NMR of 40 (400 
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MHz, CDCl3): δ 164, 142, 137, 135, 132, 129, 128, 127, 123, 120.1, 118.3, 115.0, 105.2, 84.5, 
80.9, 78.3, 73.3, 70.1, 61.3 and 40.0. 
5.6.15 Synthesis of naphthylimide-4-benzaldehyde dimethyl acetal (30-31): Compound 28 
(500mg) and trimethylorthoformate (0.4ml) dissolved in methanol (4ml) and to was added 
amberlite IR-120 H+, mixrtue was stirred at 600C for 15hrs. On completion, reaction mixture was 
cooled to room temperature and diluted with 10ml of methylenechloride. Filtered off mixture to 
remove emberlite IR-120 and concentrated to get the desired product in 85% yield. 1H NMR of 
10 (400 MHZ, CDCl3): δ 7.9 (dd, 2H), 7.8 (dd, 2H), 7.6 (d, 2H), 7.45 (d, 2H), 5.42(s, 1H), 3.38 
(s, 6H) 13C NMR of 31 (400 MHz, CDCl3): δ 162.4, 138.2, 134.5, 132.1, 130.2, 127.1, 124.0, 
40.0 and 34.0 ppm. 
Typical procedure for glycosidation at C-3 of tagged sugar 37: Trichloroacetimidate donor 41 
was prepared according to well known literature procedure. Freshly prepared 
Trichloroacetimidate donor 41 (370 mg, 0.5 mmol) and tagged thioglucopyranoside 37 (150mg, 
0.45 mmol)  were dissolved in CH2Cl2 (10 mL). The mixture was cooled to 0°C before TMSOTf 
(10 µL, 0.05 mmol) was added. The reaction was stirred at 0°C to room temperature for 2 hours, 
neutralized with triethylamine (0.3 mL). The solvents were removed under reduced pressure and 
the product was purified by gravity column chromatography (1:3 ethyl acetate: CH2Cl2) to give 
desired product 10 in 75% isolated yield. 1H NMR of 42 (400 MHz, CDCl3): δ 8.52 (s, 2H), 8.15 
(m, 2H), 8.14 – 7.82 (m, 10H), 7.68 (m, 4H), 7.23 – 7.57 (m, 19 H), 5.92 (t, 1H), 5.71 (t, 1H), 
5.57 (s, 1H), 5.56(dd, 1H), 5.22(d, 1H), 4.49(dd, 1H), 4.44 (d,1H), 4.33 (t, 1H), 4.32 (t, 1H), 3.94 
(m, 1H), 3.90 (t,1H), 3.77 (t, 1H), 3.71, (t, 1H), 3.49 – 3.44 (m, 2H) ppm. 13C NMR δ 167.1, 
166.2, 165.9, 133.9, 133.0, 132.9, 132.2, 132.0, 131.8, 130.0, 129.9, 129.8, 129.7, 129.3, 128.9, 
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128.6, 128.5, 127.6, 125.1, 123.7, 123.5, 109.2, 106.7, 93.2, 82.4, 81.9, 79.3, 74.8, 72.6, 70.9, 
70.2, 69.2, 68.1 and 64.2 ppm.  
 
Typical procedure for deprotection:  
a) deprotection of tag molecule from sugar. Substrate for deprotection compound 42  (100mg) 
was dissolved in CH2Cl2 (5mL) and trifluoroacetic acid (2mL) was added with vigorous stirring 
at room temperature. Reaction was continued at room temperature till completion of reaction 
(10-12hrs) monitored by 1H-NMR. On completion of reaction evaporated solvent and purified 
by flash column chromatography to get 71mg of desired product 44. 1H NMR of 44 (400 MHz, 
CDCl3): δ 8.14 – 7.82 (m, 10H), 7.68 (m, 4H), 7.23 – 7.57 (m, 16 H), 5.92 (t, 1H), 5.71 (t, 1H), 
5.56(dd, 1H), 5.22(d, 1H), 4.49(dd, 1H), 4.44 (d,1H), 4.33 (t, 1H), 4.32 (t, 1H), 3.94 (m, 1H), 
3.90 (t,1H), 3.77 (t, 1H), 3.71, (t, 1H), 3.49 – 3.44 (m, 2H). 13C-NMR δ 167.1, 133.9, 132.9, 
132.3, 132.2, 132.0, 131.8, 129.3, 128.5, 127.6, 125.1, 110.4, 109.2, 93.2, 82.7, 81.9, 81.5, 79.3, 
76.8, 74.1,72.6, 71.5, 68.1 and 62.2 ppm. 
 
 b) Benzoyl deprotection of tagged sugar molecule 42. Substrate for deprotection compound 42  
(50mg) was dissolved in CH2Cl2 (5mL) and methanol (5mL). Sodium methoxide was added at 
room temperature with stirring till obtain a PH of 9 for reaction mixture. Reaction was continued 
at room temperature till completion of reaction (4-5hrs) monitored by 1H-NMR. On completion 
of reaction neutralized by acidic dowex resin and filtered off to remove resin, evaporated solvent 
and purified by flash column chromatography to get 28mg of desired product 43. 1H NMR of 43 
(400 MHz, DMSO): δ 8.45 (s, 2H), 8.13 (m, 2H), 7.68 (m, 4H), 7.23 – 7.57 (m, 5H), 5.92 (t, 
1H), 5.71 (t, 1H), 5.60 (s, 1H), 5.56(dd, 1H), 5.22(d, 1H), 4.49(dd, 1H), 4.44 (d,1H), 4.33 (t, 1H), 
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4.32 (t, 1H), 3.94 (m, 1H), 3.90 (t,1H), 3.77 (t, 1H), 3.71, (t, 1H), 3.49 – 3.44 (m, 2H). 13C-NMR 
δ 165.9, 165.9, 165.8, 165.6, 133.9, 133.0, 130.1, 129.9, 129.8, 129.7, 129.3, 128.9, 128.6, 106.7, 
93.2, 86.7, 84.6, 74.8, 72.3, 70.9,70.2, 69.2, 68.9, 64.2 and 61.5 ppm. 
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